The role of plasma phospholipid transfer protein (PLTP) in the development of atherosclerosis : studies in genetically modified mice by Lie, J. (Jessica)
The Role of Plasma Phospholipid Transfer Protein 
(PLTP) in the Development of Atherosclerosis 
Studies in Genetically Modified Mice 
De rol van plasma phospholipid transfer protein 
(PLTP) in de ontwikkeling van atherosclerose 
Studies in genetisch gemodificeerde muizen 
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus 
Prof.dr. S.W.J. Lamberts 
en volgens besluit van het College voor Promoties 
De openbare verdediging zal plaatsvinden op 
woensdag 15 september 2004 om 15.45 uur 
door 
Jessica Theresa Lie 
geboren te Heemstede 
Promotiecommissie 
Promotor: 
Prof.dr. H. Jansen 
Overige leden: 
Prof.dr. D.J.G.M. Duncker 
Prof.dr. F.G. Grosveld 
Prof.dr. F. Kuipers 
Copromotoren: 
Dr. M.P.G. de Cram 
Dr. A. van Tol 
Printed @ NCopy Amsterdam 
© 2004 Jessica Lie 
No part of this thesis may be reproduced, stored or transmitted in any way by any means, 
without the permission of the author or holder of the copyright 
ISBN 90-9018096-6 
The studies described in this thesis were performed at the Departments of 
Biochemistry and Cell Biology & Genetics of the Medical Genetic Center, 
Erasmus MC, Rotterdam. 
The study described in this thesis was supported by a grant of the 
Netherlands Heart Foundation NHF 98.088. 
Financial support by the Netherlands Heart Foundation and the J.E. 
Jurriaanse Stichting for the publication of this thesis is gratefully 
acknowledged. 
The printing of this thesis was further financially supported by Hope Farms 
bv. and Pfizer bv. 
4 
!n rsrnembrance of ri'1Y rather 
Lfe ~Bn-Tong 
5 
CONTENTS 
Abbreviations 8 
CHAPTER I 9 
General Introduction 
1 Atherosclerosis and Lipoproteins 10 
1.1 Atherosclerosis 
1.2 Lipoprotein Metabolism 
1.2.1 Exogenous Pathway 
1.2.2 Endogenous Pathway 
1.2.3 Reverse Cholesterol Transport 
1.3 Mouse Models for Atherosclerosis Research 
2 Role of HDL in Atherosclerosis 20 
2.1 HDL and Atherosclerosis 
2.2 HDL Structure 
2.3 HDL Metabolism 
2.3.1 HDL Synthesis 
2.3.2 HDL Catabolism 
2.4 Anti-Atherogenic Role of HDL 
2.5 Prevention of Atherosclerosis: Lipid Regulating Drugs and Impact on HDL 
2.6 Remodeling of HDL by Plasma Factors 
2.6.1 Lipid Transfer Proteins 
3 Cholesteryl Ester Transfer Protein (CETP) 32 
3.1 Characteristics and Functions of CETP 
3.2 CETP Activity in Humans 
3.3 Regulation of CETP Gene Expression 
3.4 Role of CETP in the Development of Atherosclerosis in Animal Models 
4 Phospholipid Transfer Protein (PLTP) 38 
4.1 Characteristics of PLTP 
4.2 Functions of PL TP 
4.3 PLTP Activity in Humans 
4.4 Regulation of PLTP Gene Expression 
4.5 Mouse Models for PLTP Research 
4.5.1 PLTP Knockout Mice 
4.5.2 Mice Overexpressing PLTP 
5 Outline of the Thesis 47 
References 
6 
CHAPTER II 
Evaluation of Phospholipid Transfer Protein and Cholesteryl Ester Transfer 
Protein as Contributors to the Generation of Pre~-High-Density Lipoproteins 
Biochem J. 2001; 360(Pt 2):379-385. 
CHAPTER Ill 
Elevation of Plasma Phospholipid Transfer Protein in Transgenic Mice 
Increases VLDL Secretion 
J. Lipid Res. 2002; 43(11):1875-1880. 
CHAPTER IV 
Elevation of Plasma Phospholipid Transfer Protein Increases the Risk of 
Atherosclerosis despite Lower Apolipoprotein B-Containing Lipoproteins 
J. Lipid Res. 2004; 45(5):805-811. 
CHAPTERV 
Elevated Phospholipid Transfer Protein Activity Causes Atherosclerosis through 
Decreased Plasma High Density Lipoproteins and not through Increased 
Production of Triglycerides 
Submitted for publication. 
CHAPTER VI 
Fenofibrate Restores the Decline in HDL Cholesterol in Mice Overexpressing 
Human Phospholipid Transfer Protein 
Submitted for publication. 
CHAPTER VII 
Discussion 
Summary 
Samenvatting 
Curriculum Vitae 
List of Publications 
Dankwoord 
69 
87 
103 
119 
135 
151 
163 
167 
172 
173 
174 
7 
Abbreviations 
ABCA1 
apo 
CETP 
EL 
ELISA 
FXR 
HDL 
HL 
IDL 
LCAT 
LDL 
LDL-R 
LPL 
LPS 
LXR 
oxLDL 
PAF-AH 
PLTP 
PON 
PPAR 
RXR 
SRBI 
VLDL 
8 
ATP binding cassette A1 
apolipoprotein 
cholesteryl ester transfer protein 
endothelial lipase 
enzyme linked immunosorbant assay 
farnesoid liver X-activated receptor 
high density lipoproteins 
hepatic lipase 
intermediate density lipoproteins 
lecithin:cholesterol acyl transferase 
low density lipoproteins 
low density lipoprotein receptor 
lipoprotein lipase 
lipopolysaccharide 
liver X activated-receptor 
oxidized LDL 
platelet-activating factor acetyl hydrolase 
phospholipid transfer protein 
paraoxonase 
peroxisome proliferator activated-receptor 
retinoid X activated-receptor 
scavenger receptor class B type I 
very low density lipoproteins 
9 
Cllapter I 
1 ATHEROSLEROSIS AND liPOPROTEINS 
1.1 ATHEROSCLEROSIS 
Complications of atherosclerosis are the most common cause of death in the 
Western society. Atherosclerosis is a disease of the large arteries caused by a 
long-term process of an accumulation oflipids combined with an inflammatory 
response. The process starts with fatty streaks at the luminal side of the vascular 
wall. The development of atherosclerotic lesions accelerates at about ages 25 to 
30 in men and 40 to 45 in woman according to autopsy examinations in Western 
populations (1). The clinical manifestations of atherosclerosis often begin to 
occur in the 5th or 6th decade of life. The ultimate result of atherosclerosis may 
be a heart attack (Figure 1) or stroke. The notion that cholesterol plays a crucial 
role in the development of atherosclerosis is based on strong experimental and 
clinical evidence (2, 3). Low density lipipoproteins (LDL), the major carriers of 
plasma cholesterol in man, were shown to be a causal factor. Many randomized, 
placebo-controlled, clinical trials have shown that lowering of LDL cholesterol 
results in a substantial reduction in cardiovascular events (4-6). 
In the past two decades, research was increasingly focused on the pathobiology 
of the arterial wall during atherosclerosis (3). The arterial wall consists of three 
layers, the intima, media and adventitia (Figure 1). The intima is situated at 
the luminal side of the vessel wall, and mainly comprises endothelial cells. 
The media mainly consists of layers of smooth muscle cells and elastic fibres. 
The adventitia surrounds the media, and comprises a layer of loose connective 
tissue that merges with surrounding connective tissue, and elastic fibres that 
are less abundant than in the media. 
Atherogenesis can be viewed as an inflammatory, or healing, response of the 
endothelial cells to injury (7, 8). This response to injury hypothesis is the most 
widely accepted hypothesis for the initiation of atherosclerosis and postulates 
that the atherosclerotic process is triggered by a local dysfunction of the 
endothelial lining of the vessels. This event leads to subsequent changes in 
the vascular permeability, expression of adhesion molecules and release of 
growth factors. Physical damage, metabolic changes, toxicological damages, 
lipoproteins or other risk factors are seen as the injurious agents (2, 9). 
The development of atherosclerosis can be described by a sequence of events 
generating the fatty streak lesions or atherosclerotic plaques (3, 10, 11). The 
initiation of lipid accumulation starts with LDL, which infiltrate in the sub-
endothelial space of the arterial wall. LDL can be retained in the intima, and 
may undergo modification by oxidation or other processes. The oxidized 
lipoprotein particles and their constituents can then elicit the production of 
various cytokines, inflammatory mediators and growth factors that affect 
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Figure 1. A schematic representation of atherosclerosis. Reprinted from Nature Medicine (8) 
by kind permission from Prof. P. Libby and Nature Publishing Group. The normal human 
coronary arterial wall consists of three layers, the intima, media and adventitia. The intima 
is situated at the luminal side of the vessel wall, and comprises a single layer of endothelial 
cells that separate the vessel wall from the blood stream. The internal elastic lamina forms 
the barrier between the tunica intima and the underlying tunica media. The media consists of 
multiple layers of smooth muscle cells embedded in an interstitial matrix, mainly composed 
of elastin as well as collagen. The adventitia surrounds the media, and comprises a layer 
of loose connective tissue composed of collagen, elastin fibres and fibroblasts. In early 
atherogenesis, recruitment of inflammatory cells and the accumulation of lipids lead to an 
early atheroma which can grow if inflammatory conditions prevail and persist. The fibrous 
cap may become thinner and susceptible to rupture under the influence of proteinases and 
pro-inflammatory cytokines yielding a 'vulnerable plaque'. Lipid lowering can reduce lipid 
content and calm the intimal inflammatory response, yielding a 'stabilized plaque'. But 
under persistent dyslipidemic conditions, the plaque may rupture and thrombus formation 
is instigated by the coagulation cascade. If the thrombus occludes the vessel persistently, an 
acute myocardial infarction may occur. However, a wound healing response is triggered 
during blood coagulation which can eventually lead to the expansion of the intima in an 
inward direction yielding a constriction of the lumen. 
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the behavior of the endothelial cells in the vascular wall. Recruitment and 
expression of pro-inflammatory cytokines promote thrombosis, a complication 
of atherosclerosis. Studies in genetically modified mice showed that expression 
of adhesion molecules that promote monocyte and T-lymphocyte recruitment 
into the vascular wall can be triggered by high-cholesterol diet (12). After 
transmigration of the monocytes into the sub-endothelial space, they are 
transformed into macrophages under the influence of various growth factors 
and cytokines. Macrophages start to accumulate cholesterol from modified 
LDL and eventually become' foam cells'. Lesion progression proceeds with the 
migration of smooth muscle cells from the media into the intimal fatty streaks. 
The proliferation and migration of arterial smooth muscle cells, stimulated by 
growth factors and cytokines, generates a fibrous cap lesion. A lipid core is 
formed as a consequence of further foam cell accumulation and macrophage 
death by necrosis or apoptosis. Other features of further lesion progression 
are: continued accumulation of macrophages and T-lymphocytes, loss of 
smooth muscle cells and calcification. Eventually, plaque rupture may occur 
at sites where the concentration of lipid laden macrophages is high and the 
fibrous cap is weak. After rupture, the coagulation cascade and accumulation 
of platelets will lead to the formation of a thrombus which can occlude the 
vessel. 
Atherosclerosis is in fact a multi-factorial process in which may risk factors are 
involved, including age, gender, smoking, obesity, diabetes, lack of physical 
activity, hypertension and genetic predisposition. In the past decades much 
research was focused on lipoprotein metabolism. In 1985 Brown and Goldstein 
received the Nobel Price for discovering the involvement of the LDL receptor 
in familial hypercholesterolemia. Familial hypercholesterolemia is the first 
mono-genetic disorder found to cause coronary heart disease and provides 
strong evidence for a causal relation between elevated LDL cholesterol and 
atherosclerosis (13). With the discovery of the LDLreceptor, effective cholesterol 
lowering therapies evolved slowing down the atherosclerotic process (see 
section 2.5). However, many aspects of the relation between atherosclerosis 
and lipoprotein metabolism remain to be clarified. 
1.2 LIPOPROTEIN METABOLISM 
As the name implies, plasma lipoproteins are complexes of lipids and 
proteins. Cholesterol, phospholipids and triglycerides are quantitatively 
the most important compound lipids present in the circulation. Cholesterol 
is an essential constituent of all cellular membranes and is a precursor for 
the synthesis of steroid hormones and bile acids. Phospholipids are the 
12 
General introduction 
major class of lipids in cellular membranes. Phospholipids are also metabolic 
intermediates in the formation or degradation of other compound lipids. As 
second messengersf these intermediates regulate a broad spectrum of cellular 
activities. Triglycerides are used as an energy source for cardiac and skeletal 
muscle and are stored in adipose tissue. During the process of lipolysisf i.e. 
the breakdown of fat stored in adipose tissuef free fatty acids are released 
into the bloodstream and circulate throughout the body bound to albumin. 
Free fatty acids have a high metabolic turnover ratef are constantly recycled in 
biological systems and are also oxidized in many tissues for energy production. 
Cholesterolf phospholipids and triglycerides are not soluble in water and need 
to be packaged into lipoproteins for transport through the body via aqueous 
compartments such as lymph and blood. 
Lipoproteins contain a central hydrophobic core of cholesteryl esters and 
triglycerides and a surface layer of phospholipidsf free cholesterol and 
apolipoproteins. Apolipoproteins are proteins associated with lipoproteins 
that have several functionsf including stabilization of the lipoprotein structuref 
enzyme activation or inhibition and binding to cell membrane receptors. 
Lipoproteins in plasma can be divided into five main subclasses: chylomicronsf 
very low density lipoproteins (VLDL)f intermediate density lipoproteins 
(IDL), low density lipoproteins (LDL) and high density lipoproteins (HDL)f 
which are traditionally isolated by density ultracentrifugation. Lipoproteins 
can also be divided according to electrophoretic mobility. Lipoprotein classes 
also differ profoundly in sizef lipid composition and apolipoprotein moiety 
(Table 1) (14). 
LDL is the major cholesterol carrier in the blood. If too much LDL cholesterol 
circulates in the bloodf it can accumulate in the walls of various arteriesf 
including the coronary arteries feeding the heart. Together with other 
substances it can form plaquef a thick firm deposit that may clog these arteriesf 
which describes the condition of atherosclerosis (see Figure 1). High levels of 
LDL cholesterol reflect an increased risk for atherosclerosis. Apolipoprotein 
(apo)B is the structural protein of all atherogenic lipoproteins (Table 1). Each of 
these atherogenic lipoproteins contains one apoB molecule and therefore the 
apoB concentration is a direct reflection of the number of atherogenic particles 
in the blood (15). Roughly 25% of blood cholesterol in normolipidemic subjects 
is carried by HDL. It is believed that HDL removes excess cholesterol from 
atherosclerotic plaques and thus slows down or even prevents their growth. 
In generalf high levels of HDL protect against atherosclerosis and low HDL 
levels(< 0.9 m.M) indicate an increased risk. 
13 
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Table 1. Physical properties, lipid and apolipoprotein composition of human plasma 
lipoproteins, adapted from (14). 
Physical properties 
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12 
Density (g/ml) <0.96 0.96-1.006 1.006-1.019 1.019-1.063 1.063-1.210 
Mobility* origin pre-13 slow pre-13 13 a 
Composition** 
Triglycerides 88 53 28 9 6 
Phospholidpids 7 18 23 22 22 
Cholesteryl esters 3 14 30 38 17 
Free cholesterol 7 8 10 5 
Protein 1-2 6-10 11 21 45-55 
Apolipoproteins Al,AIV AI,AJI,AIV 
B48 8100 B100 6100 
Cl,CJI,CJII CJ,CJI,CJII CJ,CJI,CJII CI,CJI,CJII 
E E E E 
• According to electrophoretic mobility of plasma a- and 13-globulins on agarose gel electrophoresis. 
**Expressed as a percentage of total weight. 
The metabolism of lipoproteins can be conceptually discerned into two major 
pathways: 1) the exogenous pathway, concerning the uptake and transport of 
dietary lipids from the intestine to peripheral tissues, and 2) the endogenous 
pathway, covering the metabolism of lipoproteins which are synthesized in 
the liver (Figure 2). Reverse cholesterol transport involves the transport of 
cholesterol from peripheral tissues to the liver (16, 17). 
1.2.1 EXOGENOUS PATHWAY 
Dietary cholesteryl ester, phospholipids and triglycerides are hydrolysed in 
the intestinal lumen and subsequently packaged in the intestinal cells into 
chylomicrons, which contain the apolipoproteins apoB48, apoAI and apoAIV. 
The chy I omicrons are secreted into the intestinal lymph and enter the circulation 
via the thoracic duct upon which they loose apoAI and apoAIV and acquire 
apoCI apoCII, apoCIII and apoE from HDL. These apolipoproteins regulate 
the further metabolism of the chylomicrons. Since chylomicrons are too large 
to enter the endothelial barrier, they need to be metabolized in the blood. The 
enzyme lipoprotein lipase, which is present at the surface of endothelial cells 
in the capillary beds of adipose tissue, heart and skeletal muscle, hydrolyzes 
14 
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the triglyceride core of chylomicrons (18, 19). The resulting free fatty acids are 
stored as triglycerides in adipocytes or can be used as an energy source by 
muscle. As a consequence of triglyceride hydrolysis, the chylomicrons shrink 
to chylomicron remnants. During lipolyses of chylomicrons and VLDL, surface 
remnants, containing phospholipids and free cholesterol, are formed as well 
(20). These surface remnants fuse with HDL. The chylomicron remnants are 
removed from the circulation by the liver through apoE-mediated binding to 
lipoprotein receptors, i.e. the LDL-receptor (LDL-R) (21) and the LDL-receptor 
related protein (22, 23), which are briefly outlined below. 
The LDL-R controls plasma LDL levels and recognizes lipoproteins containing 
either apoB100 (present on IDL and LDL) or apoE (present on chylomicron 
remnants, IDL and a specific HDL subfraction). The LDL-R is located in 
membrane indentations of the hepatic cell membrane, called coated pits. 
After binding, the receptor-LDL complex is internalized by the hepatocyte. 
Via receptor-mediated endocytosis, the entire LDL particle is delivered to 
lysosomes, wherein it is disassembled by hydrolysis of its components, 
releasing cholesterol for subsequent cellular metabolism. mRNA expression of 
the LDL-R is regulated by cellular cholesterol by a feedback mechanism. The 
cellular LDL-R level regulates, together with the biosynthesis of cholesterol, 
cellular cholesterol homeostasis (24). The LDL-R related protein has a number 
of protein domains and motifs that are also present in the LDL-R (22). It is a 
multiligand receptor which recognizes apoE (25) and therefore is able to bind 
and internalize chylomicron remnants. 
1.2.2 ENDOGENOUS PATHWAY 
The endogenously synthesized lipids are secreted from the liver in the form 
of VLDL, containing apoB100. Upon entering the circulation, VLDL acquire 
apoE and apoCs from HDL. In addition, apoE may be obtained from the 
surface of the hepatocyte in the space of Disse (26). By the action of the enzyme 
lipoprotein lipase, which needs apoCII as a cofactor, VLDL is hydrolyzed 
into IDL, which can be further hydrolyzed or taken up by the liver via the 
LDL-R. A second lipolytic enzyme, hepatic lipase, which may function as a 
triglyceride hydrolase as well as a phospholipase, contributes to the further 
hydrolyses of IDL into LDL. During the conversion to LDL, the majority of the 
apoCs and apoE dissociate from IDL to be reassociated with HDL. The end 
product of the cascade is LDL which protein moiety consists of only apoB100. 
IDL, containing apoE, are removed by hepatic uptake trough the LDL-R and 
LDL-R related protein as described in the previous paragraph. The apoB100 
containing LDL may undergo receptor-mediated endocytosis by the LDL-R in 
hepatocytes and in peripheral cells. 
15 
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Alternatively, LDL may become modified or oxidized in the vessel wall, 
perhaps due to local inflammatory reactions (27). This modified or oxidized 
LDL (oxLDL) binds to scavenger receptors on the surface of macrophages. 
These include SRA and CD36 (3, 11). The scavenger receptors then mediate 
endocytosis and lysosomal degradation of the modified lipoprotein (28). 
Unlike the LDL-R, macrophage scavenger receptor activity is not regulated by 
intracellular cholesterol pools. Therefore the scavenger receptors can mediate 
massive accumulation of cholesterol, resulting in the formation of lipid-
laden foam cells. Incubation of foam cells with HDL leads to efflux of cellular 
cholesterol (29), which is indicative for an anti-atherogenic role of HDL. 
intestine 
~ bile acids + 
cholesterol 
Exogenous pathway 
kidney ovary testes 
Endogenous pathway 
Figure 2. The exogenous and endogenous pathways of plasma lipoproteins. Adapted figure, 
kindly provided by Dr. R. de Crom. In the exogenous pathway the lipoproteins are transported 
from the intestine to the liver, and in the endogenous pathway from the liver to the peripheral 
tissues. See text for details. 
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1.2.3 REVERSE CHOLESTEROL TRANSPORT 
Reverse cholesterol transport is a process in which cholesterol is moved from 
peripheral cells via plasma HDL to the liver for recycling or degradation and 
secretion in bile. Reverse cholesterol transport involves several identifiable 
steps (Figure 3): 1) Peripheral formation of discoidal HDL by an ATP binding 
cassette Al (ABCAl)-dependent process. The nascent prej3-HDL particles 
efficiently remove cholesterol from cells in peripheral tissues (30). ABCAl has 
been proposed to facilitate the efflux of cellular cholesterol and phospholipids 
to lipid poor apolipoproteins (31-33). 2) Esterification of cholesterol in the 
HDL discs results in spherical HDL by the enzyme lecithin:cholesterol acyl 
transferase (LCAT). LCAT plays a central role in reverse cholesterol transport 
by catalyzing the esterification of free cholesterol to cholesteryl esters on plasma 
lipoproteins. LCAT matures the nascent prej3-HDL into spherical a-HDL by the 
transfer of newly synthesized cholesteryl esters to the hydrophobic core. LCAT 
maintains a concentration gradient for cholesterol efflux from peripheral cells 
to HDL. HDL also acquires cholesterol, phospholipids and apolipoproteins 
from the surface remnants formed during hydrolysis of triglyceride-rich 
lipoproteins. 3) HDL cholesteryl esters can be transferred to apoB-containing 
lipoproteins by the action of cholesteryl ester transfer protein (CETP), partly 
in exchange for triglycerides (34). Subsequently, the LDL cholesteryl ester is 
taken up via the LDL-R (35). Thus, HDL can transport cholesterol indirectly 
to the liver following transfer to apoB-containing lipoproteins. 4) HDL can 
S ApoB peripheral cell ABCA1 Ap~oAI 
C;.. cholesterol < PLTP ~ phosphor;;~: 1~ ~ @~ lipoly~poB 
u~ LDL ~~------~ 
ApoAI v ApoAI ~ PLTP ~ HL ~ v SR-BI 
l CETP ---~ 
PLTP 
Figure 3. Reverse cholesterol transport. Adapted reprint from Hart Bulletin (2002; 33:127 -129) 
by kind permission from Drs. R de Crom, A. van Tol and Mediselect bv. In this process the 
cholesterol from peripheral tissues is transported to the liver. See text for details. In this scheme 
the actions of PLTP are indicated with bold arrows. PLTP is able to transfer phospholipids 
from VLDL to HDL during lipolysis. PLTP is involved in the maturation of HDL by fusing a-
HDL particles to form larger HDL followed by shedding off prej3-HDL. In addition, PLTP is 
also involved in hepatic VLDL secretion. 
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also directly deliver cholesterol to the liver via an endocytotic pathway or via 
selective uptake (36). In the endocytotic pathway, putative BDL receptors may 
be involved in HDL uptake (37). The selective uptake of cholesteryl esters from 
HDL is mediated by SRBI receptors (38). Once cholesterol enters the liver it can 
be re-used for lipoprotein assembly, used for bile acid synthesis, or secreted 
directly into the bile (39, 40). HDL is involved in all steps of reverse cholesterol 
transport, but its concentration in plasma is not per se the key determinant of 
the rate of reverse cholesterol transport. It is likely that processes in peripheral 
tissues, like the action of ABCA1, that make cholesterol available for uptake 
by HDL are most important (41, 42). Groen et al. showed in ABCA1 knockout 
mice that HDL levels do not always control cholesterol transport from the 
periphery via the liver into bile (43). Biliary cholesterol in ABCA1 knockout 
mice was similar to that in control mice which is surprising because one might 
have expected a decreased delivery of cholesterol to the liver due to the lower 
HDL levels in plasma. Studies in other mice with low HDL levels, e.g. CETP or 
SRBI overexpression or apoAI deficiency ( 44), show no change in centripetal 
flow of cholesterol from the periphery to the liver. These data indicate that 
HDL concentration is not always the rate limiting step in reverse cholesterol 
transport. 
1.3 MOUSE MODELS FOR ATHEROSCLEROSIS RESEARCH 
In humans, investigation of the effects of certain lipoprotein metabolism 
mediators on the development of atherosclerosis is complicated, because 
genetic variability and inter-individual differences in environmental factors 
and life style often affect the development of atherosclerosis. These factors may 
be reduced to a minimum in mice, because inbred strains are used, and similar 
housing and dietary conditions are applied. In addition, in vivo quantification 
of atherosclerosis in humans is difficult, whereas in mice atherosclerosis can 
be quantified at any time under standardized conditions (45, 46). However, 
wild-type mice are highly resistant to the development of atherosclerosis. 
In response to a low-fat, low-cholesterol (normal chow) diet, mice have low 
plasma levels of cholesterol and the main lipoprotein class in their plasma 
is the anti-atherogenic HDL. In contrast, the predominant lipoproteins in 
humans are the atherogenic VLDL and LDL. This discrepancy between the 
species may be due to several differences in lipoprotein metabolism, including 
the absence of CETP in mouse plasma, the higher efficiency of murine hepatic 
LDL receptors, leading to faster clearance of IDL and LDL, different locations 
of hepatic lipase, which is 100% hepatic in humans and partly in plasma in 
mice, and reduced synthesis of apoB100 in mice due to a higher degree of 
editing of the apoB mRNA in the liver (45). Atherosclerosis in the relatively 
18 
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atherosclerosis susceptible mouse strain C57BL6 is only developed when 
they are fed a cholesterol containing diet with cholate for several months 
(47). However; with the development of genetically modified micef several 
mouse models have been generated which are more suitable for the study of 
atherosclerosis; by overexpression or knocking out specific genes ( 45). Mice 
deficient in apoE (48; 49) or LDL-R (50) develop advanced lesions and are the 
models most commonly used in studying atherosclerosis. 
19 
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2 ROLE OF HDL IN ATHEROSCLEROSIS 
2.1 HDL AND ATHEROSCLEROSIS 
In many clinical studies HDL cholesterol levels are shown to correlate 
inversely with the risk of atherosclerosis and it is established that both high 
levels of LDL and low levels of HDL are important independent risk factors 
for atherosclerosis (51, 52). Although high levels of HDL have been shown 
to be beneficial, the clinical significance of targeting HDL therapeutically is 
unknown. One of the targets to raise HDL cholesterol is inhibition of CETP 
activi~ which indeed raises HDL cholesterol in humans (53) and protects 
against atherosclerosis in cholesterol fed rabbits (54). In addition, data from 
a multicenter pilot trial showed that five weekly infusions of a synthetic HDL 
can remove significant amounts of plaque from coronary arteries in patients 
with acute coronary syndromes (55). 
Therapies for lipid lowering focus on lowering LDL. Trials with statins, 
Table 2. HDL subclasses. 
density ultracentrifugation HDL, 1.063- 1.125 g/ml 
HDL, 1.125-1.21 g/ml 
diameter polyacrylamide HDL,. 9.7-12.9 nm 
gradient gel HDL,. 8.8-9.7 nm 
electrophoresis HDL,, 8.2-8.8 nm 
HDL,. 7.8-8.2 nm 
HDL,, 7.2-7.8 nm 
NMRsignals NMR spectroscopy H1 for more information: 
converted to size H2 www.liposcience.com 
H3 
H4 
H5 
charge agarose gel a-HDL 
electroporesis prej3-HDL-> prej31-HDL 
prej32-HDL 
prej33-HDL 
apolipoprotein- sequential immuno- LpA-1 
composition affinity LpA-1/A-11 
chromatography 
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which are drugs primarily lowering LDL cholesterol, have revealed that LDL 
reduction reduces morbidity and mortality (5, 56). However, the reduction 
in event rates in these trials was by about one third, meaning that despite 
LDL reduction, most cardiovascular events still occur. It is therefore necessary 
to look beyond LDL cholesterol and consider other risk factors that might 
explain the mortality in landmark trials. One of these risk factors is a low level 
of HDL. This is supported by strong evidence from the Framingham Heart 
Study, which revealed that low levels of HDL predict an increased incidence of 
cardiovascular diseases independent from LDL levels (51). Another landmark 
study, the VA-HIT study intervening with gemfibrozil, which increase HDL 
cholesterol, demonstrated that increasing HDL, even in the absence of LDL 
changes, is associated with a decrease in coronary events among patients with 
low HDL levels (57). The association of low levels of HDL cholesterol with an 
increased incidence of cardiovascular events implies a critical role of HDL in 
the protection against atherosclerosis. The interest in HDL is emerging and 
further clinical and fundamental research is needed since our understanding 
of the metabolism of HDL and its anti-atherogenicity is far from complete. In 
the following section HDL is introduced and the potential anti-atherogenic 
roles of HDL are discussed. 
2.2 HDL STRUCTURE 
HDL consist primarily of protein (50%), with very small amounts of triglyceride 
(6%) and moderate amounts of phospholipids (22%) and cholesterol (22%), 
accounting for approximately 25% of cholesterol in the blood in humans (58). 
The HDL fraction is a very heterogeneous lipoprotein class (59) which can be 
separated by different techniques showing differences in density, diameter, 
nuclear magnetic resonance (NMR) signal, electrophoretic mobility, shape 
and apolipoprotein content (Table 2). 
Density and diameter: The main particle populations are HDL2 and HDL3, 
which both are spherical in shape (39). These particles can be interconverted 
by hepatic lipase (60), endothelial lipase (EL) (61) LCAT (62), CETP and 
phospholipid transfer protein (PLTP) (36). HDL2 particles are less dense (1.063 
< d < 1.125 g/ml) and larger (8.8-12.9 nm diameter) than HDL3 particles (1.125-
1.21 g/ml; 7.2-8.8 nm diameter). 
NMR signal: NMR spectroscopy can measure levels and HDL subpopulations 
in plasma (63, 64). The amplitude of spectral signals emitted by HDL subclasses, 
depending on the different chemical composition of the subfractions, are 
converted to size by sophisticated calculations. The HDL subclasses H5, H4, 
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H3, H2, and Hl are closely related to the gradient gel electrophoresis subclass 
designations HDL2a, HDL2b, HDL3a, HDL3b, and HDL3c, respectively. This 
technique is mostly performed at LipoScience Inc. and its true place in HDL 
analysis remains to be determined. 
Charge: A subtle classification of the HDL population is achieved by using native 
polyacrylamide gradient gel electrophoresis: HDL2a' HDL2b, HDL3a, HDL3b 
and HDL3c are separated. Agarose gel electrophoresis allows the separation 
of a-HDL (the majority of HDL particles), which are spherically shaped, and 
pref3-HDL, which are discoidally shaped (65). These subtractions are believed 
to be functionally important in reverse cholesterol transport. The amount of 
pref3-HDL in human plasma constitutes 4 to 14% of total apoAI (66). Pref3-
HDL can be subdivided into three classes: pref31-HDL, pref32-HDL and pref33-
HDL (30, 59, 66). Pref31-HDL particles contain only apoAI and phospholipids. 
Pref32-HDL have additional cholesterol and an increased phosphatidyl choline: 
sphingomyeline ratio compared to pref31-HDL. Due to extremely low amounts 
of pref33-HDL in plasma their characteristics are not well defined. 
Apolipoprotein composition: HDL containing only apoAI (LpA-I), only apoAII 
(LpA-11) or both apoAI and All (LpA-I/A-11) have been identified. In normal 
human plasma LpA-I and LpA-I/LpA-11 particles are most abundant, 
constituting 25% and 65% respectively of circulating apoAI (67). LpA-I and 
LpA-I/LpA-11 may have different physiological functions, but it is not exactly 
clear at present how the function of LpA-I differs from LpA-I/LpA-11 with 
respect to atherosclerosis development (68-70). 
2.3 HDL METABOLISM 
HDL metabolism is extremely complex, due to multiple pathways for 
synthesis and degradation of its components. It also includes the extracellular 
modification or interconversion of HDL which occurs in the plasma 
compartment and involves various enzymes and the lipid transfer proteins, 
CETP and PLTP. 
2.3.1 HDL SYNTHESIS 
HDL is synthesized de novo in the liver and small intestine as protein-rich 
disc-shaped particles. The exact origin of HDL is not clear because there is 
no reliable non-transferable marker for HDL. As a consequence, several 
hypotheses for the first step of HDL processing have been proposed. One 
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of these is the release of lipid free apoAI from the liver and intestine which 
associates with phospholipids (71), a second possibility is the secretion of 
nascent HDL particles containing apoAI, phospholipids and cholesterol from 
the liver and intestine (72), and a third hypothesis is the release of surface 
components of triglyceride-rich lipoproteins during lipolysis which form 
nascent HDL (73). In all cases, nascent discoidal prej3-HDL is formed. Recent 
studies have unambiguously shown that ABCA1 is crucial for HDL-synthesis 
(31, 32, 74). ABCA1 is present in all tissues examined to date and facilitates the 
efflux of phospholipids and cholesterol from cells onto apoAI, thus forming 
prej3-HDL. These particles are processed into mature a-HDL through the 
activity of the HDL bound enzyme LCAT. LCAT requires apoAI for activation 
and catalyses the formation of cholesteryl esters from unesterified cholesterol 
and the fatty acyl chain at the sn2 position of phosphatidyl choline. The lipid 
transfer proteins CETP and PLTP both exchange phospholipids between 
lipoproteins, replenishing HDL with unsaturated phospholipids needed for 
an optimal LCAT reaction (36). Plasma from ABCA1 knockout mice shows 
profound changes in phospholipid composition, possibly due to the very 
low levels of PLTP activity. This altered phospholipid composition impairs 
the plasma activities of LCAT and as a consequence the maturation of HDL, 
thereby contributing to the near absence of HDL (75). During HDL maturation 
HDL increases in size, ultimately forming HDL2• The phospholipids and 
triglycerides of HDL2 are hydrolyzed by hepatic lipase, resulting in smaller 
HDL3 particles (60, 76, 77). 
2.3.2 HDL CATABOLISM 
Although in some genetic disorders changes in HDL levels can be explained 
by adjustments in the rates of HDL synthesis, clearance rather than synthesis 
appears to be the major mechanism managing the plasma levels of HDL (78). 
Because all components of HDL are exchangeable through protein mediated 
or spontaneous transfer mechanisms, the proteins and lipids of HDL can be 
catabolized independently of one another and of the HDL particle. Thus, 
plasma HDL is catabolized through different pathways. 
In humans, the half-time for the removal of apoAI from plasma is 3-5 days 
(79). The kidneys and the liver are the primary sites for catabolism of apoAI, 
the major component of HDL (80, 81). Other HDL proteins degraded in kidney 
and liver are apoAIV (82) and apoE (81). ApoAI dissociates from cholesterol 
depleted HDL and is probably internalized and degraded by the cubilin-
megalin pathway. Cubilinfunctions as aholoparticle HDLendocytosis receptor, 
and megalin functions as a co-receptor because cubilin has no transmembrane 
domain (83). 
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HDL cholesteryl esters can be transferred into triglyceride-rich lipoproteins by 
CETP (34). These lipoproteins are subsequently taken up by the liver through 
LDL-R-mediated endocytosis as described in section 1.2.1. In addition to the 
CETP-mediated pathway for HDL cholesteryl ester catabolism, which is present 
in some mammalian species, e.g. man, rabbit and hamster, but not in others, 
e.g. pig, rat and mice, HDL particles are also a direct source of cholesteryl 
esters by selective HDL uptake via SRBI (84, 85). This involves cholesteryl ester 
uptake from HDL after binding to the cell surface followed by re-entry into the 
circulation. This process occurs predominantly in the liver and steroidogenic 
tissues (86, 87). A series of genetically modified mouse models have definitively 
shown the relevance of SRBI in controlling plasma HDL levels (88, 89). These 
mouse studies established that HDL levels are inversely correlated with the 
level of SRBI expression. Macrophage studies showed that the expression of 
SRBI results in a reduction in ABCAl-mediated efflux of cholesterol to HDL 
(90). It was proposed that SRBI expression produces a re-uptake pathway in 
which cholesterol, released from the macrophage by ABCAl, is incorporated 
back into the cell by SRBI-mediated influx. However, it is possible that in 
hepatocytes SRBI and ABCAl could be expressed on different sides of the cell, 
and together might promote movement of HDL-derived cholesterol across the 
cell (90). 
Direct catabolism of HDL particles might also be exerted by other putative 
HDL receptors (37, 91). It is not clear to what extent these HDL receptors play 
a role in HDL metabolism in vivo. Alternatively, HDL might be catabolized 
after binding to proteoglycans which participate in hepatic lipase and apoE-
mediated binding and uptake of HDL (92). 
2.4 ANTI-ATHEROGENIC RoLE oF HDL 
Cholesterol cannot be degraded in peripheral tissue, including the artery 
wall. Reverse cholesterol transport provides a pathway for the transport of 
cholesterol to the liver, where it can be degraded (39, 40). A large number of in 
vivo studies support the hypothesis that HDL is anti-atherogenic due to its key 
function of HDL in reverse cholesterol transport. However, there may be other 
mechanisms by which HDL also protect against atherosclerosis, including 
protecting LDL from oxidation, reducing the inflammatory response of 
endothelial cells, promoting the availability of nitric oxide, and inhibiting the 
coagulation pathway. Thus HDL might protect against atherosclerosis through 
a variety of beneficial effects on other plasma lipoproteins, coagulation and 
vasculature. 
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HDL and its role in reverse cholesterol transport 
Below, factors involved in this process will be presented in the order of the 
distinctive steps. 
ApoAI is the major apolipoprotein of HDL. Mice that have been genetically 
modified to overexpress the human apoAI gene show increased HDL 
cholesterol. Elevation of HDL in these animals is accompanied by a protection 
against atherosclerosis (93). Further, overexpression of human apoAI in apoE 
knockout mice, which are prone to atherosclerosis, significantly decreased the 
marked atherosclerotic lesions that would otherwise develop (94). Complete 
deletion of the apoAI gene in humans results in very low levels of HDL 
cholesterol and premature cardiovascular disease (95, 96). 
ABCA1 deficiency in man causes Tangier disease, a rare disorder characterized 
by reduced HDL levels (31, 32, 97) . Fibroblasts from patients with Tangier 
disease have markedly reduced cholesterol and phospholipid efflux to 
apolipoproteins (98) that is corrected by expression of ABCA1 (99). ABCA1 
deficiency in mice (100) causes a defect in cellular lipid efflux and the absence 
of lipid rich a-HDL in plasma. As a consequence, foam cells accumulate in 
many tissues. Mutations in ABCA1 are a cause of low HDL cholesterol levels 
in some families (101, 102). It is not clear whether all patients with Tangier 
disease are at increased risk for atherosclerosis. 
LCAT deficiencyinhumansisnot always associated with atherosclerosis despite 
the virtual HDL deficiency (103). LCAT knockout mice also have markedly 
reduced levels of HDL cholesterol (104). Transient LCAT overexpression in 
dyslipidemic obese mice decreases atherosclerosis (105).The relation of LCAT 
to reverse cholesterol transport is not very well established in vivo. For instance, 
no increase in reverse cholesterol transport could be observed as assessed by 
centripetal cholesterol flux in mice overexpressing LCAT (44), and studies of 
reverse cholesterol transport in LCAT deficiency have not been performed. 
SRBI deficiency in humans has not been reported. SRBI deficiency in mice 
causes increased HDL cholesterol levels (89). SRBI overexpression (106) and 
gene transfer (107) of SRBI in LDL-R knockout mice fed a high-fat, high-
cholesterol diet resulted in decreased atherosclerosis. In both cases, HDL 
cholesterol levels were significantly decreased. However, disruption of the 
SRBI gene in apoE knockout mice accelerated the onset of atherosclerosis 
despite higher HDL cholesterol levels (108). 
Hepatic lipase, lipoprotein lipase, endothelial lipase, CETP and PLTP, which 
may also be involved in reverse cholesterol transport, will be outlined in later 
sections. 
In summary, the exact molecular mechanism by which altered gene expression 
is pro- or anti-atherogenic has not been elucidated for any of the genes 
involved in HDL metabolism. This mechanism might include enhanced 
reverse cholesterol transport via HDL or facilitated uptake by the liver of 
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plasma cholesterol transported in apoB-containing lipoproteins. Moreover, 
atherosclerosis studies in humans and genetically modified mouse models 
indicate that the relationship between HDL levels and reverse cholesterol 
transport might not always be operative. Some data indicate that the flux of 
HDL-cholesterol, rather than the absolute HDL levels, might be more indicative 
of the activity of the reverse cholesterol pathway (59). 
HDL acts as an anti-oxidant 
Another explanation for the anti-atherogenic role of HDL is that HDL is 
protective against the harmful effects of oxidized LDL. In vitro experiments 
showed that HDL impedes LDL oxidation by metal ions (109). It has been 
demonstrated that HDL abolishes the transmigration of monocytes induced by 
modified LDL in co-cultures of human aortic wall cells (110). The anti-oxidant 
effect of HDL may be due to apoAI and the enzymes platelet activating factor 
acetylhydrolase, paraoxonase (111, 112) and LCAT (105, 111, 112). Plasma 
from mice transgenic for the human apoAI gene inhibits the oxidation of LDL 
in vitro to a greater extent than plasma from control mice (111, 112). 
HDL reduces the inflammatory response of endothelial cells 
HDL may have anti-atherogenic properties by inhibiting oxidized LDL-
induced up-regulation of adhesion molecules and cytokines (113), and thereby 
inhibiting the initiation and progression of vascular plaque formation. Studies 
have shown that cytokine-induced expression of cell adhesion molecules such 
as VCAM-1, ICAM-1 and E-selectin is inhibited by HDL (113, 114). The most 
pronounced inhibition of the expression of these proteins was observed at 
physiological HDL concentrations. In vivo, elevation of HDL concentration 
reduces IL-l induced expression of E-selectin (115). 
HDL promotes the availability of nitric oxide 
HDL cholesterol was shown to be an independent predictor of the flow-
induced vasodilatation in patients with cardiovascular disease (116). Nitric 
oxide induces endothelium-dependent vasodilatation. Nitric oxide release 
is diminished in persons with risk factors for atherosclerosis, indicating 
that inhibition of vasodilatation may be contributing to the disease (117). A 
mechanism to explain the beneficial effect of HDL on endothelial function 
may be the increased expression of endothelial nitric oxide synthase, which 
increases nitric oxide bioavailability;. which in tum contributes to the observed 
enhancement in endothelial-dependent vasodilatation (118, 119). 
26 
General introduction 
HDL shows antithrombotic properties 
Plaque disruption and subsequent thrombus formation is important for the 
onset of cardiovascular diseases. It has been shown that HDL inhibits the 
coagulation pathway (120). Naqvi et al. demonstrated that low HDL cholesterol 
is an independent predictor of acute platelet-dependent thrombus formation 
(121). HDL also inhibits thrombin-induced binding of fibrinogen on platelets 
(122). 
As yet, it is not clear to what extent the anti-atherogenic effect of HDL is the 
result ofits modulating activity on the efficiency of reverse cholesterol transport, 
compared with the other HDL mediated protective effects. In addition, the 
functional properties of HDL subfractions rather than the quantity of HDL 
subtractions may determine HDL function and thereby cardiovascular risk 
(52, 59, 123). 
2.5 PREVENTION OF ATHEROSCLEROSIS: LIPID REGULATING DRUGS AND IMPACT ON 
HDL 
Drug treatment to lower plasma (V)LDL and total plasma cholesterol is usually 
considered as an option only if non-pharmacological interventions (altered 
diet and exercise) have failed. The following classes of lipid regulating drugs 
are the most widely used. 
HMG-CoA reductase inhibitors or statins: atorvastatin, simvastatin, pravastatin, 
rosuvastatin, block the synthesis of cholesterol by the liver. Diminished 
concentrations of cholesterol in the liver in turn give rise to enhanced levels of 
LDL-R on the surface of liver cells by enhancing LDL-R synthesis. Increased 
LDL-R activity leads to increased hepatic uptake of LDL. The intracellular 
synthesis of cholesterol is inhibited and cells are therefore dependent on 
extracellular sources of cholesterol. Most statins increase HDL cholesterol by 
approximately 5-10%. In addition, statins possess an array of anti-inflammatory 
properties, which may limit atherosclerosis development (124). 
Nonabsorbable resins that bind bile acids: cholestyramine, in the gut after oral 
intake binds bile acids, which therefore cannot be reabsorbed, resulting in 
enhanced excretion in the faeces. The drop in hepatic bile acids causes the 
release of the feedback inhibitory mechanism of bile acid synthesis. A greater 
amount of cholesterol is then converted into bile acids to maintain a steady level 
in the gastrointestinal tract. Additionally, the synthesis of LDL-R is stimulated 
to allow increased hepatic cholesterol uptake, which leads to reduced plasma 
cholesterol levels. 
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Fibrates: gemfibrozil, fenofibrate, bezafibrate, may promote VLDL lowering, 
via activation of lipoprotein lipases. They also induce the diversion of hepatic 
free fatty acids from esterification to oxidation, thereby decreasing the liver's 
secretion of triglyceride-rich VLDL. Fibrates increase HDL cholesterol by 
about 10%. No consistent negative correlation between effects on HDL levels 
and coronary artery disease was evident when comparing several fibrate trials 
(125-127). This may be a reflection of the different study designs, e.g. use of 
different fibrates and populations studied. Fibrates regulate HDL metabolism 
as ligands and activators of the transcription factor PPARa. This factor binds 
to PPARa responsive elements which are found in several genes involved in 
HDL metabolism. Binding of PP ARa increases the transcription of apoAI and 
therefore increases the synthesis and turnover of HDL (128). 
Nicotinic acid (derivatives, like acipimox) reduce the plasma levels of both 
VLDL and LDL by lowering hepatic VLDL secretion. These drugs suppress 
the release of free fatty acids from adipose tissue by inhibiting lipolysis, 
thereby decreasing VLDL and LDL and more specifically the number of small 
dense LDL particles. Niacin also increases the HDL half-life by reducing its 
degradation. Niacin increases HDL by more than 20% (129). 
It is often not exactly known how HDL is increased by the lipid regulating 
drugs. The elevation of HDL is partly related to VLDL and LDL lowering 
which results in less CETP-mediated lipid transfer. In addition it is not always 
clear whether the contribution of the increase in HDL by these drugs has a 
direct effect on coronary events. Modulation of HDL metabolism to reduce 
the risk of atherosclerosis has just begun (130), but is an appealing subject for 
basic and clinical research. These HDL modulators will be introduced in the 
next section. 
2.6 REMODELING OF HDL BY PLASMA FACTORS 
HDL particles are continuously remodeled during their life span by factors 
that affect their size, structure and function and therefore their role in 
atherosclerosis (131). These factors include the enzymes hepatic lipase (HL), 
lipoprotein lipase (LPL), endothelial lipase (EL), LCAT, paraoxonase 1 (PON), 
platelet activating factor acetyl hydrolase (P AF-AH) as well as the lipid transfer 
proteins CETP and PLTP. The HDL remodeling proteins are annotated below. 
The properties of both lipid transfer proteins CETP and PLTP and their relation 
to atherosclerosis will be outlined in more detail in the next two chapters 
respectively. 
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HL is a lipolytic enzyme that is synthesized and secreted exclusively by the 
liver (132, 133). In steroid hormone synthesizing tissues a lipase activity similar 
to HL has been found. In rat adrenals and ovaries full-length HL mRNA could 
not be detected (134), suggesting that the enzyme is not locally synthesized 
and presumably originates from the liver and is subsequently transported 
to the steroid hormone synthesizing organs (134). However, HL activity is 
virtually undetectable in human and rat plasma. Thus, the origin of HL in the 
steroid hormone synthesizing organs is uncertain. HL in steroidogenic tissues 
stimulates the selective uptake of HDL cholesteryl esters via SRBI (135). HL 
may also act as a ligand for the removal of apoB-containing lipoproteins (136, 
137). HL functions as an acylglycerol hydrolase, hydrolyzing triglycerides in 
chylomicron remnants, IDL and HDL (138). In addition, HL functions as a 
phospholipase, converting phospholipid-rich HDL2 into HDL3 (60). The release 
of surface fragments during HL-mediated HDL remodeling may participate in 
the initial step of reverse cholesterol transport by generating pref3-HDL (139). 
It has not been unambiguously shown whether HL is anti or pro-atherogenic 
(140). 
LPL is a key player in hydrolysis of triglycerides in triglyceride-rich lipoprotein 
chylomicrons and VLDL (141). After lipolysis, surface phospholipids, 
cholesterol and apolipoproteins dissociate and are acquired by HDL. LPL is 
widely expressed in a variety of tissues (142). Transgenic overexpression of 
LPL in mice results in increased HDL <;:holesterollevels (143). Conversely, the 
mouse without genes coding for LPL has severe hypertriglyceridemia and very 
low HDL cholesterol levels (144). In humans, deficiency of LPL is associated 
with severe hypertriglyceridemia and very low LDL and HDL levels (145). 
EL is located in the vascular endothelial cells and its expression is highly 
regulated by cytokines and physical forces, suggesting that it may play a role 
in the development of atherosclerosis (146). In in vitro assays the enzyme is 
most active on lipids present in HDL, although it will release fatty acids from 
all classes of lipoproteins (147). Consistent with this finding, adenovirus-
mediated overexpression of EL in LDL-R knockout mice reduced plasma 
concentrations of VLDL and LDL cholesterol by about 50% whereas HDL 
cholesterol decreased to almost zero in these animals (148). Inhibition of EL in 
mice results in increased HDL cholesterol and apoAI levels (149). EL knockout 
mice have increased HDL phospholipids, HDL cholesterol and HDL-associated 
apolipoproteins. In addition, EL knockout mice have large HDL particles and 
absence of EL delays HDL clearance in vivo (61). 
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LCAT is a hydrophobic plasma enzyme which catalyzes the transfer of the sn-
2 acyl group from phosphatidylcholine to cholesterol, generating cholesteryl 
esters and lysophosphatidylcholine (16). This reaction occurs on the surface of 
HDL and accounts for the generation of cholesteryl esters in human plasma. 
LCAT converts discoidal HDL into spherical HDL. Plasma from patients with 
familial LCAT deficiency show abnormal lipoprotein levels with markedly 
reduced plasma HDL cholesterol (103). A minor part of HDL is disc shaped. 
LCAT deficiency syndromes are characterized by severe HDL deficiency. 
PON1 is one of the three genes of the paraoxonase family. The antioxidant 
activity of HDL is largely due to PONl. PON2 and PON3 may also have 
antioxidant properties, but are less well understood than PONl. PON1 is 
exclusively located on HDL. PON1 was initially identified for its ability 
to hydrolyze organophosphate pesticides, and is believed to inactivate 
phospholipid hydroperoxides formed during early events of LDL oxidation. 
The immunoreactivity of PON1 is increasingly present in the arterial wall 
as atheroma advances (150). There is no way at present of knowing whether 
this is part of a protective response, but a recent study has shown that PON1 
has the ability ex vivo to hydrolyse lipid peroxides within human carotid and 
coronary atheromatous lesions (151). 
PAF-AH plays a role in the degradation of pro-inflammatory oxidized 
phospholipids and in the formation of lysophosphatidylcholine and oxidized 
fatty acids (152). Oxidized phospholipids are formed during the oxidative 
modification of LDL and play key roles in several aspects of atherogenesis. 
Consequently, by degrading these phospholipids, PAF-AH could act as a 
potent anti-atherogenic enzyme. PAF-AH in humans is associated primarily 
with LDL (153). About 15% is found in the HDL range. In mice however, this 
enzyme is transported almost exclusively on HDL (154). Recently, it was shown 
that PON1 also exhibits PAF-AH activity. It was observed that PAF-AH protein 
is lacking in HDL, suggesting that the HDL-associated PAF-AH activity is due 
to PON1 (155). HDL-associated PAF-AH activity, although much lower than 
that in LDL, may contribute substantially to protection of LDL from oxidation 
and to the HDL-mediated inhibition of cell stimulation induced by oxidized 
LDL. 
2.6.1 liPID TRANSFER PROTEINS 
Both CETP and PLTP were shown to be important factors in the reverse 
cholesterol transport pathway by regulating the size and composition of HDL 
and are therefore implicated in the pathophysiology of atherosclerosis (36). 
Both lipid transfer protein activities have been measured in various vertebrate 
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species (156, 157). In contrast to CETP activity, PLTP activity could be detected 
in all species studied. This preservation of PLTP activity among the different 
species might indicate a fundamental role of PLTP in vivo. In a comparative 
studY" PLTP activity in rats and mice was higher when compared to humans 
(158). 
CETP and PLTPbelong to a gene family that also includes lipopolysaccharide-
binding protein and bactericidal/permeability-increasing protein that are 
involved in the binding of lipopolysaccharides (LPS) of the outer membrane 
of Gram-negative bacteria (159). Conservation of intron-exon organization of 
the corresponding genes suggests that they might be derived from a common 
ancestral gene. In addition, the conservation of charged amino acids in this 
gene family suggests that they are required for structural integriry, lipid 
binding, and transfer activity. On basis of the crystal structure of the related 
BPI, computational models of CETP (36) and PLTP were built (160). They 
appear as boomerang shaped molecules that exhibit two apolar lipid binding 
sites on their concave surface. However, in spite of structural homologies, 
significant differences exist in hydrophobicities of the C-terminal domains of 
CETP and PLTP that might account for the functional specificiry, whereas the 
N-terminal regions are strongly homologous. This observation suggests that 
the C-terminal region may carry the specific properties of CETP and PLTP. 
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3 CHOLESTERYL EsTER TRANSFER PROTEIN (CETP) 
3.1 CHARACTERISTICS AND FUNCTIONS OF CETP 
CETP is a hydrophobic glycoprotein with a molecular weight that varies from 
66 kDa to 7 4 kDa as determined by SDS PAGE analysis. This variation is due to 
four potential N-linked glycosylation sites. The human CETP gene exists in a 
single copy, comprising 16 exons and encompassing about 25 kbp of genomic 
DNA. CETP contains 476 amino acid residues and the gene has been localized 
to chromosome 16q12-16q21 near the LCAT locus (161). 
CETP is mainly associated with small HDL particles (162) and facilitates the 
transfer of cholesteryl esters from HDL to triglyceride-rich particles (VLDL, 
LDL and chylomicrons ), partially in exchange for triglycerides. In vitro 
experiments showed that CETP is responsible for all plasma cholesteryl ester 
and triglyceride transfers, and for about one third of the plasma phospholipid 
transfer activity (163). The remaining of the phospholipid transfer activity 
is mediated by PLTP. However, in vivo experiments showed that there is no 
redundancy in the function of CETP and PLTP. This was based on the transfer 
of 3H-phosphatidylcholine from VLDL into HDL with plasma samples of 
mice transgenic for human CETP (huCETPtg) compared with huCETPtg 
mice in a PLTP knockout background (huCETPtg/PLTP KO). In plasma 
from huCETPtg mice there was a rapid transfer of a substantial portion of 
phosphatidylcholine radioactivity, in contrast to huCETPtg/PLTP KO mice in 
which the phosphatidylcholine transfer was absent, indicating that PLTP is 
responsible for all phospholipid transfer (164). 
One consequence of the CETP-mediated transfer of cholesteryl esters and 
triglycerides between lipoproteins is a reduction in cholesterol content and 
the size of HDL (130). The magnitude of the net flux of cholesteryl esters and 
triglycerides between lipoproteins is dependent on the sizes of the VLDL, LDL 
and HDL pools (165). 
Thus, CETP is responsible for neutral lipid exchange activity in plasma and 
can play a determinant role in the process of HDL remodeling. 
3.2 CETP ACTIVITY IN HUMANS 
It has been demonstrated that variation in CETP mass and/or activity is closely 
associated with lipoprotein phenotype, and notably with HDL cholesterol 
levels (166). Plasma CETP levels are about 2 f-Lg/ml in normolipidemic subjects 
(167). Under normal conditions, CETP-mediated transfer of HDL cholesteryl 
esters is directed preferentially to LDL. 
Various missense, nonsense and splicing mutations causing CETP deficiency in 
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plasma have been reported in humans (36, 168, 169). Taq1B is the best studied 
restriction fragment length polymorphism, for which over 10.000 individuals 
have been genotyped and HDL levels determined. Many of the restriction 
fragment length polymorphism studies demonstrate an association between 
the CETP single-nucleotide polymorphism and changes in plasma CETP 
and HDL levels. However, the relation between these polymorphisms and 
susceptibility to atherosclerosis is variable (169-172), which could be caused 
by a multiplicity of factors such as life style and environmental influences 
(173, 174). 
CETP activity measured by cholesteryl ester transfer from HDL to VLDL and 
LDL was shown to be higher in patients with familial hypercholesterolemia 
(175), and type 2 diabetes (176, 177). In patients with type 2 diabetes and 
hypertriglyceridemia, HDL cholesteryl esters are preferentially transferred by 
CETP to large VLDL particles that become richer in cholesterol and thus, more 
atherogenic (178). However, in type 1 diabetics without complications, CETP 
activity was not increased compared with the non-diabetic control group 
(176). 
In morbidly obese, middle-aged, female subjects it has been shown that weight 
loss is associated with a pronounced decrease in CETP mass and activity (179). 
Exercise training effectively reduces the plasma concentration CETP in a 
population of normolipidemic subjects (180). The CETP change was observed 
both in subjects who lost weight and in those who were weight stable. In line 
with these observations, lower plasma CETP mass (181) and CETP activity 
(182) were measured in a group of marathon runners during training periods. 
Male runners also had significantly lower apoB-containing lipoproteins, and 
significantly higher concentrations of HDL and apoAI than male controls 
(182). 
3.3 REGULATION OF CETP GENE EXPRESSION 
In humans CETP mRNA is widely expressed, with the highest level found 
in the liver, spleen and adipose tissue (183). In addition, an isoform of CETP 
mRNA exists in all human tissues. Its proportion ranges from 20 to 50% of 
total CETP mRNA among the various tissues (184). Transfection studies 
showed that expression of the alternatively spliced mRNA leads to a protein 
that is poorly secreted (185), which was confirmed with studies in transgenic 
mice which in addition showed no alteration in their lipopoprotein profile 
compared with control mice (186). 
Control of the expression of the CETP gene constitutes a major component in 
the regulation of plasma CETP mass in humans (187, 188). Dietary cholesterol 
is a major factor which influences CETP gene expression (189). Mice which 
33 
Chapter I 
are transgenic for human CETP with its natural promoter showed a marked 
increase in CETP mRNA and protein in response to a high-fat, high-cholesterol 
diet, whereas the same transgene under control of the mouse metallothionein 
promoter did not exhibit a significant change in CETP mRNA or protein in 
response to an atherogenic diet (190). Thus, the sequences necessary for the 
increment of CETP mRNA in response to dietary cholesterol are located in the 
natural flanking regions. This region was further examined by using transgenic 
mice expressing constructs that contain different lengths of natural flanking 
sequence of the CETP gene (191). Deletion of the downstream sequences 
showed no change in the response of the transgene to dietary cholesterol, 
whereas deletion of upstream sequences indicate that the region between -
138 to -370 bp upstream of the transcription site contains elements responsive 
to sterols (191). This region has a tandem repeat of a sequence with identity 
to the sterol regulatory element (SRE) in the HMG-CoA reductase promoter 
responsible for the sterol-mediated regulation of the HMG-CoA reductase 
gene. Gel shift assays showed that this element binds SRE binding protein 
(SREBP1) (192) and Red25 (193) which was identical to the transcription factor 
Yin Yang-1 (YY-1). By using CETP transgenic mice with point mutations in the 
SRE-like element, Chouinard et al. showed that SREBP1 activates the CETP 
gene in vivo (194). 
It has been shown that plasma CETP levels and hepatic CETP mRNA are also 
markedly increased in response to endogenous hypercholesterolemia in mice 
with a deficiency in LDL-R or apoE (189, 195). This is due to an enhanced 
transcription of the CETP gene in the liver and some peripheral tissues. 
Because plasma cholesterol levels are positively correlated with plasma CETP 
in huCETPtg mice as well as in humans, it has been speculated that CETP gene 
expression is driven by a mechanism which senses high levels of cholesterol 
independent of a poE and LDL-R (196). Another study revealed that the positive 
sterol response of the human CETP gene is mediated by a nuclear hormone 
receptor DR-4 element (i.e., with a spacing of 4 nucleotides between 2 direct 
repeats) (197). This element is activated by the orphan nuclear receptor liver X 
activated-receptor (LXR), which acts as a heterodimer with retinoid X receptor 
a (RXRa). LXR has been shown to mediate the upregulation of the cholesterol 
7a-hydroxylase (Cyp7a) promoter by dietary cholesteroL Cyp7a is the first 
rate-limiting enzyme in the pathway converting cholesterol into bile (198). 
Taken together, LXR may coordinate the regulation of HDL cholesteryl ester 
catabolism and bile acid synthesis in the liver. It has been demonstrated that 
nuclear receptor LRH-1 also transactivates the CETP promoter by binding to a 
proximal promoter element distinct from the DR-4 site (199). 
In normolipidemic subjects, the percentual decrease in CETP activity induced 
by a monounsaturated fatty acid diet was higher than that induced by a 
polyunsaturated fatty acid diet (200). In HepG2 cells it has been demonstrated 
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that the degree of unsaturation of the acyl carbon chain in fatty acids regulate 
the gene expression of CETP (201). 
It has also been shown that CETP expression is decreased following LPS 
administration in huCETPtg mice (202). Furthermore, transfection studies 
in HepG2 cells have shown that several regulatory elements in the CETP 
promoter are involved. These include: the CCAAT/enhancer binding protein 
(203), which may preserve the CETP gene promoter activity; the orphan nuclear 
hormone receptor apoAI regulatory protein1 (204), which was shown to play a 
dual role, i.e. it can act both as a transcriptional repressor and a transcriptional 
activator, and recently it has been shown that the nuclear transcription factor 
Sp1/Sp3 ratio is a critical factor in regulating CETP expression (205). 
3.4 ROLE OF CETP IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN ANIMAL MODELS 
Because mice and rats by nature are deficient in CE~ CETP transgenic mice 
and rats have provided models for the assessment of CETP expression on 
lipoprotein metabolism and atherosclerosis (Table 3). 
Introduction of the human CETP gene into mice results in a dose-related 
reduction in HDL levels and a small increase in VLDL and LDL cholesterol 
levels (190, 206). Transgenic mice expressing human CETP under the control of 
the mouse metallothionein promoter showed a 1.4 to 1.6-fold increase in plasma 
CETP concentration with concomitantly increased CETP activity levels after 
zinc induction (190). In addition, these mice showed a reduction in cholesterol 
levels due to a 20-30% decrease in serum HDL cholesterol concentration and 
HDL particle size (190). 
Transgenic mice expressing cynomolgus monkey CETP driven by the 
mouse metallothionein promoter develop severe atherosclerosis (207). 
These cynomolgus monkey CETP transgenic mice showed the same trend in 
lipoprotein changes compared to those of human CETP transgenic mice (208). 
In line with these results, an inverse correlation between CETP concentration, 
total cholesterol and HDL levels has been demonstrated in a series of mice 
overexpressing the human CETP gene to various levels driven by the human 
~-actin promoter (209). 
Enhanced atherosclerosis was observed in human CETP transgenic mice with 
apoE knockout (apoE KO) and apoE KO/apoAI transgenic backgrounds fed a 
chow diet, and in a LDL-Rknockout background fed a high-fat, high-cholesterol 
diet (210). CETP expression in these mouse models redistributed cholesterol 
from HDL to the VLDL/LDL pool. The atherogenicity of CETP overexpression 
was also demonstrated in transgenic Dahl salt-sensitive hypertensive rats 
expressing human CETP, which show spontaneous atherosclerosis, combined 
hyperlipidemia and decreased survival (211). 
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Rabbits have a high level of plasma CETP. Studies in these animals also 
demonstrated that CETP has pro-atherogenic properties: 1) CETP anti-sense 
oligodeoxynucleotide injections in rabbits resulted in reduced aortic cholesterol 
content (212). 2) Immunizing of these rabbits against their own CETP resulted 
in reduced activity of CETP, increased HDL cholesterol levels, decreased LDL 
cholesterol levels and protection against diet induced atherosclerosis (213). 3) 
Finally, a CETP inhibitor JTT-705 has been proven to increase HDL cholesterol, 
decrease non-HDL cholesterol and inhibit the progression of atherosclerosis 
in rabbits (54). Interestingly, a 4-week treatment with this CETP inhibitor, at 
a dose of 900 mg!day, in healthy volunteers led to a decrease in CETP activity 
(-37%), a large increase in HDL cholesterol (34%) and a decrease in LDL 
cholesterol (-7%) (53). 
In summary, all these results show that CETP may be atherogenic, possibly by 
reducing the concentration of HDL and redistributing cholesterylesters from 
HDL to apoB-containing lipoproteins. 
The expression of CETPhas also been reported to be anti-atherogenic rather than 
pro-atherogenic. For instance, mice engineered to overexpress human LCAT 
have an increase in plasma HDL levels, but paradoxically also an increased 
susceptibility to atherosclerosis (214). When simian CETP is expressed in 
these animals, a reduction of atherosclerosis is observed (215). HDL which 
accumulate in the LCAT transgenic mice are enriched in cholesteryl esters, 
and in the absence of CETP, may become dysfunctional in terms of their ability 
to promote cell cholesterol efflux. If so, CETP expression leads to the transfer 
of excess cholesteryl esters out of HDL, thereby restoring their efficiency as 
acceptors of cholesterol and decreasing atherosclerosis development. Another 
example of an anti-atherogenic effect of CETP is demonstrated in mice 
transgenic for human apoCIII and in mice transgenic for both human apoCIII 
and human apoAI, which have high levels of triglyceride rich lipoprotein 
remnants and develop atherosclerosis. Introduction and expression of the 
human CETP gene into these mice reduces the extent of atherosclerosis (216). 
An increase in reverse cholesterol transport may provide an anti-atherogenic 
balance to the remnant particles and hence reduce atherosclerosis. 
The results from these animal studies reflect the complexity of CETP function 
in lipoprotein metabolism. It is still uncertain whether high HDL levels induced 
either by genetic deficiency of CETP or by therapeutic inhibition of CETP 
would be beneficial or not (165). Controlled clinical trials on CETP inhibition 
are necessary to answer this question. 
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Table 3. CETP transgenic animals. 
mouse metallothionein human minigene WT HDLt 190 
mouse metallothionein cynomolgus monkey eDNA WT VLDLj, HDL! increased 207 
mouse metallothionein cynomolgus monkey eDNA WT apoBj, apoAit - 208 
human 13-actin human eDNA WT HDLt 209 
natural flanking regions human minigene apoEKO HDLt increased 210 
natural flanking regions human minigene apoE KO/hu-apoAI HDLt increased 210 
natural flanking regions human minigene LDL-RKO HDLt increased 210 
apoCIII human eDNA Dahl S rat~ HDLt increased 211 
mouse metallothionein cynomolgus monkey eDNA hu-LCAT HDLt decreased 215 
mouse metallothionein human minigene hu-apoCIII HDLt decreased 216 
mouse metallothionein human minigene hu-apoCIII/hu-apoAI HDL! decreased 216 
WT, wild-type; hu-, human transgene; *determined by quantifying aortic lesion areas; 
**transgenic rat 
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4 PHOSPHOLIPID TRANSFER PROTEIN (PLTP) 
4.1 CHARACTERISTICS OF PLTP 
PLTP shares structural and functional characteristics with CETP (36). The 
human PLTP gene is located in chromosome 20q12-q13, spans approximately 
13.3 kb and comprises 16 exons (217). The second exon encodes for the entire 
signal sequence as well as 16 amino acids of the mature protein. The PLTP 
gene overlaps with the gene for human protective protein (218) but the two 
genes are not cooperatively regulated because they are located on opposite 
DNA-strands (219). The murine PLTP gene is located on chromosome 2 (220) 
and shows perfect exon/intron conjunction conservation with the human gene 
(221). 
The reported human PLTP eDNA is 1750 bp in length with an open reading 
frame of 1518 nucleotides, which encodes a signal sequence of 17 amino acids 
and a mature protein of 476 residues (159). A large part of these residues are 
hydrophobic giving PLTP its special character. PLTP has a predicted molecular 
weight of 55 kDa, but due to glycosylation the mature PLTP circulating in 
blood has a mass of approximately 81 kDa (222). Human PLTP contains 
four cysteine residues and six potential N-glycosylation sites. Site-directed 
mutagenesis and cell culture studies revealed that the cysteine residues 146 
and 185 form a disulphide bridge in PLTP which is necessary for the correct 
folding and secretion of the protein (160). 
The amino acid sequences of PLTP from different species show a high degree 
of homology e.g. mouse PLTP is 83% and pig PLTP is 93% identical to the 
human sequence (223-225), suggesting that PLTP plays a crucial role in vivo. 
PLTP activity is associated with the HDL fraction in human plasma (162). 
Human PLTP expressed in transgenic mice is also associated with HDL 
particles (226, 227). It has been demonstrated that PLTP is associated with 
apoAI and apoAII (228). 
4.2 FUNCTIONS OF PLTP 
Although phospholipids are transferred spontaneously between lipoproteins, 
the process is too slow to be of physiological importance (229). Several studies 
have shown that PLTP facilitates the transfer and exchange of phospholipids 
but not neutral lipids (230-232). PLTP is unable to discriminate between 
positional isomers (233, 234). The electrostatic charge oflipoproteins influences 
the PLTP-mediated phospholipid transfer process (235). 
During LPL-mediated hydrolysis of triglycerides from the cores of 
chylomicrons and VLDL particles, surface remnants containing phospholipids 
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are released. PLTP circulates bound to HDL and mediates the net transfer of 
these phospholipids into HDL (236, 237). The physiological importance of 
PLTP in vivo was demonstrated in PLTP knockout mice, which· show a total 
absence of transfer of phospholipids in plasma. Using this mouse model, it 
was demonstrated that PLTP facilitates the transfer of phospholipids from 
VLDL to HDL upon triglyceride-rich lipoprotein lipolysis (238). In these mice 
compositional analysis indicated that the HDL was enriched in protein, and 
specifically depleted in phosphatidylcholine. These changes presumably 
reflect the defect in the transfer of phosphatidylcholine from triglyceride-
rich lipoproteins into HDL in plasma from PLTP knockout mice compared to 
plasma from wild-type mice (239). 
Although CETP is also able to transfer phospholipids, only PLTP was shown 
to promote the transfer of phospholipids from phosphatidylcholine liposomes 
to HDL (162, 230, 237). It is concluded that only PLTP is responsible for the net 
mass transfer of phospholipids from triglyceride-rich lipoproteins towards 
HDL. This was confirmed with in vivo studies using the PLTP knockout 
model, in which CETP expression could not compensate for PLTP deficiency. 
Assays determining radiolabeled phosphatidylcholine transfer from vesicles 
to HDL in vitro and from VLDL to HDL in vivo, showed that phospholipids 
transfer activity was absent in either PLTP knockout (PLTP KO) or in PLTP 
KO/huCETPtg mice (164). 
Besides transferring phospholipids, PLTP is also able to transfer other lipophilic 
substances of which cholesterol, a-tocopherol and LPS are of most interest 
with respect to lipoprotein metabolism and atherosclerosis. 
a-tocopherol is the most potent anti-oxidant form of vitamin E and may 
prevent the oxidative damage of atherogenic lipoproteins. In human serum 
PLTP catalyzed exchange of a-tocopherol between different lipoproteins (240). 
Desrumeaux et al. demonstrated that PLTP accelerates the spontaneous transfer 
of a-tocopherol between lipoproteins and endothelial cells (235). Studies with 
rabbit aortic segments showed that PLTP,. in combination with a-tocopherol-
albumin complexes, is able to counteract the harmful effect of oxidized LDL. 
It was suggested that the PLTP-mediated a-tocopherol transfer may be anti-
atherogenic by providing LDL with antioxidants and by preserving normal 
endothelial cells. In contrast, PTLP knockout mice were protected against 
atherosclerosis, presumably due to accumulation of vitamin E in VLDL and/ 
or LDL (241). It has been shown that adenoviral overexpression of murine 
PLTP in apoE knockout mice increases the oxidizability of LDL and increases 
atherosclerosis. A PLTP induced decrease in vitamin E content of VLDL and 
LDL could contribute to atherogenesis (242). 
PLTP also transfers LPS which could have consequences in vivo. LPS is a 
membrane lipid of Gram-negative bacteria able to evoke inflammatory 
responses. Incubation of LPS with purified recombinant PLTP resulted in the 
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inhibition of the ability of LPS to stimulate adhesive responses of neutrophils, 
and addition of recombinant PLTP to blood impaired cytokine production in 
response to LPS (243). 
Next to the transfer of lipophilic components, PLTP is able to promote the 
conversion of HDL into larger and smaller particles, thereby generating pre~­
HDL. HDL conversion has been studied in vitro and in vivo. PLTP purified 
from plasma converts isolated HDL3 into both larger and smaller populations (244). This activity is accompanied by the release of apoAI and is inhibited 
by polyclonal rabbit anti-PLTP antibodies (232). Similar observations have 
been made with PLTP from pigs or mice (224, 245). The conversion process 
is dependent on both time and PLTP concentration. The mechanism of 
HDL conversion has been addressed in several studies which all conclude 
that particle fusion accounts for the observed HDL conversion (233, 246, 
247). Enrichment of HDL with triglycerides enhances the rate of conversion 
(247, 248). When human plasma is incubated in the presence of PLTP, the 
amount of immuno-detectable pre~-HDL can be increased. This may be of 
physiological importance, because pre~-HDL was proposed to be the primary 
acceptor of cellular cholesterol (249), and thus may play a role in cholesterol 
efflux from cells. PLTP has been shown to enhance the removal of cholesterol 
and phospholipids from cholesterol loaded cells (250). This is probably by 
interaction withABCA1 (251 ). Oram et al. suggested that PLTP removes cellular 
lipids by the ABCA1 pathway and acts as an intermediary in the transfer of 
cellular lipids to lipoprotein particles (252). Phospholipid transfer activity is 
also positively correlated with cholesterol efflux from Fu5AH hepatoma cells 
(253) and macrophages (227). 
4.3 PLTP AcTIVITY IN HuMANS 
PLTP activity can be measured by different methods, which may explain the 
variable PLTP activity levels observed in healthy subjects from several studies 
(176, 254, 255). The physiological roles of PLTP in lipoprotein metabolism and 
the development of atherosclerosis are still far from resolved (256). Until today, 
no PLTP deficiency has been found in humans. In the immediate vicinity of the 
PLTP gene six intragenic and two neutral polymorphisms were determined, 
but showed no associations with serum PLTP activity (257). 
Several reports described studies on the relationship between PLTP mass and 
PLTP activity (254, 255, 258). A study by Oka et al. used a double monoclonal 
sandwich ELISA system for detection of PLTPmass and reported no correlation 
between PLTP mass and activity in a group of 132 Japanese subjects (258). This 
is caused by the presence of inactive PLTP which is approximately 70% of the 
total PLTP protein in human plasma (259). However, PLTP mass measurement 
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is dependent on the antibody used (260). Based on these results Karkldiinen 
et al. suggest a model in which nascent PLTP enters the circulation as a high 
specific activity form not associated with apoAI (259, 261). During or after the 
transfer of lipolytic surface remnants to HDL, PLTP is transferred to apoAI 
containing HDL particles and thereby becomes part of the low activity complex 
(259, 261). No function of inactive PLTP has been described at present. 
Various habits, such as consumption of coffee, alcohol or fat and smoking, 
may affect plasma PLTP activity. Unfiltered coffee contains the diterpenes 
cafestol and kahweol, which induce a more atherogenic lipoprotein profile 
by increasing VLDL and LDL cholesterol and lowering HDL cholesterol. 
These changes in lipoprotein profile coincided with increased plasma PLTP 
activity (262). In addition, it has been shown that a long-term consumption 
of unfiltered coffee causes an increase in PLTP activity in a group of healthy 
normolipidaemic subjects (263). In male alcohol abusers plasma PLTP activity 
was increased by 33% compared to controls (264). This result is in agreement 
with a French study, in which alcoholic patients on a cessation program 
show a decrease in HDL cholesterol levels and a reduction in plasma PLTP 
activity (265). However, moderate alcohol intake does not affect plasma PLTP 
activity despite increased HDL levels (266). PLTP activity levels have also 
been studied in healthy human subjects upon the intake of experimental diet 
containing stearic or trans fatty acids (267). These were compared with PLTP 
activity levels measured in subjects on a dairy fat-based baseline diet. Minor 
changes in PLTP activity between the trans fatty acid group and the stearic 
acid group were observed, which did not correlate with the decrease in HDL 
cholesterol observed in both groups. Another diet study in normolipidemic 
subjects showed that PLTP activity was higher in subjects fed a lauric acid 
diet than in those fed a palmitic acid diet. In addition, there was no difference 
in PLTP activity when comparing the saturated diets with an oleic acid diet 
(268). Cigarette smoking is associated with insulin resistance an atherogenic 
lipoprotein profile. In normolipidemic cigarette smoking men PLTP activity 
was 8% higher compared with non-smokers (269). Another study showed 
no differences in fasting PLTP activity levels in smokers and controls, but 
postprandially, PLTP activity was decreased in smokers (270). 
PLTP activity has also been measured in different human pathological 
settings, which are closely related to dyslipidemia and atherosclerosis, such as 
obesity and diabetes. PLTP activity was shown to correlate positively with age 
(257, 271), body mass index, plasma cholesterol and triglyceride levels (257). 
In familial combined hyperlipidemia, affected family members frequently 
have reduced levels of HDL cholesterol in addition to elevated levels of total 
cholesterol and triglycerides. PLTP activity measured in affected family 
members is only slightly higher than in· unaffected family members (272). 
PLTP activity is elevated in obese individuals (273-276) while it decreases 
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with weight loss (277). Increased PLTP activity has been associated with 
diabetes mellitus. In plasma from patients with type 1 diabetes PLTP activity 
is substantially increased and related with altered HDL subclass distribution. 
In addition, PLTP activity was positively associated with apoB-containing 
lipoproteins in these patients (176, 278). Plasma PLTP activity is also increased 
in patients with type 2 diabetes (177). Administration of insulin or Acipimox, 
a nicotinic acid drug, both decreased plasma PLTP activity in type 2 diabetics 
(279). Furthermore, increased plasma PLTP activity could also be observed in 
normolipidemic patients with peripheral vascular disease (280). 
Recently, a relationship between PLTP activity and coronary artery disease 
was established in an angiographic case control study with 1102 cases and 
444 controls. Using multivariate logistic regression analysis, PLTP activity 
was found to be related to coronary artery disease after adjusting for age, 
plasma lipids, smoking, diabetes, hypertension, homocystein and C-reactive 
protein. Patients within the highest quintile of PLTP activity revealed a 1.9-
fold increase in risk for coronary artery disease compared with patients within 
the lowest quintile (281). The findings suggest that PLTP is a novel risk factor 
for atherosclerosis and may be considered as a therapeutic target. However, 
better standardized and validated methods for measuring PLTP activity and 
PLTP mass are necessary to unravel the role of PLTP in atherosclerosis. 
4.4 REGULATION OF PLTP GENE EXPRESSION 
The m.RNA of PLTP is widely expressed in a variety of tissues. Differences 
in the mRNA levels in various tissues suggest that PLTP may also have 
local tissue specific functions. For instance, it has been speculated that the 
high PLTP expression in the lungs plays a role in regulating the alveolar 
surfactant metabolism (282), but the lungs in PLTP knockout mice showed no 
abnormalities. An increase in PLTP expression in the brain of patients with 
Alzheimer disease possibly indicate that PLTP has a specific function in brain 
lipid and lipoprotein metabolism (283). It has been demonstrated that PLTP 
is highly expressed by macrophages within human atherosclerotic lesions 
(284, 285), suggesting a potential role in lipid-loaded macrophages. Taking 
into account the mass of tissues, the liver and adipose tissue probably are the 
major sites for plasma PLTP production in humans (36). 
PLTP expression is regulated at the transcriptional leveL Characterization of 
the promoter region of the PLTP gene showed that it consists of a TATA box, a 
high GC region, and several consensus sequences for the potential binding of 
transcription factors (286). Both promoters of the human and mouse PLTP genes 
show five consensus sequences for the binding sites for transcription factors 
Sp1 and AP2 that have been shown to be necessary for PLTP transcription, 
42 
General introduction 
residing between -245 and -69 in the murine PLTP gene (287). The fact that 
these binding sites are highly conserved and essential for transcription for 
both human and murine PLTP genes, indicate that the transcription of the 
PLTP gene in mouse and human is regulated by similar mechanisms. 
Analysis of PLTP promoter activity by using cultured cells and transfection 
experiments revealed that there is no strong homology to known steroid 
response elements (221), but contains reponse elements for non-steroidal 
receptors such as farnesoid X- activated receptors (FXR), peroxisome 
proliferator activated receptor a (PPARa) and liver X-activated receptors 
(LXR). These nuclear receptors bind DNA as heterodimers with the obligate 
partner 9-cis retinoic acid receptor a (RXRa), which subsequently bind to the 
hormone response elements of the PLTP in order to initiate the transcription 
of PLTP. Urizar et al. reported that the PLTP promoter is responsive to FXR. 
They used CV-1 cells, showing that the human PLTP promoter is sensitive 
through an FXR-dependent mechanism by administrating chenodeoxycholic 
acid, a bile acid which is a ligand for FXR. When C57BL6 mice were fed a chow 
diet supplemented with bile acid, the increase in hepatic PLTP mRNA levels 
increased 1.6-fold (288). This effect was lost in FXR-knockout animals (289). 
The sensitivity for the transcription of PLTP by an FXR-dependent mechanism 
was also observed by using HepG2 cells (287). DNA sequence analysis suggests 
that DNA sequences in the mouse from -407 to -395 and from -393 to -381 
are homologous to the recognition motifs of FXR. In addition, Tu et al. found 
that DNA sequences in the mouse from -859 to -847 and from -309 to -279 
are similar to the potential recognition motifs for PPARa. The lipid lowering 
drug fenofibrate is a ligand for PPARa. Mice transgenic for human apoAI fed 
fenofibrate showed increased PLTP activity (up to 3-fold) and increased hepatic 
mRNA expression in a dose dependent manner. Concomitantly, HDL size was 
increased and the presence of human apoAI augments this phenomenon. This 
increase in HDL size is abolished in PLTP knockout mice. The induction of 
PLTP mRNA and activity was reduced in PPARa -knockout animals (290). 
Thus after fenofibrate feeding, upregulated PLTP activity through PPARa 
may contribute to HDL enlargement. 
Mak et al. demonstrated that PLTP mRNA was induced 6-fold as quantified by 
Affymetrix GeneChip® analysis or Northern blot assays when either murine 
or human macrophages were incubated in the presence of ligands for LXR 
and RXR (291). Although both the human and murine PLTP promoter region 
do not contain a typical LXR-responsive element (DR4), the administration 
of an LXR agonist in mice up-regulated PLTP mRNA and activity in a dose 
dependent fashion (292). Mouse macrophages treated with the synthetic LXR 
ligands T0901317 or GW3965, or treated with oxysterols, which are thought to 
be endogenous ligands for LXR, also induced PLTP mRNA (285, 292), which 
implies that PLTP can be regulated by LXR agonists. 
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4.5 MousE MooELs FOR PLTP RESEARCH 
Although in vitro studies suggest that PLTP influences HDL size, composition 
and transfers phospholipids between the different lipoproteins classes, its 
physiological role in vivo is poorly understood. To study its function, several 
animal models have been generated. These models include knockout and 
transgenic models (Table 4). 
4.5.1 PLTP KNOCKOUT MICE 
To evaluate the in vivo role of PLTP, a mouse model without PLTP expression 
(PLTP KO) was generated by gene targeting (239). In plasma from these mice 
the transfer of all major plasma phospholipids classes from VLDL to HDL 
was completely blocked. On a chow diet, plasma cholesterol was markedly 
decreased (-65%), as well as HDL phospholipids (-60%) and apoAI (-85%), but 
there was no change in VLDL/LDL levels compared with control mice. On 
a high- fat, high-cholesterol diet, the HDL levels were similarly decreased, 
in contrast to VLDL/LDL phospholipids which were significantly increased 
(+210%), as well as free cholesterol (+60%) without change in apoB levels, 
suggesting an accumulation of surface components from VLDL/LDL (239). 
Turnover studies in these knockout mice, using autologous HDL, revealed a 
4-fold increase in catabolism of HDL protein and cholesteryl esters compared 
with control mice, whereas there were minor differences in synthesis rates 
of apoAI (238). Thus, the impairment of phospholipid transfer from apoB-
containing lipoproteins into HDL could lead to hypoalphalipoproteinemia 
characterized by hypercatabolism of HDL protein. These data suggest that 
PLTP may be crucial for HDL maturation. 
The involvement of PLTP in atherosclerosis and VLDL synthesis was 
demonstrated in PLTP knockout mice crossbred into various hyperlipidemic 
strains with increased susceptibility to atherosclerosis (293). In mice with 
apoB transgenic and apoE knockout backgrounds, PLTP deficiency resulted 
in reduced production of apoB-containing lipoproteins and a markedly 
decrease in atherosclerosis. The decrease of VLDL synthesis provided an 
explanation for the decrease found in atherosclerosis in these PLTP deficient 
mice with apoB transgenic or apoE knockout backgrounds compared with 
control mice. In vitro experiments with hepatocytes from PLTP knockout 
mice also revealed the defect in VLDL secretion, which was corrected when 
PLTP was reintroduced by adenovirus. Another explanation for the decreased 
susceptibility to atherosclerosis of PLTP KO mice may rely on the increased 
in a-tocopherol (vitamin E) content in VLDL and LDL compared to wild-type 
mice. Vitamin E is one of the substrates of PLTP and is believed to protect 
VLDL/LDL against oxidation which can trigger atherosclerosis (241). 
44 
General introduction 
4.5.2 MICE OVEREXPRESSING PLTP 
Albers et al. generated PLTP transgenic mice which showed no significant 
difference in PLTP activity compared with non-transgenic mice (226). 
Although small differences in HDL cholesterol were found, the physiological 
relevance of these differences is uncertain. Jiang et al. generated human 
PLTP transgenic mice which showed an increase of 29% in PLTP activity, but 
analysis of plasma lipoproteins revealed no marked changes in their lipid or 
apolipoprotein content compared with non-transgenic mice (219). However, 
when these transgenic mice were crossbred with mice transgenic for human 
apoAI, PLTP activity was increased by about 47% (219). Concomitantly there 
was an increase in HDL phospholipids (+26%), apoAI levels (+22%) and pref3-
HDL formation (+56%). These large HDL are not functioning in prevention 
of cellular cholesterol accumulation, probably due to their limited capacity 
to stimulate cholesterol efflux. Van Haperen et al. generated transgenic mice 
expressing higher levels of human PLTP showing a 2.5 to 4.5 fold increase 
compared with wild-type mice, resulting in a 30 to 40% decrease in plasma 
HDL cholesterol and apoAI (227). In addition, it has also been determined that 
plasma from huPLTPtg mice was more efficient in preventing accumulation of 
intracellular cholesterol in macrophages (227). Despite the lower total plasma 
HDL concentration, plasma from huPLTPtg mice had increased potential for 
pref3-HDL formation. Jiang et al. also found increased pref3-HDL formation 
(219). These data suggested an anti-atherogenic role for PLTP, as pref3-HDL is 
considered a very efficient acceptor during efflux of cellular cholesterol (30). 
Besides PLTP, the other lipid transfer protein, CETP, has also been implicated 
in the formation of pref3-HDL (294, 295) as outlined in this thesis. We compared 
the ability of PLTP and CETP to generate pref3-HDL (296). PLTP rather than 
CETP is responsible for the generation of pref3-HDL. In plasma from PLTP 
overexpressing mice the formation of pref3-HDL was 3-fold higher compared 
with plasma from control and CETP transgenic mice, indicating that PLTP 
may play a role in the initial stage of reverse cholesterol transport. 
The same trend was found in earlier studies employing adenoviral 
overexpression of human PLTP (297, 298). Foger et al. showed that low and 
high dose adenoviral expression of PLTP resulted in an increase in PLTP 
activity (13 and 40-fold) leading to decreased HDL cholesterol (-54% and -
91%) and apoAI ( -64% and -98%) levels in mouse plasma. These mice were 
characterized by the increased formation of pref3-HDL levels, but decreased a-
HDL due to an increased fractional catabolic rate of HDL and enhanced HDL 
hepatic uptake compared with control mice (298). This suggests that PLTP 
may have a stimulating role in reverse cholesterol transport in vivo. Moreover, 
Post et al. found that PLTP overexpression results in enhanced disposal of 
cholesterol from the body via increased bile acid excretion (299). 
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However, in a series of transgenic mice with increasing PLTP expression, 
a dose-dependent relation with a reduction in plasma HDL levels and an 
increased susceptibility to diet-induced atherosclerosis was found, indicating 
a potential pro-atherogenic role for PLTP (300, 301). In addition, elevation of 
PLTP in transgenic mice increases VLDL secretion as outlined in this thesis 
(302).The potential pro-atherogenic role for PLTP is in line with the findings 
from atherosclerosis studies in PLTP knockout mice, and in apoE knockout 
mice with adenoviral overexpression of mouse PLTP which respectively 
showed decreased and increased atherosclerotic lesion areas (241, 242). 
Table 4. PLTP mouse models. 
KO WT HDL! - 239 
KO hu-apoB HDL!. apoB~ decreased 293 
KO apoE KO apoBL decreased 293 
KO LDL-RKO HDL! decreased 293 
natural flanking regions human gene WT HDUnon-HDL 1' - 226 
natural flanking regions human gene WT no change -- 219 
natural flanking regions human gene hu-apoAI HDLI - 219 
natural flanking regions human gene WT Tq,apoAI! - 227 
natural flanking regions human gene hu-CETP HDL! - 296 
natural flanking regions human gene WT apoAI! - 300 
natural flanking regions human gene LDL-R+/- HDL! increased 300 
mouse albumin human gene WT apoAI! - 300 
mouse albumin human gene LDL-R+/- HDL! increased 300 
natural flanking regions human gene hu-CETP/LDL-R+/- Tq, VLDL!, HDL! increased 301 
mouse albumin human gene hu-CETP/LDL-R+/- TC!, VLDL!, HDL! increased 301 
CMV human eDNA** WT HDL! - 297 
CMV human eDNA** WT HDL! - 298 
mouse albumin mouse eDNA** apoE KO HDL~ increased 242 
KO, knockout; WT, wild-type; hu-, human transgene; *determined by quantifying aortic lesion 
areas; **adenovirus mediated. 
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5 OUTLINE OF THE THESIS 
PLTP is an important regulator of HDL and lipoprotein metabolism. The exact 
role of PLTP in HDL and lipoprotein metabolism is far from resolved. Aim 
of the performed studies described in this thesis was to answer the question 
whether PLTP is anti- or pro-atherogenic, and thus to clarify the role of PLTP 
in HDL metabolism and in the development of atherosclerosis by using 
genetically modified mouse models. 
One of the mechanisms by which HDL may protect against atherosclerosis is 
their role in reverse cholesterol transport. An important step in this reverse 
cholesterol transport pathway is the uptake of cellular cholesterol by prej3-
HDL. The two lipid transfer proteins present in human plasma, CETP and 
PLTB have both been implicated in the formation of prej3-HDL. In chapter 2 
the relative contribution of each of these proteins is investigated. 
Studies in PLTP knockout mice have shown a reduction in atherosclerosis 
which was explained by a reduction of hepatic VLDL secretion and the 
resulting decreased LDL concentration. However, until today PLTP deficiency 
has not been found in humans and in addition mice by nature do not have 
plasma CETP activity. Thus, total deficiency of both CETP and PLTP represent 
an extreme situation from which the effects on lipoprotein metabolism cannot 
be simply extrapolated to humans. Therefore we evaluate the influence of 
PLTP on VLDL secretion in a mouse model with appreciable CETP activity in 
chapter3. 
In chapter 4 we study the susceptibility of PLTP to diet induced atherosclerosis 
in LDLR+1-jhuCETPtg mice with moderately and highly elevated plasma PLTP 
activity. These mouse models are more suitable to evaluate the role of PLTP in 
atherosclerosis than PLTP knockout mice. 
It is not clear by which mechanism PLTP affects diet induced atherosclerosis. 
From experiments in PLTP knockout mice, it was concluded that PLTP may 
stimulate hepatic VLDL secretion. This was confirmed in PLTP overexpressing 
mice. In this model the atherogenic effect of PLTP was attributed to a decrease 
in HDL cholesterol levels. In chapter 5 we study which of these two pro-
atherogenic effects are related to atherosclerosis in PLTP overexpressing mice, 
with appreciable plasma CETP activity. 
Fibrates are well known to lower the plasma concentration of triglycerides 
and increase HDL cholesterol levels. In chapter 6 we study the influence of 
fenofibrate on PLTP in several mouse lines. 
The results obtained in these studies are discussed in chapter 7. 
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ABSTRACT 
High-density lipoproteins (HDLs) are considered anti-atherogenic because 
they mediate peripheral cell cholesterol transport to the liver for excretion and 
degradation. An important step in this reverse cholesterol transport pathway 
is the uptake of cellular cholesterol by a specific subclass of small, lipid-poor 
apoA-I particles designated pre~-HDL. The two lipid-transfer proteins present 
in human plasma, cholesteryl ester transfer protein (CETP) and phospholipid 
transfer protein (PLTP), have both been implicated in the formation of pre~­
HDL. In order to investigate the relative contribution of each of these proteins, 
we used transgenic mouse models. Comparisons were made between human 
CETP transgenic mice (huCETPtg), human PLTP transgenic mice (huPLTPtg) 
and mice transgenic for both lipid-transfer proteins (huCETPtg!huPLTPtg). 
These animals showed elevated plasma levels of CETP activity, PLTP activity 
or both activities, respectively. We evaluated the generation of pre~-HDL 
in mouse plasma by immunoblotting and crossed immuno-electrophoresis. 
Generation of pre~-HDL was equal in huCETPtg and in wild-type mice. In 
contrast, in huPLTPtg and huCETPtg/huPLTPtg, pre~-HDL generation was 
3-fold higher than in plasma from either wild-type or huCETPtg mice. Our 
findings demonstrate that of the two plasma lipid transfer proteins PLT.P-
rather than CETP, is responsible for the generation of pre~-HDL. These 
data support the hypothesis of a role for PLTP in the initial stage of reverse 
cholesterol transport. 
INTRODUCTION 
Plasma levels ofhigh-density lipoprotein (HDL) cholesterol correlate negatively 
with the risk of coronary artery disease, and raising HDL-cholesterollevels by 
drug treatment results in prevention of coronary artery disease (1-4). HDL is 
considered to protect against atherosclerosis via its role in reverse cholesterol 
transport (5). This pathway involves the uptake of cholesterol from peripheral 
cells and subsequent transport and delivery to the liver for degradation and 
excretion. Recent data indicate that the ATP-binding cassette transporter 
Al (ABCAl) plays a key role in the efflux of cholesterol from cells (6-8). 
Patients suffering from Tangier disease, with a mutated form of the ABCAl 
gene, show premature atherosclerosis, providing compelling evidence for a 
substantial protective role of reverse cholesterol transport in the development 
of atherosclerosis. The initial extracellular acceptor of cellular cholesterol is 
a specific subclass of HDL, designated prej3-HDL (9). Cellular cholesterol 
taken up by pre~-HDL is subsequently esterified by the action of lecithin: 
cholesterol acyltransferase (LCAT). As a consequence pre~-HDL matures 
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into a-HDL. Esterified cholesterol from a-HDL can be taken up in the liver 
either directly by selective uptake, or indirectly via low-density lipoproteins 
(LDLs ). The indirect pathway follows transfer of cholesteryl esters to very low-
density lipoproteins (VLDLs) and LDLs by cholesteryl ester transfer protein 
(CETP) (9, 10). Thus, pre[3-HDL is a key factor in reverse cholesterol transport. 
Although the plasma lipid-transfer proteins phospholipid transfer 
protein (PLTP) and CETP have non-overlapping functions (11), 
studies both in vitro and in vivo have demonstrated that CETP and 
PLTP may both contribute to the formation of pre[3-HDL (12-18). 
PLTP is involved in the transfer of phospholipids between lipoproteins and 
in the remodeling of HDL (19-21). Its physiological function has been studied 
in several mouse models (12, 22-24). PLTP deficient mice show an impaired 
transfer of post-lipolytic VLDL surface remnant phospholipids to HDL and, 
as a consequence, decreased plasma HDL levels (21). In PLTP transgenic 
mice with slightly elevated PLTP activity levels minor effects on plasma 
lipids and lipoprotein patterns were found (15, 23). However, in double 
transgenic mice expressing both PLTP and human apolipoprotein (apo) A-
I, pre[3-HDL levels were increased (23). We generated transgenic human 
PLTP mice which show a moderate, though substantial overexpression 
of PLTP (2.5-3 fold in hemizygous transgenic mice) (12). Plasma from 
these mice has an increased ability to generate pre[3-HDL and prevents 
cholesterol accumulation in macrophages to a greater extent than plasma 
from wild-type animals. From these studies, we concluded that PLTP could 
have anti-atherogenic properties via its ability to generate pre[3-HDL. 
Both CETP and PLTP belong to a family of lipid-transfer/lipopolysaccharide-
binding proteins (10, 25). Although CETP has profound effects on lipoprotein 
metabolism in humans, some species including mice, lack CETP activity (26). 
In vitro studies demonstrate that CETP transfers cholesteryl esters from HDL 
to apoB-containing lipoproteins in exchange for triglycerides, whereas PLTP 
does not transfer neutral lipids (5). In addition to PLTP, CETP is able to transfer 
phospholipids in vitro, but it is unknown whether they share this ability in vivo. 
In the present study we evaluated the relative contributions of CETP and PLTP 
in the formation of pre[3-HDL. To this end, we made comparisons between 
various lines of transgenic mice expressing human CETP, human PLTP, or 
both lipid-transfer proteins. 
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MATERIAL AND METHODS 
Breeding and treatment of transgenic mice 
Human CETP transgenic mice Oine 5203; huCETPtg) were kindly donated 
by Dr A.R. Tall (Columbia University, New York) (27) and have a C57BL/6 
background. Human PLTP transgenic mice (huPLTPtg) were generated as 
described previously (12) and were backcrossed to C57BL/6 background for 
at least 7 generations. Mice expressing the human CETP and PLTP transgenes 
(huCETPtg/huPLTPtg) were obtained by crossbreeding huCETPtg and 
huPLTPtg mice. Both transgenes had the natural flanking sequences, including 
the autologous promoters. Animals were housed in a temperature-controlled 
room operating under a 12 h: 12 h light/dark cycle. Animals were fed regular 
chow and water ad libitum. Blood samples were collected after fasting overnight 
from the orbital plexus by using Vitrex™ sodium-heparinized micropipettes 
(80 IU) (Modulohm A/S, Copenhagen, Denmark) and were immediately 
stored on ice. Blood was centrifuged at 1500 gmax for 15 min at 4 oc_ Plasma 
was either used directly or stored in small aliquots at -80°C before analysis. 
All animal experiments were done in compliance with the Guidelines of the 
Ethical Committee on the Use of Laboratory Animals of the Erasmus University 
Rotterdam (prot.nr. 120.99.05) and with the European Committee Standards 
on the care and use of laboratory animals (Ministry of Welfare, Health and 
Cultural Affairs, The Netherlands). 
DNA analysis 
Genomic DNA was isolated from tail clips of 10-day-old mice and analyzed 
for the presence of the huCETP transgene and/or huPLTP transgene by PCR 
analysis; huCETP: sense primer 5' -CACTAGCCCAGAGAGAGGAGTGC-
3', antisense primer 5'- CTGAGCCCAGCC GCACACTAAC-3', 28 cycles 
(94 °C, 1 min; 65 oc, 1 min; 72 oc, 1.5 min); huPLTP: sense primer 5'-
GCCACAGCAGGAGCTGATGC-3', antisense primer 5'-GCGGATGGAC 
ACACCCTCAGC-3', 28 cycles (94 oc, 1 min; 65 oc, 1 min, 72 oc, 2 min). 
Plasma activity assays 
CETP and PLTP assays were performed according to Speijer et al. (28). CETP 
activity was determined by measuring the rate of transfer/exchange of 
radiolabeled cholesteryl oleate between exogeneously added human LDL and 
HDL. PLTP activity was determined by measuring the transfer of radiolabeled 
dipalmitoyl phosphatidyl choline (DPPC) from liposomes {composed of egg 
lecithin, Amersham, Beckinghamshire U.K. and [3H]-DPPC as a tracer} to 
exogenously added human HDL (density, 1.063 g/ml < d < 1.21 g/ml). CETP 
and PLTP activities are expressed as percentage of human reference plasma: 
100% is equivalent to the following activities; CETP, 215.6 nmol/ml per h; PLTP 
13.9 1-1mol/ml per h. 
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Hepatic lipase activity was measured as described by Jansen et al. (29). LCAT 
activity was determined by measuring the formation of radio labeled cholesteryl 
ester after addition of 10 or 20 f.ll of mouse plasma to excess heat-inactivated 
plasma containing [3H]-cholesterol (Amersham, Bucking ham shire, U.K.) 
(30). Hepatic lipase and LCAT activities are expressed as percentage of plasma 
from wild-type mice (C57BL/6). 
Quantitation of plasma lipids and apolipoproteins 
Plasma lipids were determined enzymatically with commercially available 
kits: total cholesterol with the F-chol kit of Boehringer Mannheim (Mannheim, 
Germany) after hydrolysis of cholesteryl esters with cholesterol esterase from 
Candida cylindracea (Boehringer Mannheim). Phospholipids were measured 
with the PAP150 kit from BioMerieux (Lyon, France). Mouse apoA-1 was 
quantitated by sandwich ELISA as reported (12). 
Gel filtration chromatography of mouse plasma lipoproteins 
Lipoprotein profiles were determined by gel filtration of freshly isolated 
plasma on two HR10/30 FPLC columns in tandem (Superose 6 prepgrade 
and Superdex 200 prepgrade; Pharmacia Biotech, Uppsala, Sweden). The 
columns were equilibrated with 2 mM Na~PO/Na2HP04, pH 7.4 containing 
0.9% NaCl (w/v), 0.02% NaN3 (w/v) and 5 mM EDTA. Combined plasma 
samples from four to seven mice were passed through 0.45 J.Lm filters from 
Millipore S.A. (Molsheim, France), and 0.5 ml was subjected to gel filtration. 
The columns were run at 4 oc with a flow rate of 0.1 ml/min. Fractions of 0.8 
ml were collected. Recoveries were > 90% for all analyses. 
Quantitation of pref3-HDL 
Mouse plasma samples were either frozen directly or incubated in the presence 
of iodoacetate in order to measure pre~-HDL formation. Incubation conditions 
were as reported in (12). Plasma samples were separated by agarose-gel 
electrophoresis under non-reducing, non-denaturing conditions and low ionic 
strength according to the manufacturer's instructions (Paragon Lipo system; 
Beckman, Fullerton, CA, U.S.A) to separate pre~- and a-migrating HDL. 
Proteins were transferred by capillary blotting to nitrocellulose membranes 
(Schleicher & Schuell NY 13N 6214/95, Dassel, Germany). Membranes were 
blocked for 1 h in 5% (w/v) skimmed milk in 20 mM Tris/HCl pH 7.4/0.5 M 
NaCL Membranes were subsequently incubated with an affinity-purified 
rabbit anti-mouse apoA-1 polyclonal antibody. 1251-labeled donkey anti rabbit 
F(ab')2 fragment (17 Ci/g; Amersham) was used as the detection antibody. The 
relative abundance of apo-AI among the a- orpre~-HDL species was calculated 
by quantitative scanning using a Phosphorlmager (GS-363; BioRad). Crossed 
immuno-electrophoresis was performed as described in (12). 
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Statistical analysis 
Data are expressed as means± SD. Differences between two genotypes were 
analysed by two sample Wilcoxon rank-sum tests. Differences between three 
genotypes were analysed by AN OVA followed by Bonferroni correction. 
RESULTS 
Plasma activities of CETP and PLTP 
CETP activies were measured in plasma from huCETPtg mice and huCETPtg/ 
huPLTPtg mice (Figure 1A). CETP activity in wild-type mice was virtually 
absent (<4% ofhumanreferenceplasma). HuCETPtgmicehad a CETP activity 
of 144 ± 34% of human reference plasma whereas CETP activity in huCETPtg/ 
huPLTPtg mice was about 20% lower (P < 0.01). 
PLTP activity levels were measured in plasma samples of huCETPtg mice 
and huCETPtg/huPLTPtg mice (Figure 1B). The PLTP activity in plasma of 
huCETPtg mice was somewhat higher than human PLTP activity levels: 136 
± 16% of human reference plasma, which is in agreement with measurements 
in wild-type mice (12). The PLTP activity in the huCETPtg/huPLTPtg was 4-
fold higher (Figure 1B). This activity level closely resembles the level reported 
previously for huPLTPtg mice (12). 
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Figure 1. Plasma CETP and PLTP activities in transgenic mice. Plasma activities were 
determined in individual plasma samples from huCETPtg mice (n = 12) and huCETPtg/ 
huPLTPtg mice (n = 10). Values are expressed as percentage of human reference plasma (mean 
± SD). (A) CETP activity: 100% human reference plasma is equivalent to 215.6 mnol/ml!h 
CETP activity. *P < 0.01 (rank-sum test). (B) PLTP activity: 100% human reference plasma is 
equivalent to 13.9 f.liilOl/ml/h PLTP activity. **P < 0.0001 (rank-sum test). 
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Plasma hepatic lipase activity and LCAT activity 
Mice express hepatic lipase activity in plasma, even without intravenous 
injection of heparin (31 ). We investigated whether any differences in the activity 
of hepatic lipase in plasma between huCETPtg mice and huCETPtg/huPLTPtg 
mice could be observed. As shown in Figure 2A, the huCETPtg/huPLTPtg mice 
have lower levelsofhepaticlipase activitythanhuCETPtgmice (P<O.OS). Hepatic 
lipase activity in the huPLTPtg mice was 91 ± 27% of wild-type mouse plasma. 
In plasma, pre~-HDL matures into a-HDL by the action of LCAT. The levels 
of LCAT activity were not significantly different between the three tested 
genotypes (Figure 2B). 
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Figure 2. Plasma hepatic lipase and LCAT activities in transgenic mice. Plasma activities were 
measured in individual plasma samples from wild-type mice (wt; n = 16), huCETPtg mice (n 
= 12), huPLTPtg mice (n = 8) and huCETPtg!huPLTPtg mice (n = 10). Values are mean ± SD 
and are expressed as percentage of wt. (A) Hepatic lipase activity: 100% hepatic lipase activity 
of wt is equivalent to 56.1 nmol/ml/h. *significantly different from huCETPtg mice (P < 0.05, 
ANOVA followed by Bonferroni correction). (B) LCAT activity: 100% LCAT activity of wt is 
equivalent to 71.3 nmol/ml/h. Transgenic mice show similar LCAT activities (not significantly 
different). 
Lipid and lipoprotein analysis 
Plasma samples from either huCETPtg or huCETPtg/huPLTPtg animals were 
analysed by gel-filtration chromatography in order to examine the lipoprotein 
profile. Cholesterol and phospholipid contents as well as CETP and PLTP 
activities were determined in all fractions (Figure 3). In unfractionated plasma, 
huCETPtg/huPLTPtg mice had lower levels of plasma cholesterol than 
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huCETPtg mice (1.09 ± 0.15 mM, n = 9 versus 1.43 ± 0.16 mM, n = 11; P < 0.01), 
whereas triglyceride levels were similar (huCETPtg mice, 0.38 ± 0.14 mM, n = 5; 
huCETPtg/huPLTPtg mice, 0.48 ± 0.25 mM, n = 5, not statistically significant). 
As evident from Figure 3A, which shows the cholesterol profile, this is due to a 
decrease in HDL cholesterol. The phospholipids have a similar profile, showing 
a decrease in HDL phospholipids due to PLTP overexpression (Figure 3B). The 
phospholipids present in fractions 20-25 represent lysophosphatidylcholine 
bound to albumin. In both groups of mice CETP activity eluted in fractions 14-
18, corresponding to the position of HDL particles (Figure 3C). PLTP activity 
eluted in fractions 11-15, the position of relatively large HDLs (Figure 3D), a 
situation also found in humans. 
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Figure 3. Lipoprotein profiles of plasma from transgenic mice. Equal amounts of plasma 
from either huCETPtg mice (n = 4) or huCETPtg/huPLTPtg mice (n = 7) were pooled and 
subjected to gel filtration on Superose 6 and Superdex 200 columns connected in tandem as 
described in the Materials and Methods section. Fractions were analyzed for (A) cholesterol, 
(B) phospholipids, (C) CETP activity and (D) PLTP activity. Fractions 1-4 contain VLDL, 5-
10 contain LDL, 11-19 contain HDL and 20-25 contain lysophosphatidyl choline bound to 
albumin. 
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Effects ofhuPLTP and huCETP expression on pref3-HDLformation 
To investigate the formation of pre[3-HDL, incubated plasma samples from 
wild-type, huCETPtg, huPLTPtg and huCETPtg/huPLTPtg mice were 
subjected to agarose-gel electrophoresis followed by immunoblotting. Upon 
incubation, the levels of pre[3-HDL are increased in mice expressing human 
PLTP, whereas neither wild-type nor huCETPtg mice showed appreciable levels 
of pre[3-HDL formation (Figure 4). In order to quantify pre[3-HDL formation, 
crossed immuno-electrophoresis experiments were performed (Figure 5). The 
results corroborated the findings from the immunoblotting experiments, since 
incubated samples from mice expressing human PLTP showed relatively higher 
pre[3-HDL peaks. Measurements of pre[3-HDL in plasma without incubation 
revealed no significant differences between the genotypes tested (Table 1). 
However, in incubated samples, significant differences were observed in both 
relative and absolute concentrations of pre[3-HDL between huPLTPtg mice on 
the one hand and wild-type mice or huCETPtg mice on the other (Table 1). 
Using the data in Table 1, the formation of pre[3-HDL during incubation of 
plasma was calculated (see Figure 6). Pre[3-HDL formation in plasma from 
huCETPtg!huPLTPtg and huPLTPtg mice was at least 3-fold higher than in 
plasma from wild-type mice and huCETPtg mice. Thus CETP does not seem 
to make a substantial contribution towards the formation of pre[3-HDL. 
Table 1. Pre~-HDL levels in plasma of transgenic mice. 
wild type 
huCETPtg 
huPLTPtg 
huCETPtg/huPLTPtg 
1.0 ± 0.07 
0.88 ± 0.05 
0.73 ± 0.24 
0.7 ± 0.09 
3.7 ± 0.9 
5.0 ± 0.8 
6.0 ± 0.8 
7.3 ± 1.7 
7.3 ±0.5 
7.3 ±0.5 
16.7 ±0.9* 
17.3 ± 1.3* 
36.7 ± 12.1 
44.1 ± 10.9 
44.2 ± 14.8 
52.3 ±20.2 
73.5 ± 10.2 
64.5 ± 8.6 
125.1 ± 49.4* 
121.2 ± 22.7* 
Plasma samples were incubated as described in the legend of Figure 4. Values represent the 
relative and absolute amounts of pre~-HDL in plasma before and after incubation at 37 oc 
for 3h. These were calculated as described in the legend of Figure 6, from the percentage of 
apoA-1 present in pre~-HDL and the total plasma apoA-1 concentrations respectively. Values 
are mean ± SD (n = 3). "Significantly different from wild type mice, P < 0.05 (rank-sum test). 
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Figure 4. HDL subfractions of incubated plasma samples from transgenic mice. Analysis of 
HDL subfractions was performed in plasma from huCETPtg (lane 1), huCETPtg/huPLTPtg 
(lane 2), huPLTPtg (lane 3) and wild-type (lane 4) mice. Mouse plasma (10 ~) was incubated 
in the presence of an LCAT inhibitor (1 mM iodoacetic add) at 37 oc for 3 h. Equal amounts of 
plasma were run on a 0.5% agarose gel, transferred to nitrocellulose membranes and subjected 
to immunoblotting using rabbit anti-mouse apoA-I IgG. 
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Figure 5. Crossed immuno-electrophoresis of incubated plasma samples from transgenic 
mice. Plasma samples from transgenic were incubated as described in the legend of Figure 4 
and in the Materials and Methods section. Subsequently, 5 ~ aliquots were applied to agarose 
gels for the first dimension, followed by electrophoresis into an anti-mouse apoA-I containing 
gel for the second dimension. (A) Wild-type mice, (B) huCETPtg mice, (C) huPLTPtg mice, 
and (D) huCETPtg/huPLTPtg mice. 
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Figure 6. Prej3-HDL formation in plasma samples from transgenic mice. Plasma samples 
from wild-type, huCETPtg, huPLTPtg and huCETPtg!huPLTPtg mice were incubated as 
described in the legend of Figure 4. Values represent the differences in the relative amounts 
of prej3-HDL, expressed as percentage of total plasma apoA-1 before and after incubation. 
These were calculated based on the areas underneath the peaks of prej3-HDL and a-HDL 
following crossed immuno electrophoresis. Values are mean± SD, *P < 0.001 compared with 
both wild-type and huCETPtg mice (AN OVA followed by Bonferroni correction). 
DISCUSSION 
CETP and PLTP are important factors in modulating plasma lipid transport 
and both have been implicated in the generation of pre~-HDL particles (12, 
13, 15, 16, 18). However, to date their relative importance to this process has 
not been established unequivocally. This is due to the fact that all available 
data originate from studies in which only one of the lipid transfer proteins 
was investigated. Besides, the use of different models, either in vivo or in 
vitro, as well as the use of different techniques, hampers a comparative 
evaluation. For this reason we have used transgenic mouse models 
with relatively modest overexpression of the human PLTP and/or CETP 
proteins, enabling us to make direct comparisons of pre!3-HDL formation. 
The human PLTP mice that we used as the parental strain to generate 
huPLTPtg/huCETPtg mice have been described previously (12). These 
mice have approximately 3-fold higher plasma PLTP activity levels 
than wild-type mice. This results in more pronounced effects on plasma 
lipids, compared to those reported by other groups using transgenic mice 
with low levels of PLTP expression (15, 23). Strong overexpression, as 
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found in mice expressing human PLTP after transfection with adenoviral 
constructs, was avoided since this causes extreme effects on lipoprotein 
metabolism, resulting in near absence of plasma cholesterol (22, 24). 
The huCETPtg mice that were used in the present study have been created and 
characterized by Jiang et al. (27). In addition to a human CETP mini-gene, these 
mice have the natural flanking DNA sequences of the human CETP gene (3.2 
kb upstream and 2.0 kb downstream sequence). This construct results in CETP 
plasma activity levels that are much lower than other CETP-overexpression 
models (32, 33). Moderate expression of CETP in the huCETPtg mice used 
in the present study was confirmed by measuring CETP mass by ELISA. 
Concentrations ranged from 2.7 to 4.1 f--lg/ml in plasma samples from huCETPtg 
mice (T. van Gent, J.T. Lie and A. van Tol, unpublished work), which is about 
1.5-fold higher than values found in human plasma (34). Thus this mouse 
model shows modest CETP expression and resembles the human condition 
in terms of plasma CETP activity and mass. In both models, expression of 
the transgene resulted in distinct effects on plasma lipids/lipoproteins. 
In order to evaluate possible interactions between the two lipid transfer 
proteins, in terms of either their respective transfer activities or on the formation 
of pref:3-HDL, we extended our studies with double transgenic animals, 
huCETPtg/huPLTPtg mice. This model resembles the situation in humans 
since, in contrast to mice, humans express both plasma transfer proteins. 
huCETPtg and huCETPtg/huPLTPtg mice showed a small difference in plasma 
CETP activity levels. The expression of the human PLTP gene is associated with 
a decrease in CETP activity of about 20%. This decrease is confirmed on analysis 
of the CETP activity profiles after gel filtration (Figure 3C). This effect could 
be the result of a direct effect of overexpression of human PLTP on the level 
of expression of the CETP transgene. An alternative explanation is that PLTP 
expression causes a lower plasma HDL concentration. Since HDLis the carrier of 
CETP, this could eventually result in a decrease in CETPlevels. The profiles show 
that CETP activity elutes at a position corresponding to that of HDL particles. 
PLTP activity measured in huCETPtg/huPLTPtg mice equals the PLTP activity 
in the huPLTPtg mice described previously (12). PLTP activity in huCETPtg 
mice is comparable with that in wild-type mice. Therefore CETP does not seem 
to affect the activity of the endogenous mouse PLTP in plasma. In comparison 
with the lipoprotein profile found in huPLTPtg mice (12), huCETPtg/huPLTPtg 
mice have somewhat smaller HDLs, which is in agreement with previous 
studies in transgenic mice expressing human CETP (35). The activity profiles 
of PLTP in huCETPtg mice and huCETPtg/huPLTPtg mice were measured 
after gel filtration of plasma (Figure 3D). The profiles show that PLTP activity 
elutes at the position corresponding to relatively large-sized HDL particles in 
both groups of mice. Thus CETP and PLTP co-elute with particles of different 
sizes, a situation also found in humans (28). 
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The main purpose of the present study was to determine the relative 
contribution of PLTP and CETP to pre~-HDL generation. We evaluated 
the formation of pre~-HDL in plasma using two different methods and 
demonstrated that pre~-HDL formation is increased in plasma from transgenic 
mice expressing human PLTP, whereas expression of human CETP did not 
affect this process. These findings cannot be attributed to differences in 
preference towards human versus mouse HDL, since incubations of plasma 
from huCETPtg mice with freshly isolated human HDL did not show 
formation of pre~-HDL (J.T. Lie, R. de Crom, M. Jauhiainen, T. van Gent, R. 
van Haperen, L.M. Scheek, C. Ehnholm and A. van Tol, unpublished work). 
LCAT activity was similar in plasma of the various transgenic 
mice, which implies that a difference in maturation of pre~-HDL 
into a-HDL is unlikely. Therefore differences in LCAT activity 
cannot explain the observed distinctions in pre~-HDL formation. 
The involvement of hepatic lipase in the formation of pre~-HDL has been 
suggested (36). In humans, virtually all hepatic lipase is bound to liver 
endothelial cells, whereas in mice hepatic lipase circulates in plasma (31). 
It was therefore important to know whether plasma from huCETPtg/ 
huPLTPtg mice display higher hepatic lipase activity than plasma from 
huCETPtg mice. Hepatic lipase activity was found to be lower in plasma 
from huCETPtg!huPLTPtg compared with plasma from huCETPtg mice, so 
this activity cannot explain the observed differences in pre~-HDL generation. 
Other groups have reported a role for CETP in pre~-HDL formation (13, 
17, 18). Kunitake et al. (13) showed that pre~-HDL formation is stimulated 
by CETP in vitro. Francone et al. (18), using double transgenic animals that 
overexpressed CETP (driven by the metallothionein promoter) as well as 
human apolipoprotein A-I, observed increased levels of pre~-HDL in these 
mice. In the mouse models used here, CETP expression is driven by its native 
promoter and CETP levels and activities were comparable with those in 
human plasma. An increase in the generation of relative and absolute plasma 
levels of pre~-HDL formation was only observed in huPLTPtg mice. Despite 
lower HDL concentrations in huCETPtg/huPLTPtg mice compared with 
huCETPtg mice, plasma of huCETPtg/huPLTPtg mice had a greater ability 
to produce pre~-HDL. This finding of a combination of low HDL cholesterol 
levels and increased pre~-HDL formation was also observed in huPLTPtg 
mice (12), as well as in mice using adenoviral overexpression of PLTP (22, 24). 
Although CETP and PLTP share similar structural properties and belong 
to the same gene family, it has been found that they have non-overlapping 
functions in vivo (11). The roles of the HDL modulators CETP and PLTP in 
atherosclerosis have not yet been elucidated. CETP participates in reverse 
cholesterol transport, a function that may mean it has an anti-atherogenic 
potential (10). On the other hand, CETP mediates the exchange of cholesteryl 
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esters in HDL for triglycerides in VLDL. This process leads to a decrease of 
HDL cholesterol and to an increase of potentially pro-atherogenic VLDL and 
LDL cholesterol (37). Although substantial overexpression of human CETP was 
reported to cause increased susceptibility to diet-induced atherosclerosis (32), 
CETP has been proved to be anti-atherogenic in other (compound) transgenic 
mouse models (38, 39). In rats, high level expression of human CETP is highly 
atherogenic (33), whereas in rabbits inhibition of CETP proved to be anti-
atherogenic (40). The impact of CETP on atherosclerosis in humans remains 
inconclusive (37). The present study supports the notion that PLTP- rather than 
CETP- is responsible for the generation of prej3-HDL. The impact of PLTP on 
diet-induced atherosclerosis will be the subject of future investigations. 
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ABSTRACT 
Two lipid transfer proteins are active in human plasma, cholesteryl ester 
transfer protein (CETP) and phospholipid transfer protein (PLTP). Mice by 
nature do not express CETP. Additional inactivation of the PLTP gene resulted 
in reduced secretion of VLDL and subsequently in decreased susceptibility to 
diet-induced atherosclerosis. The aim of this study is to assess possible effects of 
differences in PLTP expression on VLDL secretion in mice that are proficient in 
CETP and PLTP. We compared human CETP transgenic (huCETPtg) mice with 
mice expressing both human lipid transfer proteins (huCETPtg/huPLTPtg). 
Plasma cholesterol in huCETPtg mice was 1.5-fold higher compared with 
huCETPtg/huPLTPtg mice (P < 0.001). This difference was mostly due to a 
lower HDL level in the huCETPtg/huPLTPtg mice, which subsequently could 
lead to the somewhat decreased CETP activity and concentration that was 
found in huCETPtg/huPLTPtg mice (P < 0.05). PLTP activity was 2.8-fold 
increased in these animals (P < 0.001). The human PLTP concentration was 5 
flg/ml. 
Moderate overexpression of PLTP resulted in a 1.5-fold higher VLDL secretion 
compared with huCETPtg mice (P < 0.05). The composition of nascent VLDL 
was similar in both strains. These results indicate that elevated PLTP activity 
in huCETPtg mice results in an increase in VLDL secretion. In addition, PLTP 
overexpression decreases plasma HDL cholesterol as well as CETP. 
INTRODUCTION 
Phospholipid transfer protein (PLTP) is an important modulator of plasma 
HDL levels, size and composition (1-5). HDL is considered to protect against 
atherosclerosis by transporting cellular cholesterol from cells in the arterial 
wall to the liver for further excretion via the bile, as well as by exerting anti-
inflammatory and anti-oxidant effects (6-8). 
The role of PLTP in atherosclerosis was recently evaluated in PLTP deficient 
mice (5). PLTP deficiency in hyperlipidemic mouse models resulted in 
decreased atherosclerosis. In vitro experiments with cultured hepatocytes 
from PLTP deficient mice revealed a defect in VLDL secretion. These effects 
on VLDL secretion provided an explanation for the decreased atherosclerosis 
found in PLTP deficient mice (5). 
Earlier we reported anti-atherogenic properties in mice overexpressing human 
PLTP (huPLTPtg). Despite lower HDL levels, plasma from these mice is more 
effective in preventing in vitro accumulation of cholesterol by macrophages 
and is able to generate more pre!3-HDL (3, 9). Studies in mice with adenovirus-
mediated overexpression of human PLTP showed similar effects on HDL 
subclass distribution (10, 11). 
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Thus, depending on the metabolic setting, PLTP may have anti- or pro-
atherogenic properties that require further investigation. Presently, we aimed 
to evaluate whether VLDL secretion is affected by variations in PLTP activity. 
For this purpose, we crossbred transgenic mice for human CETP (huCETPtg) 
with huPLTPtg mice (9) and obtained huCETPtg!huPLTPtg mice. These mice 
provide a unique model to study the role of PLTP in VLDL metabolism in 
the presence of CETP, which by nature is the situation in humans. Plasma 
lipoproteins, plasma CETP, and PLTP activities, as well as human CETP 
and human PLTP mass were also measured to study the impact of PLTP in 
huCETPtg mice. 
MATERIALS AND METHODS 
Breeding and treatment of transgenic mice 
The huCETPtg mice were kindly provided by Dr. A.R. Tall (Columbia 
University;. New York) and are in C57BL6 background (9). HuPLTPtg mice 
(3) were backcrossed to C57BL6 background for at least seven generations. 
Mice expressing both human CETP and human PLTP (huCETPtg/huPLTPtg) 
were obtained by crossbreeding homozygous huCETPtg with homozygous 
huPLTPtg mice. Both transgenes have the natural flanking sequences, including 
the native promoters. Female mice were used in further experiments. Animals 
were housed under standard conditions with free access to water and regular 
chow diet. 
After fasting overnight blood samples were collected from the orbital plexus 
by using Vitrex™ sodium-heparinized micropipettes (80 IU) (Modulohm A/S, 
Copenhagen, Denmark) and immediately stored on ice. Blood was centrifuged 
at 2700 rpm for 15 min at 4 oc. Plasma was either used directly or stored in 
small aliquots at -80 °C before analysis. All experiments were approved by 
institutional and national guidelines (protocol nr.120.99.05). 
In vivo hepatic VLDL secretion and composition 
VLDL secretion experiments were performed according to Jong et al. (12). 
VLDL secretion was measured in overnight fasted mice which were injected 
intravenously with 15% (w/v) Triton WR1339 (Sigma, StLouis, MO, USA)(500 
mg/kg body weight) dissolved in 0.9% NaCL After injection of Triton WR1339, 
blood samples were drawn at appropriate time points (up to 90 min) and 
triglyceride content was measured as described below. The triglyceride 
accumulation in plasma was linear during this time period. Hepatic triglyceride 
secretion rate was calculated from the slope of the line and expressed as ~mol/ 
h per kg body weight. 
From the blood samples obtained at t = 90 min after Triton WR1339 
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administration, plasma was taken and centrifuged at d = 1.006 g/ml in a 
Beckman 42.2 Ti rotor (34200 rpm, 3 h, 12 °C). The top fraction containing 
VLDL was isolated by tube slicing. 
Quantification of plasma lipids and protein 
Cholesterol was determined enzymatically with the Free Cholesterol C kit 
no. 274-47109 (WAKO, Neuss, Germany) after hydrolysis of cholesteryl esters 
with cholesterol esterase from Candida cylindracea (Boehringer, Mannheim, 
Germany). Triglycerides were measured with the Sigma GPO-Trinder kit 
no.337-B (Sigma, StLouis, MO, USA) and free fatty acids were measured with 
the NEFA C kit no. 994-75409 (WAKO, Neuss, Germany). Phospholipids were 
measured with the PAP150 kit from Bio Merieux (Lyon, France). Protein was 
measured with a modification of the Lowry assay (13). 
Separation of plasma lipoproteins by gelfiltration 
Plasma from transgenic mice was analyzed by gelfiltration on two HR10/30 
FPLC columns in tandem (Superdex 200 prepgrade, Superose 6 prepgrade, 
Pharmacia Biotech., Uppsala, Sweden). The columns were equilibrated with 
2 mM NaH2PO/Na2HP04, pH 7.4 [containing 0.9% NaCl (w/v), 0.02% NaN3 (w/v) and 5 mM EDTA]. Combined plasma samples from seven to ten mice 
were passed through 0.45-J.lm filters from Millipore S.A. (Molsheim, France), 
and 0.5 ml was subjected to gelfiltration. The columns were run at 4 oc with a 
flow rate of 0.1 ml/min. Fractions of 0.8 ml were collected. Recoveries were > 
90% for all analyses. 
Plasma activity assays 
CETP and PLTP activity assays were performed according to Speijer et al. (14) 
as described before (9). The activities are expressed as percentage of human 
reference pool plasma. One hundred percent is equivalent to the following 
activities: CETP 215.6 nmol/ml/h; PLTP 13.9 !-ffi10l/ml/h. 
Human CETP and human PLTP mass determinations by ELISA 
The CETP ELISA assay was essentially performed as described by Mezdour 
et al. (15). CETP mass was measured by a two-site antibody immunoassay 
using a combination of two specific monoclonal antibodies for CETP: TP1 
and TP2 (Ottawa Heart Institute, Canada), which are able to inhibit the 
transfer of cholesterylesters as well as triglycerides and recognize a similar 
epitope localized in the carboxyterminal region of the CETP molecule (16). 
Both antibodies (10 ~g/ml) were coated overnight by incubation in phosphate 
buffered saline (PBS, pH 7.4) at 4 oc on microwell plates (Immunoplate 
MaxiSorp; Nunc, Roskilde, Denmark). After washing the plates 5 times with 
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washing buffer [PBS containing 6% (v/v) methanol and 0.2% (w/v) Thesit 
(Boehringer, Mannheim, Germany)], the plates were incubated for 1 h at 37 °C 
with PBS containing 1% of bovine serum albumin (BSA; ICN, Ohio, USA) to 
prevent non-specific binding. After incubation, the wells were washed 5 times 
and standard solution or plasma samples, diluted in assaybuffer [washing 
buffer containing 1% (w/v) BSA], were added and incubated for 2 hat 37 °C. 
After washing 5 times, antibody TP20 labeled with digoxigenine (Ottawa 
Heart Institute, Canada) was added and the plates were incubated for 2 hat 
37 oc followed by 5 times washing and incubation with a solution containing 
anti-digoxigenine Fab fragments for another 2 hat 37 oc. Then, after washing 
5 times, a solution with anti-digoxigenine coupled to peroxidase (Boehringer, 
Mannheim, Germany) was added followed by incubation for 45 min at 37 
oc. Tetramethylbenzidine (TMB, Merck, Darmstadt, Germany) was freshly 
prepared in DMSO (6 mg/ml). 500fll of the TMB/DMSO solution and 3 fll of 
H 20 2 were added to 30 ml citrate buffer (35 mM, pH 5.5). 100 I-ll of this TMB 
solution was added to the wells after washing the plates 5 times. After 30 min, 
the reaction was stopped by the addition of 100 fll 2 N ~S04• Absorbance 
was read at 450 nm. The intra- and inter-assay coefficients of variation were 
3.6% and 8.0% respectively. In the present study CETP activity correlated with 
human CETP mass (r = 0.93, P < 0.001). 
Human PLTP mass was measured with a sandwich-type ELISA essentially 
as described previously (17) with minor modifications: the washing buffer 
contained 6% methanol (v/v) with 0.2% Thesit (w/v) (Boehringer, Mannheim, 
Germany) and 0.1% (w/v) Tween 20. The substrate solution used and the 
absorbance measurements were performed as described for the CETP mass 
determination. PLTP antibodies and standards were a generous gift from Dr. 
H. Hattori (BML incorporated, Saitama, Japan). In the present study PLTP 
activity correlated with human PLTP mass (r = 0.84, P < 0.05). 
Statistical analysis 
Data are expressed as mean± SD. Differences between huCETPtg mice and 
huCETPtg/huPLTPtg mice were analyzed by two sample Wilcoxon rank-sum 
tests. 
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RESULTS 
Plasma activities of CETP and PLTP 
The activities of CETP and PLTP were measured in plasma samples from 
huCETPtg mice and huCETPtg/huPLTPtg mice. CETP activity was 1.15-fold 
higher in huCETPtg mice compared with huCETPtg/huPLTPtg mice (P < 0.05) 
(Table 1). PLTP activity in plasma of huCETPtg mice was equal to activity 
levels found in wild-type mice (3). In huCETPtg/huPLTPtg mice PLTP activity 
was 2.8-fold higher (P < 0.001). 
Table 1. Plasma levels of lipids, CETP and PLTP activities as well as human CETP and human 
PLTP concentrations in transgenic mice. 
Cholesterol (mM) 10 1.9· ± 0.3 11 1.3 ± 0.1 
Triglycerides (mM) 9 0.3 ± 0.4 5 0.2 ± 0.1 
CETP activity(%) 12 126b ± 13 11 110 ± 22 
Human CETP (IJg/ml) 6 4.4b ± 1.9 7 2.9 ± 0.5 
PLTP activity (%) 13 148a ± 24 11 418 ± 54 
Human PLTP (IJg/ml) 4 NO 4 5.1 ± 0.7 
CETP and PLTP activities are expressed as percentage of human reference pool plasma 
values(%). One hundred percent of the human reference pool plasma is equivalent to a CETP 
activity of 215.6 nmol/ml/h and to a PLTP activity of 13.9 1-Jmol/ml/h. Differences between 
huCETPtg and huCETPtg/huPLTPtg mice were analyzed by two sample Wilcoxon rank-sum 
tests. Values are means ± SD. n , individual mouse plasma samples measured. •p < 0.001, 
bp < 0.05. ND, not detectable. 
Lipoprotein analyses 
Plasma samples from either huCETPtg or huCETPtg/huPLTPtg mice were 
analyzed by gelfiltration chromatography to examine their lipoprotein 
profiles. Phospholipid contents as well as CETP and PLTP activities were 
determined in all fractions (Figure 1). The HDL phospholipids in huCETPtg! 
huPLTPtg mice show a decrease due to PLTP overexpression (Figure 1A). The 
phospholipids in fractions 20-25 represent lysophosphatidylcholine bound to 
albumin. A similar profile, apart from the peak in fractions 20-25, was obtained 
for cholesterol (not shown). CETP activity eluted in fractions corresponding 
to the size of HDL (Figure 1B) and PLTP activity eluted in the fractions 9-15 
corresponding with relatively large HDL particles (Figure 1C), a situation also 
found in humans (14). 
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Figure 1. Lipoprotein profiles of plasma from transgenic mice. Equal amounts of plasma from 
either huCETPtg mice (n = 7) or huCETPtg!huPLTPtg mice (n = 10) were pooled and subjected 
to gel filtration on Superose 6 and Superdex 200 columns connected in tandem as described 
in Materials and Methods. Fractions were analyzed for (A) Phospholipids, (B) CETP activity: 
100% human reference pool plasma is equivalent to CETP activity of 215.6 nmol/ml/h. (C) 
PLTP activity: 100% human reference pool plasma is equivalent to PLTP activity of 13.9 fliDOl/ 
ml/h. Fractions 1-5 contain VLDL; 6-11 contain LDL; 12-20 contain HDL and; 21-25 contain 
lysophosphatidylcholine bound to albumin. 
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Figure 2. Human CETP and PLTP concentrations with their corresponding activities measured 
in gelfiltration fractions of plasma from transgenic mice. (A) Human CETP concentrations and 
CETP activities in huCETPtg mice (n = 7, r = 0.99, P < 0.001). (B) Human CETP concentrations 
and CETP activities in huCETPtg/huPLTPtg mice (n = 10, r = 0.92, P < 0.001). (C) Human PLTP 
concentrations and PLTP activities in huCETPtg/huPLTPtg mice (n = 13, r = 0.97, P < 0.001). 
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Determination ofhuman CETP and human PLTP concentrations 
Human CETP and human PLTP mass were analyzed in the plasma of 
huCETPtg and huCETPtg/huPLTPtg mice. CETP concentration was higher in 
huCETPtg mice compared with huCETPtg/huPLTPtg mice (P < 0.05). Human 
CETP mass co-eluted with CETP activity in the lipoprotein profiles of both 
huCETPtg and huCETPtg/huPLTPtg mice (Figure 2A and 2B respectively). 
PLTP concentration in huCETPtg/huPLTPtg mice was 5.1 ± 0.7 f.lg/ml. In 
huCETPtg/huPLTPtg mice human PLTP mass co-eluted with PLTP activity in 
the lipoprotein profile (Figure 2C). 
Cholesterol, triglyceride and free fatty acid measurements 
Before studying the influence of PLTP on VLDL metabolism, we measured 
cholesterol, triglyceride and free fatty acid content in plasma of huCETPtg 
mice and huCETPtg/huPLTPtg mice. Plasma cholesterol in huCETPtg mice 
was 1.5-fold higher than in huCETPtg/huPLTPtg mice (P < 0.001) (Table 1). 
The triglyceride and free fatty acid levels were similar in both groups of mice 
(Table 1). 
Effect of human PLTP on hepatic VLDL secretion 
After intravenous injection of Triton WR1339, the rate of plasma triglyceride 
accumulation was measured by determining triglycerides in plasma at 
appropriate time points (Figure 3A). The triglyceride accumulation rates 
calculated for each individual mouse were related to their body weights. 
There was no difference in body weight between the mice from the two 
groups (huCETPtg mice 19.6 ± 1.3 g; huCETPtg/huPLTPtg mice 19.2 ± 0.9 g). 
The secretion rate was calculated from the slope of the individual lines and is 
expressed as f.!mol/kg/h. As shown in Figure 3B, the VLDL secretion rate was 
1.5 fold higher in huCETPtg/huPLTPtg mice. HuCETPtg mice showed a rate 
of 140 ± 49 versus 208 ± 41 f.!IDOl/kg/h in huCETPtg/huPLTPtg mice (P < 0.05). 
The chemical composition ofVLDL was analyzed at 90 min after Triton WR1339 
injection. The composition of nascent VLDL (Figure 3C) was similar in the two 
groups of mice. Others have verified that catabolism of VLDL is completely 
blocked by Triton WR1339 and therefore the composition of the accumulated 
VLDL is a direct measure of the composition of nascent VLDL ). 
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Figure 3. In vivo hepatic VLDL secretion in transgenic mice. (A) Triglyceride production rates 
in transgenic mice were measured after Triton WR1339 administration. HuCETPtg mice are 
represented by open squares (n = 7) and huCETPtg/huPLTPtg mice are represented by closed 
squares (n = 6). Differences between huCETPtg and huCETPtg/huPLTPtg mice were analyzed 
by two sample Wilcoxon rank-sum tests. The lines represent the mean triglyceride rates± SD of 
individual mice within huCETPtg and huCETPtg/huPLTPtg mice (*P < 0.05). (B) Lipoprotein 
composition in nascent VLDL. VLDL was isolated from transgenic mouse plasma 90 min after 
Triton WR1339 administration by density ultracentrifugation at d = 1.006 g/ml (34200 rpm, 3 
h, l2°C). Lipids and protein were determined and expressed in percentage of total weight. 
Black segments represent the percentage of triglycerides, hatched segments represent the 
percentage of protein, white segments represent the percentage of phospholipids, and cross-
hatched segments represent the percentage of cholesterol in nascent VLDL. 
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DISCUSSION 
The exact role ofPLTPin lipoprotein metabolism is not clear. Earlier studies have 
shown that PLTP has both anti- and pro-atherogenic effects on lipoproteins (3, 
5, 9). It was demonstrated that mouse models lacking PLTP are less prone to 
diet-induced atherosclerosis. In two out of three models studied (5), this could 
be attributed to a reduced secretion of VLDL. PLTP deficiency or functional 
gene polymorphisms have not been found in humans. Moreover, unlike 
humans, mice do not have plasma CETP activity (19). Thus, total deficiency of 
both CETP and PLTP represent an extreme situation from which the effects on 
lipoprotein metabolism cannot be simply extrapolated to humans. 
The purpose of the present study is to evaluate the influence of PLTP on VLDL 
metabolism in a mouse model with appreciable CETP activity. In this study we 
demonstrate that elevated expression of PLTP increases hepatic VLDL secretion 
in mice in the presence of human CETP, without affecting the composition of 
the secreted VLDL. Despite the increase of VLDL secretion in the huCETPtg/ 
huPLTPtgmice, we did not observe an increase in plasma VLDLlevels. This may 
be due to an increased turnover of VLDL, or to increased receptor-mediated 
uptake by the liver. It is unlikely that the augmented VLDL secretion by PLTP 
is caused by an increased provision of free fatty acids from plasma to the liver, 
since no difference was found between the free fatty acid content in plasma of 
huCETPtg and huCETPtg/huPLTPtg mice (Table 1). Additional experiments 
showed that the elevation ofVLDL secretion can be specifically attributed to the 
PLTP transgene. Using mice solely transgenic for human PLTP, we observed a 
1.6-fold increase in VLDL secretion, if compared to wild-type mice. As recently 
demonstrated (5), PLTP plays a possible intracellular role in the liver. Because 
PLTP activity has been found in the Golgi, PLTP could be involved in the process 
of adding lipids to nascent VLDL particles. Plasma cholesterol content was 
1.5-fold higher in huCETPtg mice compared with huCETPtg/huPLTPtg mice 
(Table 1). Thus, overexpression of human PLTP in huCETPtg mice results in a 
decrease in total plasma cholesterol, mostly due to HDL lowering, as HDL is 
the major component of the plasma lipoproteins in mice. Raised PLTP activity 
in other transgenic mouse models also give rise to low HDL cholesterol levels 
(3, 10, 11). The decrease in plasma HDL is explained by an enhanced uptake of 
HDL cholesteryl esters by the liver (10). Interestingly, PLTP deficient mice also 
show markedly reduced HDL, probably due to HDL hypercatabolism (20, 21 ). 
Kawano et al. demonstrated that CETP overexpression could not compensate 
PLTP deficiency and caused an additional lowering of HDL (22). Plasma CETP 
activity measured in huCETPtg mice is higher than in huCETPtg/huPLTPtg 
mice (Table 1). The lower CETP activity found in huCETPtg/huPLTPtg mice 
may be a result from the lower plasma HDL concentrations caused by PLTP 
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overexpression (9). Because CETP is carried on HDL (14),lower plasma HDL 
concentrations could eventually give rise to lower CETP levels. The CETP 
concentrations in both groups of mice (Table 1) are within the range of human 
values, indicating that the mouse models used resemble the human situation 
both in terms of CETP activity and mass (23). 
PLTP activity levels in plasma of huCETPtg were equal to the activities found 
in wild-type mice (3). As expected, PLTP activity was higher in huCETPtg! 
huPLTPtg mice than in the huCETPtg mice (Table 1). The human PLTP 
mass measured in huCETPtg/huPLTPtg mice is within the range of reported 
plasma PLTP concentrations in humans (17, 24, 25). In contrast to what has 
been reported in humans (26, 27), in our mice PLTP activity correlates with 
human PLTP mass. In human plasma, such a correlation is not found due 
to the presence of inactive PLTP mass. In our studies, we found no evidence 
of inactive forms of PLTP in mice, since PLTP activity and PLTP mass elute 
in the same fractions in the lipoprotein profile (Figure 2C). At present, the 
physiological importance, if any, of inactive PLTP is unknown. Studies showed 
that type II diabetic patients have higher PLTP mass and activity compared 
with nondiabetic subjects (24, 28). Increased PLTP activity has also been 
reported in type I diabetic patients (29) and in the obese (30, 31). Both diabetes 
and obesity have been associated with an increased risk of coronary artery 
disease, indicating a possible pro-atherogenic potential for PLTP. 
By comparing huCETPtg mice with huCETPtg/huPLTPtg mice we observed 
that elevated PLTP leads to increased hepatic VLDL secretion. This is in line 
with experiments by Jiang et al. performed with cultured hepatocytes isolated 
from PLTP deficient mice, which showed a defect in VLDL secretion (5), and 
strengthens their suggestion that PLTP has an intracellular function in liver 
cells. 
In the present study we showed for the first time that elevation of plasma PLTP 
in transgenic mice increases VLDL secretion. Concomitantly with increased 
VLDL secretion, elevated PLTP resulted in lower levels of plasma HDL, both 
effects resulting in a more atherogenic lipoprotein profile. The huCETPtg! 
huPLTPtg mice used in this study provide a unique model because it resembles 
the human condition in terms of CETP activity and mass. In future studies we 
will test the impact of PLTP overexpression on diet induced atherosclerosis in 
huCETPtg mice. 
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ABSTRACT 
Plasma phospholipid transfer protein (PLTP) transfers phospholipids between 
lipoproteins and mediates HDL-conversion. PLTP overexpressing mice have 
increased atherosclerosis. However, mice do not express cholesteryl ester 
transfer protein (CETP), which is involved in the same metabolic pathways 
as PLTP. Therefore, we studied atherosclerosis in heterozygous LDL-receptor 
deficient (LDLR+I-) mice expressing both human CETP and human PLTP. 
We used two transgenic lines with moderately and highly elevated plasma 
PLTP activity. In LDLR+I-jhuCETPtg mice, cholesterol is present in both LDL 
and HDL. Both are decreased in LDLR+I-jhuCETPtg/huPLTPtg mice(> 50%). 
An atherogenic diet resulted in high levels of VLDL+LDL cholesterol. PLTP 
expression caused a strong PLTP-dose dependent decrease in VLDL+LDL 
cholesterol (-26% and -69%) and a decrease in HDL cholesterol (-70%). 
Surprisingly;. atherosclerosis was increased in the two transgenic lines with 
moderately and highly elevated plasma PLTP activity (1.9-fold and 4.4-fold, 
respectively), indicating that the adverse effect of the reduction in plasma 
HDL outweighs the beneficial effect of the reduction in apolipoprotein B 
(apoB)-containing lipoproteins. The activities of the anti-atherogenic enzymes, 
paraoxonase (PON) and platelet activating factor acetyl hydrolase (PAF-AH), 
were bothPLTP dose dependently reduced (about-33 and -65%, respectively). 
We conclude that expression of PLTP in this animal model results in increased 
atherosclerosis in spite of reduced apoB-containing lipoproteins, by reduction 
of HDL and of HDL-associated anti-oxidant enzyme activities. 
INTRODUCTION 
Plasma levels of high density lipoproteins (HDL) are inversely correlated with 
the risk for development of atherosclerosis (1). HDL are considered to have 
various atheroprotective effects, including anti-inflammatory and anti-oxidant 
properties and the potential to transport excess cholesterol from peripheral 
cells to the liver for degradation and excretion via the bile (1-4). 
Phospholipid transfer protein (PLTP) plays several key roles in HDL 
metabolism (5-8). PLTP facilitates the transfer of phospholipids, a-tocopherol 
and possibly unesterified cholesterol from triglyceride rich lipoproteins to 
HDL particles during lipolysis (9, 10). PLTP is able to modulate HDL size and 
composition (11-13) and may also be involved in HDL cellular mediated efflux 
of phospholipids and cholesterol (14). 
Elevation of PLTP in transgenic mice results in a PLTP-dose dependent 
decrease in plasma HDL levels, coinciding with an increased susceptibility 
to diet-induced atherosclerosis (15). These results are in agreement with the 
previous study by Jiang et al. (16), who demonstrated that PLTP deficient mice 
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are less prone to atherosclerosis. However, the explanation was different in 
both cases, as the changes in athero-susceptibility in PLTP deficient mice were 
not explained by an HDL effect, but by a decrease of hepatic VLDL secretion. 
Elevation of PLTP results in a stimulation of VLDL secretion (17), but this 
effect was found to be PLTP-dose independent. Therefore, it was considered 
to be a contributor but not the main cause for the atherogenic effect of elevated 
PLTP (15). Mice do not have cholesteryl ester transfer protein (CETP). Thus, 
the previously described genetically modified mice might be considered poor 
models to study the relation between PLTP and atherosclerosis, inasmuch 
as CETP is thought to be critically involved in atherogenesis (18). Moreover, 
although PLTP and CETP function independently (19, 20), CETP affects the 
metabolism of both HDL and of apoB-containing lipoproteins (18). Therefore, 
we decided to study the effect of elevated PLTP activity on atherosclerosis 
using mice genetically modified to express CETP. We found that also in this 
context, PLTP increases the susceptibility to diet-induced atherosclerosis. 
Surprisingly, this effect was found in spite of lowered levels of apolipoprotein 
apoB-containing lipoproteins. 
MATERIALS AND METHODS 
Animals 
The human PLTP transgenic mice were obtained as described before (15). In 
this study we used mice with moderately and highly elevated PLTP activity 
(lines huPLTPtgP4 and huPLTPtgA2, respectively). LDL-receptor (LDLR) 
knockout mice were purchased from Jackson Laboratory. The huCETPtg 
mice were kindly provided by Dr. A.R. Tall (Columbia University, New 
York). All mice were in C57BL/6J background. We created LDLR+1-jhuCETPtg 
mice, which were used as control mice. By crossbreeding these mice with the 
PLTP transgenic mouse lines expresssing various levels of PLTP, we obtained 
LDLR+1-jhuCETPtg/huPLTPtgP4 and LDLR+I-jhuCETPtg/huPLTPtgA2 mice. 
Male mice were used in further experiments. 
After weaning, animals were kept on a standard chow diet (Hope Farms, The 
Netherlands). At 4 months of age all groups of mice were put on a high fat, 
high cholesterol (HFHC) diet for 14 weeks which contained 40% w/w sucrose 
15% w/w fat, 1% w/w cholesterol and 0.5% w/w cholate to increase uptake of 
fat and cholesterol leading to high plasma cholesterol levels. Animals had free 
access to water and food. After fasting overnight blood samples were collected 
from the orbital plexus by using Vitrex™ sodium-heparinized micropipettes 
(80 IU) (Modulohm A/S, Copenhagen, Denmark) and immediately stored 
on ice. Blood was centrifuged at 2700 rpm for 15 min at 4 oc_ Plasma was 
either used directly or stored in small aliquots at -80 oc before analysis. All 
experiments were approved by national and institutional guidelines. 
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Separation of plasma lipoproteins by gelfiltration 
Plasma from transgenic mice was analyzed by gelfiltration on two HR10/30 
FPLC columns in tandem (Superdex 200 prepgrade, Superose 6 prepgrade, 
Pharmacia Biotech., Uppsala, Sweden). The columns were equilibrated with 2 
mM Na~PO/N~HP04' pH 7.4 (containing 0.9% NaCl (w/v), 0.02% NaN3 (w/ 
v) and 5 mM EDTA). Combined plasma samples were passed through 0.45-
J..Lm filters from Millipore S.A. (Molsheim, France), and 0.5 ml was subjected 
to gel filtration. The columns were run at 4 °C with a flow rate of 0.1 ml/min. 
Fractions of 0.8 ml were collected. Recoveries were > 90% for all analyses. 
Separation of plasma lipoproteins by density gradient centrifugation 
Lipoprotein fractions were obtained by density gradient ultracentrifugation 
of plasma samples in a Beckman SW60 Ti rotor (36500 rpm, 21 h 12 min, 12°C) 
(21). Alternatively, HDL and VLDL/LDL lipoprotein fractions were obtained 
by density gradient ultracentrifugation of plasma samples in a Beckman 42.2 Ti 
rotor (42000 rpm, 3h, 12 min, 12°C) at d = 1.063 g/ml. The lipoprotein fractions 
were collected by tube slicing. 
Quantification of cholesterol 
Cholesterol was determined enzymatically with the Free Cholesterol C kit 
no. 274-47109 (WAKO, Neuss, Germany) after hydrolysis of cholesteryl esters 
with cholesterol esterase from Candida cylindracea (Boehringer, Mannheim, 
Germany). 
Plasma activity assays 
CETP and PLTP activity assays were performed as described before (22). The 
activities are expressed as arbitrary units (AU); 1 AU is the activity found in 
human reference pool plasma. The activities are: CETP 216 nmol/ml/h; PLTP 
14 fllllOl/ml/h. 
PON activity towards paraoxon was quantified spectrophotometrically 
essentially as described (23). In short, 10-20 !J.l of serum or heparin-plasma 
was added to 1 ml incubation medium with 50 mM Tris-HCL buffer (pH 8.0), 
containing 1 mM CaC12 and 6.0 mM paraoxon. The reaction was monitored 
for up to 30 min at 25 oc by measuring the appearance of p-nitrophenol at 412 
nm in a CARY 1E UV visible spectrophotometer. PON activity is expressed as 
Units/mi. 
PAF-AH was determined as described by Tselepis et al. (24), using 2-[acetyl-
3H PAF] as substrate. In short, 80 nmoles of substrate (final concentration 0.33 
mM) were incubated with 10 f-11 diluted (10-fold) plasma samples in incubation 
medium (total volume 0.24 ml) with 0.1 M Tris-HCl buffer pH 7.4, containing 
0.9% NaCl and 1 mM EDTA. After incubation for 20 min at 37 oc, the reaction 
was stopped on ice and 300 J..Ll CHC13 and 600 !J.l methanol were added. After 
mixing, another 300 J..Ll of CHC13 was added with 300 J..Ll 0.9% NaCl pH 2.0. 
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After after mixing again, phase separation was obtained by centrifugation for 
30 min. 700 ~1 of the upper layer was used for counting radioactive acetid acid. 
PAF-AH activity is expressed as nmol/min/ml plasma or serum. 
Histological assessment of atherosclerosis 
After 14 weeks of feeding the HFHC diet, mice were sacrificed after collection 
of blood as described above. The hearts were dissected, stored in phosphate-
buffered 4% formaldehyde until processed, and embedded in paraffin. 
Serial cross sections of 5 f.liil throughout the aortic valve area were used for 
histological analysis. Sections were stained with hematoxylin and eosin. Per 
mouse 5 sections with intervals of 60 1-1m were used for quantification of 
atherosclerotic lesions. To evaluate whether PLTP has an effect on accumulation 
of free cholesterol in atherosclerotic lesions, the amount of sections containing 
free cholesterol clefts was counted in each group as described by Delsing et al. 
(25). 
Statistical analysis 
Data are expressed as means ± SEM. Differences were analyzed by two 
sample Wilcoxon rank-sum tests by using Intercooled Stata 6.0 software (Stata 
Corporation, College Station, TX, USA). 
RESULTS 
Elevation of PLTP activity lowers plasma cholesterol 
Plasma levels of total cholesterol, VLDL+LDL cholesterol and HDL cholesterol 
were measured in LDLR+I-jhuCETPtg, LDLR+I-jhuCETPtg/huPLTPtgP4 
and LDLR+f-jhuCETPtg/huPLTPtgA2 mice, respectively (Table 1). The 
PLTP overexpressing mouse lines were compared with LDLR+I-jhuCETPtg 
mice, which are referred to as control mice throughout the present study. 
Overexpression of PLTP resulted in a dramatic reduction of plasma levels 
of total cholesterol (-50% and -70% in LDLR+1-jhuCETPtg/huPLTPtgP4 and 
LDLR+I-jhuCETPtg/huPLTPtgA2 mice, respectively, compared to control). This 
reduction in plasma cholesterol was found in both VLDL+LDL and in HDL 
lipoprotein classes. On a chow diet, the majority of the plasma cholesterol in is 
HDL, in which class the strongest reduction in cholesterol was found. 
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Table 1. Plasma cholesterol levels in mice fed normal chow diet. 
TC(mM) 
HDL-TC(mM) 
VLDULDL-TC (mM) 
2.7 ± 0.1 
1.7 ± 0.1 
0.8 ± 0.1 
1.4 ± 0.1 • 
0.7 ± 0.1. 
0.4 ± 0.1 • 
0.8 ± 0.1. 
0.04 ± 0.01. 
0.44 ± 0.06. 
CETP, cholesteryl ester transfer protein; PLTP, phospholipid transfer protein; TC, total 
cholesterol. asignificantly different from LDLR+1·fhuCETPtg, P < 0.001. 
Table 2. Plasma cholesterol levels in mice fed HFHC diet. 
HFHC, high fat, high cholesterol. 3Significantly different from LDLR+'·fhuCETPtg P < 0.05. 
bSignificantly different from LDLR+'·fhuCETPtg P < 0.001. 
Overexpression ofPLTP increases susceptibilty to atherosclerosis 
After the animals had been fed an HFHC diet for 14 weeks, the areas of the 
atherosclerotic lesions were quantified in cross sections of the aortic valves 
from individual mice. As shown in Figure lA, atherosclerosis was more severe 
in LDLR+I-jhuCETPtg!huPLTPtgP4 mice as compared with control mice, while 
a further increase was found in LDLR+f-jhuCETPtg/huPLTPtgA2 mice. 
We also evaluated whether PLTP overexpression increased the number of 
sections containing cholesterol clefts (Figure lB). In control mice, cholesterol 
clefts were not observed. However, in mice overexpressing human PLTP 
cholesterol clefts were present. Moreover.~ atherosclerotic lesions from 
LDLR+f-jhuCETPtg/huPLTPtgA2 mice showed more cholesterol clefts than 
those from LDLR+I-jhuCETPtg/huPLTPtgP4 mice (P = 0.05). Figure lC shows 
representative photographs of the atherosclerotic lesions from mice of the 
various genotypes. 
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Figure 1. Atherosclerosis in transgenic mice after 14 weeks of a high-fat, high-cholesterol 
(HFHC) diet. Mice (n = 9 -13 per group) were sacrificed, and aortas were removed and 
atherosclerotic lesion areas in the aortic roots were determined as described in Materials and 
Methods. (A) aortic valve lesion areas; (B) percentage of sections containing free cholesterol 
clefts in the aortic lesions; (C) representative lesion areas of LDLR•1-!huCETPtg, LDLR•1· 
/huCETPtg/huPLTPtgP4, and LDLR+'·JhuCETPtg/huPLTPtgA2 mice. Cholesterol clefts 
are particularly conspicuous in the lowest panel. Values represent means± SEM. *P < 0.05 
compared with LDLR•1·JhuCETPtg mice. 
PLTP expression reduces diet-induced hypercholesterolemia 
In order to find out why LDLR+1-jhuCETPtg/huPLTPtgP4 and LDLR+I·j 
huCETPtg/huPLTPtgA2 mice have more atherosclerosis than control mice, we 
analyzed the levels of plasma cholesterol after feeding the animals a HFHC 
cholesterol diet for 14 weeks (Table 2). As expected, the diet resulted in a strong 
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increase of the plasma levels of total cholesterol in all three genotypes (compare 
Tables 1 and 2). However, overexpression of PLTP reduced total cholesterol 
in plasma compared with control mice. As a consequence of the diet, the 
bulk of the plasma cholesterol was in VLDL+LDL in all the three genotypes 
analyzed. A PLTP-dose dependent decrease in VLDL+LDL cholesterol was 
found in PLTP overexpressing mice compared to control mice (-26% and-
69% in LDLR+I-jhuCETPtg/huPLTPtgP4 and LDLR+I-jhuCETPtg/huPLTPtgA2 
mice, respectively). HDL-cholesterol was also strongly reduced in the PLTP 
overexpressing animals (-70% in both genotypes compared to control mice). 
To examine the effects on lipoprotein classes in more detail, plasma samples 
from the various transgenic mouse lines were analyzed by gel filtration 
chromatography (Figure 2). The HFHC diet resulted in an increase of total 
plasma cholesterol in all lipoprotein fractions of all transgenic mouse lines 
compared with the cholesterol profiles found on chow diet (results not 
shown). The HFHC diet also induced a strong shift of the cholesterol profiles 
to the more atherogenic lipoproteins intermediate density lipoproteins and 
VLDLs. The effect of PLTP expression was a decrease in cholesterol in these 
lipoprotein fractions. The biggest effect was found in the mice with the highest 
plasma PLTP activity level, i.e. the LDLR+I-jhuCETPtg/huPLTPtgA2 mice. HDL 
cholesterol was almost absent after feeding the diet for 14 weeks in both PLTP 
expressing lines (Figure 2). 
Therefore, overexpression of PLTP in the presence of CETP results in an 
elevation of diet-induced atherosclerosis in spite of markedly reduced levels of 
apoB-containing lipoproteins. This suggests that the effect on atherosclerosis 
is caused by the strong reduction in HDL. However, LDLR+1-jhuCETPtg/ 
huPLTPtgP4 and LDLR+I-jhuCETPtg/huPLTPtgA2 mice hardly differ in HDL 
cholesterol levels after feeding the animals 14 weeks of the HFHC diet, while 
the atherosclerotic lesion size is considerably higher in the LDLR+1-jhuCETPtg/ 
huPLTPtgA2 mice. Therefore, we proceeded with examining HDL associated 
lipid transfer and enzymatic activities. 
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Figure 2. Distribution of lipoproteins in plasma from transgenic mice. Equal amounts of plasma 
from transgenic mice (n = 16-20) fed a HFHC diet for 14 weeks were pooled and subjected to 
gel filtration on Superose 6 and Superdex 200 columns connected in tandem as described in 
Materials and Methods. Fractions 1-5 contain VLDL, fractions 6-11 contain LDL, fractions 12-20 
contain HDL and fractions 21-25 contain albumin. Circles, LDLR+i-jhuCETPtg mice; triangles, 
LDLR+i·jhuCETPtg/huPLTPtgP4 mice; squares, LDLR+i·jhuCETPtg/huPLTPtgA2 mice. 
CETP and PLTP activities 
After the animals had been fed a HFHC diet for 14 weeks, CETP activities 
were slightly decreased in PLTP overexpressing mice compared with control 
mice (Figure 3A). However, no difference was found in plasma CETP activity 
between mice with moderate and those with high PLTP expression. Differences 
in plasma PLTP activity levels were maintained after the diet period (Figure 
3B). 
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Figure 3. Cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) 
activities in plasma from transgenic mice. Plasma samples from the various transgenic mouse 
lines were analyzed for CETP (A) and PLTP (B) activities as described in Materials and 
Methods after the mice had been fed a HFHC diet for 14 weeks. Values shown are means± 
SEM obtained from >13 mice per group. *P < 0.05 compared with LDLR+i·jhuCETPtg mice. 
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Effect of PLTP overexpression on PON and PAF-AH activities 
PON and PAF-AH are HDL associated enzymes which may have anti-
atherogenic properties (26r 27) . Because PLTP overexpression lowers the 
plasma HDL concentrations in our micer we examined whether this might affect 
these enzymes as well (Figure 4). Indeedr we found that PLTP overexpression 
was associated with decreased activities of both PON and PAF-AH. In 
LDLR+I·JhuCETPtg/huPLTPtgP4 and LDLR+I·JhuCETPtg/huPLTPtgA2 micef 
respectively;. PON activity was 33% and 60% lower compared with control mice 
(Figure 4A). The reduction in PAF-AH activity was 33% and 70%r respectively 
(Figure 4B). The difference in activity between the two lines of PLTP expressing 
mice was statistically significant for both enzymes, suggesting PLTP dose-
dependent lowering effects. 
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Figure 4. Anti-oxidant enzyme activities in plasma from transgenic mice. Plasma samples 
from the various transgenic mouse lines were analyzed for paraoxonase (PON) and platelet-
activating factor acetyl hydrolase (P AF-AH) activities as described in Materials and Methods. 
Values shown are means± SEM obtained from 4-7 mice per group. *P < 0.05 compared with 
LDLR+I-jhuCETPtg mice; tp < 0.05 compared with LDLR+I·fhuCETPtg/huPLTPtgP4 mice. 
DISCUSSION 
In the present study;. we corroborated our previous finding that elevated PLTP 
activity in plasma results in increased atherosclerosis in mice (15). However, 
the crucial difference with the previous study is that we now used transgenic 
mouse models that express CETP in addition to PLTP. Increased CETP activity 
has been found to result in increased atherosclerosis in mice (28r 29)r rats (30)r 
and rabbits (31). We demonstrated that variations in PLTP activity modulate 
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the susceptibility to diet-induced atherosclerosis on top of the CETP effect. 
Surprisingly;. the atherogenic effect of PLTP was found in spite of a decrease 
of plasma cholesterol in apoB-containing lipoproteins. Plasma levels of HDL 
were also lower in PLTP overexpressing mice. This is in agreement with what 
has been reported before in other mouse models with elevated PLTP activity 
from our as well as other laboratories (15, 32, 33). In the present study;. we found 
that the decrease in plasma cholesterol in both lipoprotein classes studied, i.e. 
apoB-containing lipoproteins and HDL, persist after feeding the animals the 
HFHC diet for 14 weeks. These findings suggest that the reduction in plasma 
HDL affects the development of atherosclerosis to a greater extent than the 
reduction in apoB-containing lipoproteins. 
We used two lines of transgenic mice overexpressing human PLTP to different 
levels. The LDLR+I-jhuCETPtg/huPLTPtgA2 mice have the highest level ofPLTP 
activity, and also have the highest level of atherosclerosis. However, the levels 
of plasma HDL cholesterol are similar between both lines at the end of the 14 
weeks period of HFHC diet. On the other hand, on a chow diet, the LDLR+/-
/huCETPtg/huPLTPtgA2 mice have lower levels of plasma HDL cholesterol 
than the LDLR+I-jhuCETPtg/huPLTPtgP4 mice. Therefore, the variation in 
atherosclerosis could be caused by the difference in HDL cholesterol, even 
though this equals out during the diet period. The presence of a larger number 
of cholesterol clefts in LDLR+I-jhuCETPtg/huPLTPtgA2 mice compared with 
LDLR+I-jhuCETPtg/huPLTPtgP4 mice is indicative of a less efficient removal 
of cholesterol from the atherosclerotic lesions by reverse cholesterol transport, 
allowing the formation of extracellular cholesterol crystalline deposits, which 
are inert and cannot be mobilized (34 ). However, there could also be a qualitative 
difference between the HDL from the LDLR+I-jhuCETPtg/huPLTPtgP4 and the 
LDLR+I-jhuCETPtg/huPLTPtgA2 mice. Therefore, we analyzed the activity of 
transfer proteins and enzymes which have been found to be associated with 
HDL in various mouse models (17, 35, 36). 
A small but statistically significant decrease in CETP activity was found in 
the mice expressing PLTP. This is in agreement with previous findings from 
our laboratory (20) and may be caused by the drop in HDL levels caused by 
PLTP expression, inasmuch as HDL is the carrier of CETP. As outlined above, 
CETP is atherogenic in various animal models. Therefore, a small decrease in 
CETP activity cannot explain the increase in atherosclerosis found in PLTP 
overexpressing animals. Moreover, CETP activity is not different between 
LDLR+1-jhuCETPtg/huPLTPtgP4 and LDLR+I-jhuCETPtg/huPLTPtgA2 mice. 
As expected, the mice have different levels of plasma PLTP activity;. which 
persist at the end of the diet period. 
In addition, the activity of PON and PAF-AH were found to be decreased 
in PLTP overexpressing mice. Both enzymatic activities are lower in LDLR+I-
/huCETPtg/huPLTPtgA2 mice than in LDLR+I-jhuCETPtg/huPLTPtgP4 mice. 
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Elevation of the activity of either PON (37) or PAF-AH (38) results in decreased 
atherosclerosis in mice. Moreover, PON deficient mice have increased 
atherosclerosis (39), while decreased activities of both enzymes have been 
found in mouse models susceptible for atherosclerosis (36). It is likely that the 
decrease in PON and PAF-AH activities are related with the decrease in HDL, 
because in mice, these enzymes are mainly associated with HDL (35, 36), even 
in animals with extremely elevated plasma cholesterol in apoB-containing 
lipoproteins. 
At present, it is not clear why overexpression of PLTP results in a decrease 
in VLDL+LDL cholesterol in plasma in LDLR+I-jhuCETPtg/huPLTPtgP4 
and LDLR+I-jhuCETPtg/huPLTPtgA2 mice. In the absence of CETP, PLTP 
overexpression does not affect VLDL+LDL cholesterol levels (15). On the 
other hand, in mice that have no mutations in the LDLR (LDLR+I+), VLDL+LDL 
cholesterol levels in huCETPtg mice and in huCETPtg/huPLTPtg mice are 
similar (20). Therefore, the LDLR seems to play a critical role in the effect by 
PLTP in CETP transgenic mice. An alternative explanation is that the effect of 
PLTP on apoB-containing lipoproteins exists only above a certain threshold 
level of these lipoproteins. Both heterozygous deficiency for the LDLR (15, 40) 
as well as the CETP transgene (20, 29) result in an increase in plasma levels of 
apoB-containing lipoproteins. Consequently, the levels of these lipoproteins are 
higher in the mice analyzed in the present study than in the earlier studies. 
PLTP deficiency has been shown to increase the vitamin E content ofVLDL and 
LDL, thereby protecting these lipoproteins from oxidation (41). Conversely, 
elevated PLTP expression might result in decreased vitamin E in VLDL+LDL 
and thus in a higher susceptibility to oxidative modification of these 
lipoproteins, resulting in a more rapid removal from the plasma compartment. 
This mechanism could contribute to the atherogenicity of PLTP overexpression, 
despite a decrease in plasma VLDL+LDL cholesterol concentration. 
In conclusion, elevated expression of PLTP results in decreased plasma 
cholesterol in both atherogenic apoB-containing lipoproteins and in anti-
atherogenic HDL. Inasmuch as the susceptibility to atherosclerosis is increased 
in a PLTP dose-dependent fashion, the effect on HDL apparently outweighs the 
effect on apoB-containing lipoproteins. The mechanism may include various 
atheroprotective properties of HDL, including the involvement in reverse 
cholesterol transport and the association with anti-oxidant enzymes. 
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ABSTRACT 
We previously demonstrated that overexpression of human plasma 
phospholipid transfer protein (PLTP) in transgenic mice results in increased 
susceptibility to diet-induced atherosclerosis [J. Bioi. Chern. 2002; 277:48938-
48943]. This is in agreement with findings in PLTP deficient mice which 
have less atherosclerosis [Jiang et al., Nat. Med. 2001; 7:847-852]. However, 
different mechanisms have been proposed in these two mouse models to 
explain the atherogenicity of PLTP. From experiments in PLTP deficient 
mice, it was concluded that PLTP stimulates hepatic secretion of triglycerides 
in apolipoprotein B-containing lipoproteins. This was confirmed in PLTP 
overexpressing transgenic mice, but in this model the atherogenic effect was 
attributed to the observed decline in high density lipoproteins (HDL). In order 
to find evidence to relate the increased atherosclerosis in PLTP transgenic 
mice to one of these atherogenic effects, a comparison was made between 
male and female mice with relatively modest overexpression of PLTP, as the 
development of atherosclerosis is known to be sex-dependent in most mouse 
models. Indeed, after feeding the animals an atherogenic diet atherosclerosis 
was about 7-fold higher in female mice than in male mice, while PLTP 
activity levels were virtually identical. Also, the rates of hepatic secretion of 
triglycerides were identical in male and female mice. In contrast, plasma levels 
of HDL were about 2-fold lower in female mice than in male mice after feeding 
an atherogenic diet. We conclude that overexpression of PLTP in transgenic 
mice causes atherosclerosis through a decrease in HDL, rather than through 
elevated hepatic secretion of triglycerides. 
INTRODUCTION 
Atherosclerosis is the leading cause of death and morbidity in industrialized 
countries (1-3). It is generally accepted that an elevated level of plasma 
cholesterol is an important risk factor for atherosclerosis. While the level of 
cholesterol in low density lipoproteins (LDL) correlates positively with the 
incidence of atherosclerotic disease, cholesterol in high density lipoproteins 
(HDL) appears to protect against the development of atherosclerosis (1, 2, 
4). HDL is thought to have several anti-atherogenic properties. First, HDL 
is involved in the reverse cholesterol transport pathway, by which excess 
cholesterol is transported back to the liver for excretion (5-7). In addition, 
HDL has both anti-inflammatory and anti-oxidant properties (4, 8-10). One 
of the proteins involved in HDL metabolism is plasma phospholipid transfer 
protein (PLTP)(ll). We previously demonstrated that transgenic mice 
overexpressing human PLTP to various activity levels are more prone to the 
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development of diet-induced atherosclerosis in a PLTP-dose dependent way 
(12). Concomitantly, the plasma level of HDL was decreased. We concluded 
that the increase in atherosclerosis is caused by this decrease in plasma HDL. 
However, in addition to an effect on HDL, PLTP has an effect on the production 
of very low density lipoproteins (VLDL), which was first described in PLTP 
deficient mice (13). The decreased atherosclerosis found in these mice was 
explained by decreased synthesis of apoB-containing lipoproteins by the 
liver. We examined whether elevated PLTP activity levels would affect hepatic 
VLDL secretion. Indeed, PLTP overexpressing mice were found to have an 
increase in the synthesis of apoB-containing lipoproteins (12, 14), which could 
contribute to the increased susceptibility to atherosclerosis found in these mice. 
Thus, elevated PLTP has two atherogenic effects on lipoprotein metabolism, 
i.e. increasing hepatic VLDL secretion and decreasing plasma levels of HDL. 
In order to find out which of these mechanisms is the most importa nt one 
for the development of atherosclerosis, we first determined whether male 
and female mice with similar levels of overexpression of PLTP differ in their 
susceptibility to atherosclerosis. Sex differences have been frequently found in 
mouse models, including the commonly used low density lipoprotein receptor 
(LDLR) deficient mice and apolipoprotein (apo) E deficient mice (15, 16). The 
present data show that the susceptibility to diet-induced atherosclerosis is sex-
dependent in PLTP overexpressing mice, enabling us to relate these differences 
with the effects on apoB-containing lipoproteins versus the effects on HDL. 
We used transgenic mouse models which express also human cholesteryl ester 
transfer protein (CETP) (14, 17). CETP is normally not expressed in mice, but 
is involved in the same pathways of lipoprotein metabolism as PLTP and may 
be crucially involved in the process of atherosclerosis in man (18, 19). 
MATERIALS AND METHODS 
Animals 
The human PLTP transgenic mice (huPLTPtg) were described before (line 
P1;(12, 20)). LDL receptor knockout mice were purchased from Jackson 
Laboratory. Human CETP transgenic mice (huCETPtg) were kindly provided 
by Dr. A.R. Tall (Columbia University, New York). All mice were in C57BL/ 
6J background for at least 8 generations. LDLR+f-jhuCETPtg and LDLR+/-
/huCETPtg/huPLTPtg mice were created by crossbreeding. After weening, 
animals were kept on a chow diet (Hope Farms, The Netherlands). For the 
induction of atherosclerosis, mice were fed a high fat high cholesterol (HFHC) 
diet for 14 weeks, which contained 40% w/w sucrose 15% w/w fat, 1% w/w 
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cholesterol and 0.5% w/w sodium cholate (Hope Farms, The Netherlands). 
Mice were 12 weeks old at the beginning of the diet studies. Animals were 
housed under standard conditions and had free access to water and food. 
After fasting overnight, blood samples were collected from the orbital plexus 
by using Vitrex™ sodium-heparinized micropipettes (80 IV) (Modulohm A/S, 
Copenhagen, Denmark) and immediately stored on ice. Blood was centrifuged 
at 2700 rpm for 15 min at 4 oc. Plasma was either used directly or stored in 
small aliquots at -80 °C before analysis. All experiments were performed 
according to national and institutional guidelines. 
Separation of plasma lipoproteins by density gradient centrifugation 
Lipoproteinfractionsusedin Table 1 werecollectedfollowingultracentrifugation 
in a Beckman 42.2 Ti rotor ( 42000 rpm, 3 h, 12 °C). Alternatively, the lipoprotein 
fractions used in Figure 2 were obtained by density gradient ultracentrifugation 
of plasma samples in a Beckman SW60 Ti rotor (36500 rpm, 21 h 12 min, 12 °C) 
as described (21). 
Quantification of cholesterol 
Total plasma cholesterol (TC) was determined enzymatically with the Free 
Cholesterol C kit no. 274-47109 (WAKO, Neuss, Germany) after hydrolysis of 
cholesteryl esters with cholesterol esterase from Candida cylindracea (Boehringer, 
Mannheim, Germany). 
Plasma activity assays 
CETP and PLTP activity assays were performed as described before (20). The 
activities are expressed as arbitrary units (AU); 1 AU is the activity found in 
human reference pool plasma. The activities are: CETP 216 nmol/ml/h; PLTP 
14 !JIDOl/ml/h. 
In vivo hepatic VLDL secretion 
VLDL secretion experiments were performed using the Triton WR1339 method, 
as described (14). 
Histological assessment of atherosclerosis 
After 14 weeks of HFHC diet feeding, mice were sacrificed after blood 
collection as described in the animal section. The hearts were dissected, stored 
in phosphate buffered 4% formaldehyde until processed. Atherosclerotic areas 
in the aortic valves were quantified by computer assisted measurements as 
described (12, 22). To evaluate whether PLTP has an effect on accumulation of 
free cholesterol in atherosclerotic lesions, the presence of cholesterol clefts in 
the sections was evaluated as described (23). 
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Statistical analysis 
Data are expressed as means ± SEM. Differences between two groups of mice 
were analyzed by two sample Wilcoxon rank-sum tests by using Intercooled 
Stata 6.0 software (Stata Corporation, College Station, TX, USA). 
RESULTS 
Levels of plasma cholesterol 
Throughout the present study, comparisons are made between LDLR+I-j 
huCETPtg and LDLR+1-jhuCETPtg/huPLTPtg mice of both sexes. As shown 
in Figure 1, there is no difference in the plasma level of cholesterol (total 
cholesterol) between male and female LDLR+1-jhuCETPtg mice. In contrast, in 
LDLR+1-jhuCETPtg/huPLTPtg mice plasma cholesterol is somewhat higher in 
females than in males. Plasma cholesterol is lower in the LDLR+f-jhuCETPtg/ 
huPLTPtg mice compared with LDLR+I-jhuCETPtg mice in either sex. HDL 
was separated from VLDL+LDL via ultracentrifugation in order to study the 
distribution of cholesterol between the lipoproteins (Table 1). Plasma levels of 
HDL-cholesterol are decreased in both male and female LDLR+f-jhuCETPtg! 
huPLTPtg mice when compared to LDLR+I-jhuCETPtg mice. The difference 
is -35% for the male mice and -44% for the female mice. The concentrations 
of HDL-cholesterol are not different between males and females of either 
genotype. In mice fed a regular chow diet, a minor fraction of plasma 
cholesterol is in VLDL+LDL. Only small differences were found between 
the various groups. After feeding the mice a HFHC diet, the plasma levels of 
VLDL+LDL cholesterol are greatly increased (Table 1 ). There are no statistically 
significant differences between males and females of either genotype. The 
VLDL+LDL cholesterol levels are somewhat lower in plasma from LDLR+I-j 
huCETPtg/huPLTPtg mice when compared to LDLR+1-jhuCETPtg mice, but 
this difference was not statistically significant for the females. In contrast, 
striking differences were found in HDL cholesterol levels. These were about 
2-fold higher in male mice than in female mice in either genotype. In both 
sexes, LDLR+I-jhuCETPtg/huPLTPtg mice have lower levels of plasma HDL 
cholesterol than LDLR+I-jhuCETPtg mice. The lowest concentration of plasma 
HDL cholesterol was found in female LDLR+f-jhuCETPtg!huPLTPtg mice. In 
a separate experiment, the relative distribution of VLDL/IDL, LDL and HDL 
cholesterol was measured in larger samples of pooled plasma from mice fed a 
HFHC diet (Figure 2). This distribution is not different between male LDLR+f-j 
huCETPtg versus LDLR+1-jhuCETPtg/huPLTPtg mice. In female mice however, 
LDLR+1-!huCETPtg/huPLTPtg mice have relatively less HDL and more apoB-
containing lipoproteins in comparison with LDLR+1-jhuCETPtg mice. 
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Table 1. Plasma levels of lipoprotein cholesterol on chow and HFHC diet. 
CHOW diet 
VLDL+LDL-C 0.8 ± 0.1 1.1 ± 0.1§ 0.6±0.1* 0.8 ± 0.1*§ 
HDL-C 1.7±0.1 1.8 ± 0.1 1.1 ± 0.1* 1.0±0.1* 
HFHC diet 
VLDL+LDL-C 9.9 ± 1.3 8.2 ± 0.9 7.3 ± 0.8 6.9 ± 0.7 
HDL-C 1.4±0.1 0.6 ± 0.1 0.6 ± 0.1 0.3 ± 0.03 
*P < 0.001, LDLR+'·JhuCETPtg versus LDLR+1-/huCETPtg/huPLTPtg mice. §p < 0.001, male 
versus female. Cholesterol concentrations are in mM. n = 14-20 per group. 
P<O 001 
P<O 005 
LDLR+/-IhuCETPtg LDLR+/-/huCETPtg/huPLTPtg 
Figure 1. Plasma concentration of total cholesterol in transgenic mice on chow diet. 
Measurements represent means± SEM of 14-20 mice. 
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Figure 2. Distribution of plasma cholesterol between lipoprotein classes in transgenic mice 
fed a HFHC diet. Lipoproteins were by separated by density gradient ultracentrifugation of 
plasma samples in a Beckman SW60 Ti rotor (36500 rpm, 21 h 12 min, 12 °C). Data represent 
measurements in pooled plasma samples from 14-20 mice. 
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VLDL triglyceride secretion 
PLTP is known to stimulate hepatic secretion of VLDL (13, 14). Therefore, 
a comparison was made between male and female LDLR+f·JhuCETPtg/ 
huPLTPtg mice in a set of experiments investigating the hepatic secretion of 
VLDL triglycerides by the Triton WR1339 method (Figure 3A). No significant 
differences between males and females are observed. After correction for body 
weight, the rates of VLDL secretion between these two groups are identical 
(males: 195 ± 40 f.llilOl/kg/h; females: 195 ± 48 ~mol/kg/h). In order to check 
whether the atherogenic diet could possibly induce a sex-specific difference, 
VLDL secretion was also measured in animals fed the HFHC diet. As shown 
in Figure 3B, the rate of VLDL secretion is considerably lower in these animals 
than in animals fed a chow diet. However, there is no statistically significant 
difference in the VLDL secretion rates after correction for body weight between 
males and females (males 69±9 ~mol/kg/h; females 54±6 f.llilOl/kg/h; P = 0.18). 
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Figure 3. Hepatic secretion of triglycerides in transgenic mice fed a chow diet (A) or an HFHC 
diet (B). Plasma levels of triglycerides were measured at the indicated times in male (open 
circles) and female (closed circles) LDLR+I·fhuCETPtglhuPLTPtg mice after administration of 
Triton WR 1339. Measurements represent means± SEM of 7 (A) or 10 (B) mice per group. 
Plasma activities of CETP and PLTP 
Figure 4 shows plasma CETP and PLTP activities in male and female mice 
fed a HFHC diet for 14 weeks. While the plasma activities of CETP and PLTP 
in mice expressing either only PLTP or the combination of the two proteins 
have been described in previous studies from our laboratory (14, 17), we did 
not investigate possible sex-related differences. As expected, PLTP activity is 
much higher in LDLR+I-jhuCETPtg/huPLTPtg mice than in LDLR+I·JhuCETPtg 
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mice. PLTP activity is not different between males and females from either 
genotype (Figure 4A). CETP activity is identical in male LDLR+1-jhuCETPtg 
mice and male LDLR+I·fhuCETPtg/huPLTPtg mice. In female mice, CETP 
activity is slightly increased in LDLR+1-jhuCETPtg/huPLTPtg mice versus 
LDLR+1-jhuCETPtg mice. CETP activity is lower in females than in males of 
either genotype (Figure 4B). The HFHC diet causes a small increase in PLTP 
activity, but a strong induction of CETP activity in mice of both genotypes and 
of both sexes (PLTP activity: 124 ± 6%, P < O.OS; CETP activity: 344 ± 13%, P < 
0.001; results not shown). 
A B 
P<0.001 
8 
male female male female 
LDLR+/-/huCETPtg LDLR+/-/huCETP!g/huPLTPtg LDLR+/-/huCETP!g LDLR+/-/huCETP!g/huPLTP!g 
Figure 4. Activities of CE1P and PL1P in plasma from transgenic mice fed a HFHC diet. (A) 
PL1P activities. 1 AU is equal to 14 !JIDOI/ml/h. (B) CE1P activities. 1 AU is equal to 216 nmol/ 
ml/h. Data represent means± SEM of 17-19 mice. 
Atherosclerosis 
Diet-induced atherosclerosis was evaluated by measuring the atherosclerotic 
area in the aortic root (Figure SA). Male mice show small lesion areas that are 
similar in size between the two genotypes. In contrast, female mice develop 
substantial lesion areas in both genotypes. When comparing sexes, female 
mice show 3.4-fold LDLR+I·jhuCETPtg mice) and 7.0-fold (LDLR+1-jhuCETPtg/ 
huPLTPtg mice) larger lesion areas than male mice (both P < 0.001) (Figure SA). 
PLTP overexpression in female mice results in a 1.8-fold further increase (P < 
O.OOS) in aortic lesion area. In addition, female mice overexpressing human 
PLTP show more severe plaques with larger numbers of cholesterol clefts 
(Figure SB). In male mice, the severity of the plaque appears higher too, as 
no cholesterol clefts are observed in LDLR+I·jhuCETPtg mice, while a modest 
percentage of the plaques in the LDLR+f·jhuCETPtg/huPLTPtg mice do contain 
cholesterol clefts. Representative images are shown in Figure 6. 
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Figure 5. Atherosclerosis in transgenic mice fed a :HFHC diet. (A) Atherosclerotic lesion 
areas were measured in 5 sections per animal from the aortic root. (B) Percentage of sections 
containing free cholesterol clefts in the aortic lesion. Data represent means± SEM of 11-18 
mice. 
Figure 6.Atherosclerotic lesions in the aortic valves. Photomicrographs showing representative 
atherosclerotic lesions in aortic valves. (A) male LDLR+i·jhuCETPtg mice; (B) male LDLR+1·; 
huCETPtg!huPLTPtg mice; (C) female LDLR+i·jhuCETPtg mice; (D) female LDLR+1·fhuCETPtg/ 
huPLTPtg mice. Scale bars: 200 ~-tm. 
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DISCUSSION 
In the present study we investigated whether a sex difference in susceptibility 
to diet-induced atherosclerosis exists in PLTP transgenic mice, and whether 
such a difference would be indicative for the mechanism involved in the 
increased development of atherosclerosis in PLTP overexpressing mice. 
Indeed, more atherosclerosis was found in female than in male mice in the 
control group (LDLR+I-jlmCETPtg mice). These result are in agreement with 
those from Arai et al.(16), who compared atherosclerosis between males and 
females in LDLR+I- mice. A similar difference of about 3-fold in atherosclerotic 
lesion area was found in both studies. 
Higher susceptibility to diet-induced atherosclerosis in female mice has been 
reported by several groups (15, 16, 24-28). The reason for this observation is 
unclear, but the genetic background of the mice is important (29). The mice 
used in the present study are all in C57BL/6J background, which is the most 
susceptible strain for diet-induced atherosclersosis. 
When LDLR+I-jhuCETPtg mice are compared with LDLR+I-jhuCETPtg/ 
huPLTPtg mice, the atherosclerotic lesion areas are not different in male 
mice. In a previous report studying male mice with various levels of PLTP 
overexpression, we demonstrated that the development of atherosclerosis was 
PLTP-dose dependent (12). However, in the line with the lowest level of PLTP 
overexpression the difference in atherosclerotic lesion formation with the 
controls did not reach statistical significance (12). This is in agreement with 
our current findings, in which the same line of PLTP transgenic mice has been 
used for the generation of the LDLR+I-jhuCETPtg/huPLTPtg mice. Both the 
stimulation of VLDL secretion and the decrease of plasma HDL-cholesterol 
levels were statistically significant in these mice (12). In the present studY" 
the effect on plasma HDL is confirmed in the male mice. Although there is 
no obvious increase of the atherosclerotic area, the number of lesions with 
cholesterol clefts is increased. Taken together, these results suggest that a 
moderate overexpression of PLTP is atherogenic in male mice, although the 
effect is too small to be detected unambiguously in the mouse models used. 
In contrast, the atherogenic effect of increased PLTP is very obvious in female 
mice (Figure SA: P < 0.005 in LDLR+I-jhuCETPtg mice versus LDLR+I-jhuCETPtg/ 
huPLTPtg mice). Thus, under circumstances where the susceptibility to 
atherosclerosis is increased, in this case by female sex, the atherogenicity 
of elevated PLTP becomes much more pronounced and therefore easier to 
detect. 
This situation offered the opportunity to evaluate the contribution of two known 
atherogenic effects of PLTP on lipoprotein metabolism, i.e. the stimulatory 
effect on hepatic VLDL secretion and the lowering effect on plasma HDL. The 
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rate of VLDL secretion in LDLR+I /huCETPtg/huPLTPtg mice was similar in 
male and female mice, either on chow or on HFHC diet. The female mice even 
tended to have a lower VLDL triglyceride secretion rate on HFHC diet, but this 
difference was not statistically significant. VLDL secretion is considerably less 
on HFHC diet when compared to the situation on chow diet, which is caused 
by the HFHC diet, which causes high hepatic cholesterol levels resulting in 
cholesterol-rich and triglyceride-poor VLDL (30). Female LDLR+I /huCETPtg/ 
huPLTPtg mice had the lowest levels of plasma HDL after feeding of the HFHC 
diet. This is true for both the absolute concentration and the relative amount 
of HDL cholesteroL Therefore, we conclude that the decrease in plasma HDL 
has a more substantial contribution to the atherogenicity of elevated PLTP 
than the stimulation of VLDL secretion. 
In a comparison of the atherosclerotic lesion areas with published data (12, 
16), it appears that in the present study the contribution of the CETP transgene 
to the development of atherosclerosis is not substantial. This is in agreement 
with previous findings from our group (31), and also with earlier reports from 
others in which the same line of CETP transgenic mice was used to study 
atherosclerosis in a background of either LDLR deficiency or apoE deficiency 
(32), showing that a moderate increase in atherosclerosis was found only when 
several points of time were taken into account, but not for any individual time. 
The HFHC diet resulted in a marked increase in CETP activity't as reported 
before (32, 33). However, it is likely that CETP activity levels have to be 
increased much stronger in order to find a clear atherogenic effect, as has been 
done in transgenic mice overexpressing simian CETP (34) and in transgenic rats 
overexpressing human CETP (35). Still, from all these studies CETP emerges 
as an atherogenic protein, which is further corroborated by the finding that 
CETP inhibition reduces atherosclerosis in rabbits (36). Therefore, the lower 
CETP activity in female mice compared to male mice after HFHC diet found 
in the present study is probably not related to the differences observed in the 
susceptibility to atherosclerosis. 
In conclusion, we report that female mice with moderate overexpression of 
PLTP are more prone to the development of diet-induced atherosclerosis than 
male mice due to low levels of plasma HDL. HDL has several anti-atherogenic 
properties, including a key role in reverse cholesterol transport as well as anti-
oxidant and anti-inflammatory properties. The relative importance of these 
different mechanisms is presently unkown. 
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ABSTRACT 
Objective: Overexpression of human phospholipid transfer protein (PLTP) 
results in decreased plasma HDL levels and increased diet-induced 
atherosclerosis. Treatment with fibrates increases PLTP expression in mice. In 
humans, fibrates raise HDL cholesterol and lower plasma triglycerides. Our 
aim was to find out whether fibrate treatment affects human PLTP expression, 
plasma PLTP activity and HDL levels in human PLTP transgenic mice. 
Methods and Results: Treatment with different fibrates did not influence PLTP 
rn.RNA levels in human hepatocytes. Hepatic human PLTP rn.RNA was not 
affected by fenofibrate treatment in two different human PLTP transgenic 
mouse lines tested, while PLTP activity was only slightly elevated. In wild-type 
mice however, fenofibrate elevated PLTP rn.RNA, resulting in a more than 4-
fold increased PLTP activity. Plasma triglycerides were reduced in all mice by 
48% or more by fenofibrate treatment. HDL-cholesterol concentrations were 
substantially increased by fenofibrate in PLTP overexpressing mice(+ 167% in 
line A3 and +72 % in line P4), but unaffected in wild-type mice. 
Conclusions: Fenofibrate treatment restores the HDL-lowering effect of PLTP 
overexpression in human PLTP transgenic mice. These results suggest that 
species differences in PLTP regulation contribute to the differences in HDL 
response upon fibrate treatment. 
INTRODUCTION 
A number of epidemiological studies have documented an inverse relationship 
between high density lipoprotein (HDL) levels and cardiovascular diseases (1, 
2). Phospholipid transfer protein (PLTP) is a key player in HDL metabolism (3) 
and modulates HDL size and composition via remodelling of HDL particles 
(4-6). PLTP also facilitates the transfer of phospholipids, vitamin E and 
possibly unesterified cholesterol from triglyceride-rich lipoproteins to HDL 
particles during lipolysis (7, 8). In addition, PLTP may be involved in HDL-
mediated cellular efflux of phospholipids and cholesterol (9, 10), an early step 
in reverse cholesterol transport, as well as in the excretion of cholesterol from 
the body (11). Although the latter effects are potentially anti-atherogenic, PLTP 
is atherogenic in mouse models and has been described as a risk factor for 
atherosclerosis in humans (12-15). The pro-atherogenic actions of PLTP may, 
at least in part, be attributed to its HDL-lowering effect (12, 14, 16). 
Fibrates constitute a class of drugs which reduce plasma triglycerides and 
increase plasma HDL cholesterol in humans (17, 18). These effects are related 
to the activation of the transcription factor peroxisome proliferator-activated 
receptor alpha (PPARa) (18). PPARa mediates fibrate action on HDL levels 
directly through the transcriptional activation of apo AI and apo All, the major 
apolipoproteins of HDL (19, 20). Fibrates also increase lipolytic activity via 
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PP ARa resulting in lower plasma triglyceride levels (18), which may indirectly 
lead to increased HDL levels due to lower rates of cholesterylester transfer 
out of HDL as a consequence of the decreased plasma VLDL triglycerides 
(21). Several intervention trials have shown that fibrate treatment leads to 
a reduction of coronary events and a delay in the progression of coronary 
atherosclerosis (22, 23). 
In mice, fenofibrate treatment does not result in an increase in plasma HDL 
cholesterol (24) and the activity of plasma PLTP is highly increased (25). The 
latter effect has to be considered atherogenic (14). However, in vitro studies, 
using the human PLTP promoter, have suggested that human PLTP promoter 
activity might be reduced rather than stimulated by fenofibrate (26). The effect 
of fibrates on the in vivo regulation of PLTP has never been studied in man. 
Because of the potential of fibrates to prevent atherosclerosis and coronary 
heart disease and of PLTP as a risk factor, it is important to understand 
the regulation of PLTP by these drugs. Among other factors, differences in 
PLTP regulation could contribute to the species differences in HDL response 
after fibrate treatment. To test this hypothesis, we first studied the effect of 
different fibrates on human PLTP gene expression in cultured primary human 
hepatocytes. Because effects on PLTP mRNA were not apparent in these in 
vitro studies, we subsequently studied PLTP regulation by fenofibrate in vivo 
in mice and compared the effects of fenofibrate feeding in wild-type mice with 
those in two lines of mice, one line expressing human PLTP under the control 
of its native promoter and one line with a heterologous, hepatocyte-specific 
promoter. 
MATERIALS AND METHODS 
Mice 
The human PLTP transgenic mice (C57BL/6J background) were described 
before (lines A3 and P4 (14)). C57BL/6J mice were used as control wild-type 
mice. Male mice were used for all experiments. The animals were 18 to 20 
weeks old at the beginning of the study. The mice were fed either regular 
chow or fenofibrate-containing chow ad libitum for two weeks. Fenofibrate 
was mixed in the regular mouse chow at 0.2% (w/w) (25). Blood samples were 
collected by orbital bleedings after fasting the animals overnight. Plasma was 
obtained using a refrigerated centrifuge. All procedures in this study were 
approved by institutional and national guidelines. 
Human hepatocytes 
Human hepatocytes isolated from 5 independent donors were obtained as 
previously described (27). The cells were incubated with 200 f..l.M of gemfibrozil 
or 200 f..1.M of fenofibric acid for 48 h. 
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Plasma activity assays 
PLTP activity assays were performed with exogenous substrates, using the 
liposome vesicles-HDL system, according to Speijer et al. (28). LCAT activity 
was determined by measuring the formation of radiolabeled cholesteryl ester 
after addition of mouse plasma to excess heat-inactivated plasma containing 
3H-cholesterol (29). Both activities are expressed as percentage of the activity 
in a reference pool of human plasma. 100% is equivalent to the following 
activities: PLTP: 17.7 fJ.mol/ml/h, LCAT: 103.3 nmol/ml/h. 
Gene expression analyses 
RNA was isolated from the cultured hepatocytes and the expression of PLTP 
was measured by real time PCR on a MX4000 (Stratagene), as previously 
described (27), using specific primers for human PLTP : 5' -CAT GCT GCA 
GAT TGG GGT GAT-3' and 5'-ACG GTG TGG GGG CAG TGG AC-3' and 
human L-CPT1: 5' -ACA GTC GGT GAG GCC TCT TAT GAA-3' and 5'-TCT 
TGC TGC CTG AAT GTG AGT TGG-3'. 
PCR amplification was performed in a volume of 25 f.ll containing 100 nM of 
each primer, and the Brilliant SYBR Green QPCRMaster mix as recommended 
by the manufacturer (Stratagene). The conditions were 95°C for 10 min, 
followed by 40 cycles of 30s at 95°C, 30s at 55°C and 30s at 72°C. PLTP and 
CPT1 mRNA levels were subsequently normalized to 28S RNA. 
Total RNA was prepared from frozen livers of mice by the Ultraspec RNA 
isolation reagent from Biotecxs Laboratories Inc (Houston, TX) and used as a 
template for reverse transcription primed by oligo( dT). RNA expression was 
analyzed by semi-quantitative PCR. 
The primer sequences of the sense and antisense were; 5' -GCTGAAGCTA 
GAGGCCACG-3' and 5'-GCATCACTCCGATTTGCAGC-3' for mouse PLTP; 
5'- CCTGCTGAGCCCAGCAGTG-3' and 5' -CTGGACCTCAGGCTGGT 
CTG-3' for human PLTP; 5'- CCATCAAGGCCATGCGGATC-3' 
and 5' -CGAGACTGAAGAAACATGTGC-3' for mouse LCAT; 5'-
CGAAGTGTTGGATACAGGCC-3' and 5'-GGCAACATCAACAGGACTCC-
3' for mouse hypoxanthine guanine phosphoribosyltransferase (mHPRT). 
PCR products were run on agarose gels, visualized with ethidium bromide 
staining and quantified. 
Quantification of plasma lipids 
Cholesterol was determined enzymatically with the F-cholkit ofWAKO (Neuss, 
Germany) after hydrolysis of cholesteryl esters with cholesterol esterase from 
Candida cylindracea (Boehringer, Mannheim, Germany). Triglycerides were 
measured with the Sigma GPO-Trinder kit no.337-B (Sigma, StLouis, MO, 
USA). 
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Separation of plasma lipoproteins by density gradient ultracentrifugation 
Lipoprotein fractions were collected following ultracentrifugation in a 
Beckman 42.2 Ti rotor (42000 rpm, 3 h, 12 °C) at d = 1.063 g/ml. Two fractions 
were collected for cholesterol determination by tube slicing: a top fraction 
containing very low density lipoproteins (VLDL) +low density lipoproteins 
(LDL) and a bottom fraction containing HDL. 
Statistical analyses 
Data are expressed as means± SD. Differences between mice fed control chow 
and fenofibrate-containing chow were analyzed by two sample Wilcoxon 
rank-sum tests. Differences between the various mouse lines were analyzed 
by AN OVA, followed by Bonferoni correction. The tests were performed using 
Intercooled Stata 6.0 software (Stata Corporation, College Station, TX, USA). 
RESULTS 
Effect of fibrate treatment on PLTP expression in primary human hepatocytes 
Human hepatocytes were treated with 200 !J.M gemfibrozil or 200 !J.M fenofibric 
acid in the medium for 48 h, RNA was isolated and the expression of PLTP was 
measured by real time PCR. There was no difference in PLTP expression of the 
treated and non-treated cells (Figure 1). Expression of the CPT1 gene, which 
was measured as a positive control, was increased by 1.55 ± 0.22 and 1.95 ± 0.27 
fold respectively in the gemfibrozil and fenofibric acid treated cells. 
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Figure 1. Fibrates do not affect PLTP mRNA levels in human primary hepatocytes. Human 
primary hepatocytes were treated with gemfibrozil (200 ~;hatched bar) or fenofibric acid 
(200 f1M; black bar). Data were standardized with 28S and the expression in control cells were 
set to 100%. Values represent means of 5 independent donor preparations± SD. 
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Effect of fenofibrate feeding on hepatic PLTP and LCAT mRNA levels in human PLTP 
transgenic mice 
Next, it was tested whether fenofibrate regulates human PLTP in vivo. Therefore 
two lines of transgenic mice that overexpress human PLTP were treated with 
fenofibrate. Mice from line P4 expresses human PLTP under the control of its 
native promoter, while mice of line A3 mice express human PLTP under the 
control of the albumin promoter and enhancer (14). Therefore, with the use of 
these two lines it would be possible to discriminate between transcriptional 
and post-transcriptional effects of fenofibrate. Hepatic mRNA levels of PLTP 
and LCAT were determined by semi-quantitative PCR (Figure 2). The level of 
hepatic mouse PLTP mRNA was clearly increased by fenofibrate in all groups. 
By contrast, human PLTP and mouse LCAT mRNA levels were not regulated 
by fenofibrate treatment. 
control P4 A3 
mPLTP 
hPLTP 
mLCAT 
fenofibrate + + + + + + 
Figure 2. Fenofibrate increases hepatic murine, but not human PL1P expression. Hepatic 
m.RNA levels were determined in wild-type and PL1P overexpressing mice fed control diet (-) 
or fenofibrate diet(+) for mPLTP, hPL1P and mLCAT. Control: wild-type mice; P4: transgenic 
mice expressing human PL1P under the control of its native promoter; A3: transgenic mice 
expressing human PL1P under the control of the albumin promoter and enhancer (14). 
Effect of fenofibrate treatment on plasma PLTP and LCAT activities in human PLTP 
transgenic mice 
The effect of fenofibrate feeding on plasma PLTP activity was measured in 
wild-type mice and two lines of PLTP transgenic mice (Table 1). In addition, the 
activity of plasma LCAT was measured (Table 1). As expected, plasma PLTP 
activities were higher in mice overexpressing human PLTP compared with 
wild-type mice. PLTP activities were clearly elevated in plasma from wild-
type mice after fenofibrate treatment (4.4-fold, P < 0.05). By contrast, PLTP 
activity was only marginally increased by fenofibrate in mice overexpressing 
human PLTP. In line P4, a modest increase of 1.2-fold was found, which was 
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not statistically significant. The A3 mice showed a 1.3-fold increase. Plasma 
LCAT activities were increased (about 1.5-fold, P < 0.05) in mice overexpressing 
human PLTP fed normal chow versus wild-type control mice. This effect of 
the transgene on LCAT activity was absent after feeding fenofibrate. However, 
fenofibrate feeding caused an increase in LCAT activity in all mouse lines 
tested (P < 0.05). 
Table 1. Plasma activity levels of PLTP and LCAT in wild-type and human PLTP transgenic 
mice. 
wild-type 
P4. 
A3 
209 ± 12 
1594 ± 319t 
1253 ± 105t 
38 ± 
54 ± 
63 ± 
924 ± 182* 
1856 ± 161t 
1600 ± 238*t 
70 ± 14* 
73 ± 11* 
80 ± 12* 
Mice were fed control or fenofibrate diet for two weeks (n = 5 per group). Plasma activities 
are expressed as percentage of human reference pool plasma values(%). P4: transgenic 
mice expressing human PLTP under the control of its native promoter; A3: transgenic mice 
expressing human PLTP under the control of the albumin promoter and enhancer (14 ). 
Differences between the two diets were analyzed by two sample Wilcoxon rank-sum tests. 
Values are means± SO. *P < 0.05, versus control diet; tp < 0.05, versus control. 
Fenofibrate feeding decreases plasma triglycerides 
In order to check whether there is an equal response to fenofibrate in the three 
lines of mice studied, plasma levels of triglycerides were measured. Treatment 
with fenofibrate caused a decrease in plasma triglyceride levels, both in wild-
type mice and in PLTP transgenic mice (Figure 3). The decrease in the wild-type 
mice was 67%, compared with 48% and 52% in the transgenic lines P4 and A3, 
respectively (all P < 0.05). There were no statistically significant differences in 
triglyceride levels between the various mouse lines. 
Fenoftbrate feeding increases plasma HDL-cholesterol in PLTP transgenic mice, but 
not in wild-type mice 
Plasma HDL levels are known to be reduced in human PLTP transgenic mice 
(14, 30). Fenofibrate feeding had no effect on HDL-cholesterol in wild-type 
mice. By contrast, fenofibrate had a substantial HDL-cholesterol raising effect 
in both PLTP transgenic mouse lines (Figure 4). The increase was 72% in line 
P4 and 167% in line A3. As the bulk of plasma cholesterol is present in HDL in 
these mice, we found similar effects of fenofibrate treatment on total plasma 
cholesterol (increases o£177% and 118% in lines P4 andA3, respectively; results 
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Figure 3. Fenofibrate reduces plasma triglycerides in wild-type and human PLTP transgenic 
mice. Plasma triglycerides were measured in wild-type mice and PLTP transgenic mice fed 
control (black bars) or fenofibrate-containing diets (white bars) (n = 5 per group). P4: transgenic 
mice expressing human PLTP under the control of its native promoter; A3: transgenic mice 
expressing human PLTP under the control of the albumin promoter and enhancer (14). Values 
represent means± SD. *P < 0.05, control versus fenofibrate diet. 
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Figure 4. Fenofibrate counteracts the decrease in HDL cholesterol in human PLTP transgenic 
mice. Plasma HDL-cholesterol was determined in wild-type and PLTP transgenic mice fed 
control (black bars) or fenofibrate-containing diets (white bars) (n = 5 per group). P4: transgenic 
mice expressing human PLTP under the control of its native promoter; A3: transgenic mice 
expressing human PLTP under the control of the albumin promoter and enhancer (14). Values 
represent means± SD. *P < 0.05, control versus fenofibrate diet. 
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not shown). The differences in HDL-cholesterol that normally exist between 
the wild-type mice and the two PLTP transgenic lines when fed control 
chow were almost completely counterbalanced by two weeks of fenofibrate 
feeding. 
DISCUSSION 
Fibrates increase HDL cholesterol levels in man (31) which has largely been 
attributed to their action on PPARa, resulting in the transcriptional induction 
of apoAI and apo All, the main apolipoproteins of HDL (18) and in the 
induction of ABCA1 in macrophages (32). In addition to changes in plasma 
HDL levels, fibrates also increase HDL size in mice via PP ARa by inducing 
PLTP gene expression and decreasing SR-BI expression in the liver (25, 33, 34). 
Overexpression of human PLTP in mice results in decreased plasma HDL levels 
(14, 16), but it has not been studied previously how fibrates affect this pro-
atherogenic property of PLTP. Actually, the effect of fenofibrate on human PLTP 
mRNA levels has not been studied before. Therefore, we first investigated the 
regulation of PLTP expression by fibrates in human hepatocytes. Subsequently, 
we evaluated the influence of a fenofibrate-containing diet on PLTP activity 
and expression, as well as on plasma HDL-cholesterol in transgenic mice 
overexpressing human PLTP. 
It was reported earlier that fenofibrate feeding leads to increased plasma 
PLTP activity in wild-type mice (25). We were able to confirm these findings 
and observed a 4.4-fold increase in plasma PLTP activity in wild-type mice 
consistent with the induction of hepatic mouse PLTP mRNA by fenofibrate, as 
previously reported (25). In contrast, such a strong increase in PLTP activity 
by fenofibrate was not found in human PLTP transgenic mice. Expression 
of human PLTP did not respond to fenofibrate treatment, neither in human 
hepatocytes nor in transgenic mice. Data from in vitro promoter analysis 
already showed that fenofibrate increases the transcriptional activity of the 
mouse PLTP promoter (35), but not of the human PLTP promoter (36). Thus, 
PLTP is regulated in a species-specific manner by fibrates. As in both PLTP 
overexpressing mouse lines an effect of fenofibrate on PLTP expression and 
activity is absent, a post-transcriptional effect is also excluded. 
ElevationofPLTP activityresultsindecreased plasmaHDLlevelsinmice (9,14, 
16, 37, 38), which is also found in the present study. Treatment with fenofibrate 
resulted in dramatically increased HDL levels in mouse lines overexpressing 
human PLTP (2.7-fold and 1.7-fold higher in line A3 and P4 respectively). It 
has been reported that administration of PP ARa agonists leads to elevation of 
expression of ABCA1, a crucial factor for the generation of HDL, in mice (33) 
and in human macrophages (32). This may have contributed to the HDL raising 
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effect of fenofibrate. In the present study, fenofibrate caused an elevation of 
LCAT activity (Table 1), which also may have contributed to the increase in 
HDL cholesterol. The increment in HDL levels of PLTP transgenic mice by 
fenofibrate treatment was to such an extent that it virtually abolished all HDL 
differences between the wild-type mice and the PLTP transgenic mice. Thus, 
it can be concluded that fenofibrate is able to counteract the HDL lowering 
induced by PLTP overexpression and elevated plasma PLTP activities. The 
HDL raising effect of fenofibrate was accompanied with an increase in total 
plasma cholesterol, which is in agreement with results from other fenofibrate 
studies using mouse models (24, 39). This increase in total plasma cholesterol 
is as expected because HDL is quantitatively the most important plasma 
lipoprotein in mice. 
It is known that fenofibrate treatment increases HDL size in mice by an 
upregulation of PLTP expression through a PPARa-dependent mechanism 
(25). LXRs, another group of transcription factors, govern the expression of 
many of the proteins that are crucial to cholesterol homeostasis, including 
ABCA1 and the lipid transfer proteins CETP and PLTP (40). Studies in mice 
showed that LXR-regulated transcriptional activity may lead to the induction 
of hepatic PLTP expression and elevated plasma PLTP activity, resulting 
in HDL enlargement (41). In addition there is a possibility of cross talk 
between LXRs and PP ARa ( 42) and it has recently been demonstrated that co-
administration of LXR and PP ARa agonists leads to elevation of hepatic PLTP 
m.RNA expression and plasma PLTP activity resulting in enlarged HDL (33). 
Increased LCAT activity may also result in increased HDL size, mediated via 
the esterification of plasma cholesterol on HDL (43, 44). ABCA1 is crucial for 
the synthesis of HDL, and it has been demonstrated that both PLTP and LCAT 
activities were dramatically reduced in ABCA1-deficient mice ( 45), indicating 
theirimportanceinHDLmaturation. In the present study, we measured elevated 
LCAT activities after feeding the fenofibrate-containing diet, both in wild-type 
mice as well as in both lines of PLTP transgenic mice. However, in an earlier 
study, the HDL enlargement induced by fenofibrate feeding was accompanied 
by a slightly decreased plasma LCAT activity (25). This discrepancy might be 
due to different methodologies used to measure LCAT activity. Together with 
the increased LCAT activity, we found unchanged hepatic LCAT m.RNA levels 
(25). 
PLTP is reported to be a potential risk factor for atherosclerosis in mice (9, 
11) and man (12). Its pro-atherogenic action has been related, at least in part, 
to HDL lowering (14, 16). In this study we showed that fenofibrate is able 
to counteract the HDL lowering effect of elevated plasma PLTP activity. 
Therefore we conclude that fenofibrate treatment may prevent lowering of 
plasma HDL-cholesterol induced by elevated plasma PLTP activity. Hence, 
fenofibrate appears to be a suitable drug to treat the dyslipidemia observed in 
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insulin-resistant states such as obesity and type 2 diabetes mellitus, which are 
characterized by high plasma triglycerides, low HDL cholesterol and elevated 
PLTP activity (46). 
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Chapter VII 
There is a large body of evidence indicating that high plasma levels of HDL 
cholesterol reduce the risk for development of atherosclerosis. As PLTP has 
been shown to affect HDL metabolism, it is a potential factor in the development 
of atherosclerosis. Until recently however, there was no evidence showing 
whether PLTP was anti-atherogenic or pro-atherogenic. Therefore the aim 
of this thesis was to clarify the role of PLTP in lipoprotein metabolism and 
its involvement in the development of atherosclerosis. To this end we used 
genetically modified mouse models with elevated expression of PLTP, which 
in addition have a human-like lipoprotein profile. Wild-type mice are resistant 
to atherosclerosis as they have low plasma levels of cholesterol and the major 
class of circulating lipoproteins in the fasted state is HDL. This is in contrast to 
humans, in which the predominant lipoprotein classes in plasma are VLDL and 
LDL. This discrepancy between the species may be due to several differences 
in lipoprotein metabolism, including the absence of CETP in mouse plasma 
and the higher efficiency of murine hepatic LDL receptors, leading to faster 
clearance of LDL. Therefore we used models that express human CETP and 
have one inactivated LDL receptor allele (LDL-R+I-). 
Anti-atherogenic properties of PLTP 
It has been well documented that PLTP has multiple effects in lipoprotein 
metabolism (1-3). Some of its effects are believed to be anti-atherogenic while 
others are considered pro-atherogenic. A few years ago, PLTP was considered 
to have anti-atherogenic potential because of its role in pre~-HDLformation (4). 
Pre~-HDL is the initial acceptor of cellular cholesterol following efflux, which 
subsequently ends up in larger HDL particles, where cholesterol accumulates 
before being transferred along the reverse cholesterol transport pathway (5, 
6). Thus pre~-HDL may be considered as an anti-atherogenic factor. Still, 
some clinical data show that relatively high pre~-HDL concentrations are 
found in conditions of increased risk of cardiovascular disease (7, 8). This 
could be explained by an inefficient esterification of pre~-HDL by the enzyme 
LCAT (9). PLTP increases the formation, but not necessarily the concentration 
of pre~-HDL particles in vivo (6, 10, 11). In addition, plasma from huPLTPtg 
mice is more efficient in preventing cholesterol accumulation in cultured 
macrophages compared with plasma from control mice, indicating that the 
expressed PLTP is mediating an increase in cholesterol efflux (6). Thus the rate 
of pre~-HDL formation is probably more important than its concentration and 
may contribute to the anti-atherogenic potential of PLTP. 
CETP, the other lipid transfer protein, has also been reported to play a role in 
pre~-HDL formation (12). In chapter 2 we established that PLTP rather than 
CETP is responsible for the generation of pre~-HDL particles using various 
mouse models expressing either human PLTP, human CETP, or both lipid 
transfer proteins (11). 
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In vivo evidence demonstratingthatelevatedPLTP expression actually enhances 
reverse cholesterol transport originates from a study showing a 92% decrease 
in plasma HDL levels in huPLTPtg mice (13). The reduced HDL cholesterol 
level was caused by a rapid clearance via the liver leading to increased 
fecal bile acid excretionr indicating increased reverse cholesterol transport. 
Howeverr these mice have a 15-fold overexpression of PLTP.It remains to be 
demonstrated whether these findings also apply to mouse models with a more 
modest increase in PLTP expression. 
It has been shown that PLTP is present in human atherosclerotic lesions and 
is expressed in macrophages (14-16). As PLTP has been demonstrated to 
enhance cholesterol and phospholipids efflux from cholesterol loaded cells 
(17r 18)r PLTP present in atherosclerotic lesions could play a pivotal role in the 
removal of excess cholesterol from foam cellsr and thereby prevent the progress 
of atherosclerosis. On the other handr PLTP associated with the extracellular 
matrix could mediate lipoprotein retention and lipid accumulation. Whether 
PLTP is anti-or pro-atherogenic in atherosclerotic lesions requires further 
investigation. 
Finally, another potential anti-atherogenic property of PLTP has been 
suggested which is not related to the reverse cholesterol transport pathway. 
PLTP promotes a net mass transfer of vitamin E toward oxLDL or endothelial 
cellsr thereby preventing endothelial dysfunction (19). 
Pro-atherogenic properties of PLTP 
Most PLTP overexpressing mouse models show decreased HDL levels (lOr 
llr 20-22). Therefore the question was raised whether PLTP could be pro-
atherogenic. The role of PLTP in atherosclerosis has been studied in various 
mouse models (2) (see also chapter 1 Table 4). PLTP overexpressing mice 
are more susceptible to diet induced atherosclerosis than control mice in a 
PLTP dose-dependent manner (20r 23). Conversely, PLTP knockout mouse 
models are less susceptible to diet induced atherosclerosis than control mice 
(24). Howeverr a modest increase in PLTP activity of 1.3-fold does not result 
in a statistically significant increase in atherosclerosis (22). Likewiser 40-50% 
decrease of PLTP activity in mice heterozygous for PLTP deficiency did not 
affect the plasma lipid and lipoprotein levels (25). On the other handr moderate 
variations in PLTP activity might affect the development of atherosclerosis in 
humansr because this is a long term process. Indeedr it was reported recently 
that patients with coronary heart disease have a statistically signicant 1.1-fold 
elevation of PLTP activity levels compared with controls independent of other 
risk factors (26)r indicating that PLTP is a potential pro-atherogenic factor. 
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Possible pro-atherogenic mechanisms of PLTP 
The pro-atherogenic effect of PLTP can be explained by several mechanisms: 
1) PLTP affects hepatic VLDL secretion. This was demonstrated in vitro by 
using hepatocytes from PLTP deficient mice. The defect could be corrected 
by reintroduction of PLTP through adenoviral vectors (24). As a follow up, 
in chapter 3, we measured VLDL secretion in vivo in mice overexpressing 
human PLTP as well as human CETP, and found that modest overexpression 
of PLTP caused a 48% increase in VLDL secretion (27). 2) PLTP increases the 
susceptibility to atherosclerosis by lowering HDL concentrations as was shown 
in various PLTP overexpressing mouse models constitutively overexpressing 
PLTP (20, 23) and in mice expressing PLTP by using an adenovirus associated 
virus system (22). 3) PLTP may decrease the protection of LDL from oxidation, 
which is presumably due to accumulation of vitamin E in LDL which was 
shown in both PLTP deficient and in PLTP overexpressing mice (22, 28), and 
may therefore accelerate the development in atherosclerosis. 
However, a decrease in hepatic VLDL secretion only partially explains 
the decrease in atherosclerosis in PLTP deficient mice because it could not 
be demonstrated in all of the tested PLTP deficient mouse models (24). In 
addition, in PLTP overexpressing mice it was found that hepatic VLDL 
secretion is not dose dependently related to PLTP activity levels (20). From 
the results of studies in PLTP overexpressing mice it was concluded that 
high plasma activity levels of PLTP are pro-atherogenic via a lowering effect 
on HDL cholesterol (20, 23). In chapter 4 it is shown that the reduction in 
HDL levels in PLTP overexpressing mice which are also transgenic for human 
CETP, coincides with a reduction of the HDL-associated PON and PAF-AH 
activities. This may contribute to the pro-atherogenicity of PLTP (23), because 
these enzymes protect LDL from oxidation and hence retard the development 
of atherosclerosis. Surprisingly, atherosclerosis was increased in these mice in 
spite of reduced VLDL+ LDL cholesterol. Apparently the adverse effect of the 
reduction in plasma HDL is more significant than the beneficial effect of the 
reduction in VLDL+LDL cholesterol. 
In chapter 5 we concluded that the increased atherosclerosis could be 
attributed to a decrease in plasma HDL, rather than through an increased 
hepatic secretion of VLDL. 
Although decreasing the protection ofLDLfrom oxidation due to accumulation 
of vitamin E in LDL is another possible pro-atherogenic feature of PLTP, the 
relationship between vitamin E and atherosclerosis presents a confusing 
picture in humans (29). PLTP might account for this discordance but this has 
never been evaluated. However, the conflicting results with vitamin E are 
inconsistent with the epidemiologically established relation between decreased 
HDL concentration and increased atherosclerosis. 
In view of these considerations, it can be concluded that the most likely pro-
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atherogenic mechanism of PLTP is its HDL lowering ability. In addition, it 
has been demonstrated that a decrease in HDL outweighs the potentially 
beneficial anti-ahterogenic effect of decreased apoB-containing lipoprotein 
concentrations. 
PLTP and plasma HDL cholesterol 
It is remarkable that both PLTP knockout and PLTP transgenic mice show 
reduced plasma HDL levels. Different mechanisms are involved. In the case 
of PLTP knockout mice, the transfer of phospholipids and cholesterol from 
triglyceride-rich lipoproteins into HDL is arrested. This probably prevents 
the formation of mature HDL by decreasing their lipidation (30). In PLTP 
transgenic mice the redistribution of phospholipids among lipoproteins 
facilitated by PLTP causes instability of HDL particles and leads to increased 
HDL catabolism (10). 
Because PLTP activity affects plasma HDL concentration, PLTP possibly 
interacts with other key factors involved in reverse cholesterol transport like 
ABCA1 and SRBL 
PLTP activity plays a role in the maturation ofHDL which also involvesABCA1 
(31-33). ABCA1 facilitates the efflux of phospholipids toward apoAI which 
may be provided with phospholipids from surface fragments by the action of 
PLTP. ABCA1 deficiency in mice results in a more than 80% decrease in PLTP 
activity and changes in phospholipid composition of HDL which affects their 
maturation (34), and thus plasma HDL concentration. Reports on the relation 
between ABCA1 expression and the development of atherosclerosis are 
conflicting (35-38). Both PLTP andABCA1 are key factors in reverse cholesterol 
transport, but it is not clear whether they function in concert and how this 
would affect atherosclerosis. SRBI is another factor that may play a role in the 
relation between PLTP and plasma HDL concentration. HDL particles are a 
direct source of cholesteryl esters by selective HDL uptake via SRBI (39, 40). A 
series of genetically modified mouse models have established that HDL levels 
are inversely correlated with the level of SRBI expression ( 41, 42). We observed 
that the expression of hepatic SRBI mRNA is elevated in huCETPtg/huPLTPtg 
mice compared with huCETPtg mice, suggesting that overexpression of human 
PLTP may enhance the uptake of HDL via SRBI (unpublished observation). 
In the circulation of SRBI deficient mice, an accumulation of cholesterol-rich 
HDL was observed indicating a decreased delivery to the liver. In addition an 
increased susceptibility to atherosclerosis has been found in these mice, which 
is attributed to disrupted cholesterol metabolism in the vascular wall (43). 
The PLTP gene is a target of the transcription factors FXR, LXR and PPARa. 
Therefore, these transcription factors might play a role in the relation 
between PLTP on the one hand, and plasma HDL composition, plasma HDL 
concentration and the susceptibility to atherosclerosis on the other hand. Bile 
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acid is an important component of the high fat high cholesterol diet used to 
induce atherosclerosis in mice and is a potent activator of F:XR. In livers from 
mice fed a normal chow diet supplemented with bile acid both FXR and PLTP 
transcription were stimulated (44). These results suggest that FXRmight affect 
HDL metabolism through PLTP. 
The impact of LXR was evaluated by treating mice with the LXR agonist, 
T0901317 (45). This resulted in an elevation of hepatic PLTP mRNA and in 
increased HDL size and plasma concentration. However, similar effects on HDL 
were found in PLTP deficient mice, indicating that these were independent 
from PLTP activity (45). 
Fibrates are drugs that activate PP ARa, increase HDL cholesterol levels 
in humans (46, 47) and increase HDL size in mice by inducing PLTP gene 
expression in liver (48-50). In addition, it has been reported that fenofibrate 
treatment reduces atherosclerosis in mice (51). In chapter 6 we demonstrated 
that fenofibrate restores the decline in HDL caused by PLTP in transgenic 
mouse models. 
Influence of CETP and LDL-R in PLTP mouse models 
Although CETP and PLTP function independently in at least some of the 
metabolic pathways in which the transfer proteins are involved (11, 52), CETP 
clearly affects the metabolism of both HDL and apoB-containing lipoproteins 
(53). Therefore, it cannot be excluded that it does play a role in other PLTP 
functions, like VLDL secretion. In chapter 3 we investigated whether PLTP-
stimulated VLDL secretion is affected by CETP by comparing huCETPtg 
mice with huCETPtg/huPLTPtg mice. It is concluded that elevation of PLTP 
increases the rate of VLDL secretion. The presence of CETP did neither affect 
the VLDL secretion rate nor the composition of the secreted VLDL. These 
results are in line with findings in other PLTP overexpressing mice which do 
not express CETP (20). Apparently CETP does not interfere with the hepatic 
VLDL secretion caused by PLTP overexpression. On the other hand, the LDL-
R does have an impact on the VLDL secretion. It has been demonstrated in 
hepatocytes from PLTP deficient mice that the total absence of the LDL-R 
prevents the decrease in VLDL secretion which was found in PLTP deficient 
mice with either apoB transgenic or apoE knockout backgrounds (24). It has 
been suggested that LDL-Rs might interact with nascent apoB-containing 
lipoproteins within the secretory pathway (54), suggesting that functional 
LDL-Rs are necessary for apoB secretion, explaining the unchanged secretion 
in PLTP deficient mice without LDL-Rs. Therefore the presence of one allele 
of LDL-R in PLTP overexpressing mice may be sufficient for PLTP to increase 
hepatic VLDL secretion (20). 
In chapter 4 we performed atherosclerosis studies in huCETPtg!LDL-R+I· 
mice with various PLTP activities. Increased PLTP activity leads to larger 
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atherosclerotic lesion areas which were accompanied with a reduction of 
plasma HDL concentrations. The presence of CETP does not seem to affect 
the pro-atherogenicity of PLTP when comparing the results of chapter 4 with 
earlier published results from PLTP overexpressing mice bred into an LDL-R+I-
background without human CETP overexpression (20). CETP is atherogenic 
in various animal models. In chapter 4 we demonstrated that CETP activity 
is decreased in PLTP overexpressing mice and thus cannot be the reason for 
the increase in atherosclerosis found in these mice. Surprisingly, the increased 
atherosclerosis occurred in spite of reduced VLDL+ LDL cholesteroL The effect 
on HDL apparently outweighs the effect on apoB-containing lipoproteins (23). 
PLTP overexpression in mice with an LDL-R+I- background in the absence of 
CETP does not affect apoB-containing lipoprotein levels (20). The underlying 
mechanism is not clear at present. In mice without mutations in the LDL-R the 
plasma levels of apoB-containing lipoproteins are similar between huCETPtg 
and huCETPtg/huPLTPtg mice (11 ). These results suggest that the combination 
of CETPtg and LDL-R+I- is crucial for the observed decrease in apoB-containing 
lipoproteins in PLTP overexpressing mice. 
Concluding remarks and future directions 
The results presented in this thesis indicate that PLTP is pro-atherogenic in 
genetically modified mouse models. The pro-atherogenic effect of elevated 
PLTP activity is attributed to its HDL-lowering capacity with a concomitant 
lowering in anti-oxidant enzyme activities. This was found despite a reduction 
of atherogenic apoB-containing lipoproteins. The results described in this thesis 
demonstrate that PLTP affects the plasma lipoprotein distribution and suggest 
that elevated PLTP activity may be a novel risk factor for atherosclerosis. 
Although the atherogenic potential of PLTP is revealed in various mouse 
models (20, 22-24), it is not yet known whether PLTP is a causal factor for 
the development of atherosclerosis in humans. High plasma PLTP activity is 
found in disorders with increased risk for atherosclerosis and coronary heart 
disease such as diabetes mellitus, obesity and hypertriglyceridemia. In these 
patients, high PLTP often coincides with low HDL, although not in all cases, 
notably diabetes mellitus type 1. In addition, it was found that PLTP is highly 
expressed by macrophages within human atherosclerotic lesions. Although 
this may indicate that PLTP plays a role in the development of atherosclerosis 
in humans, further research is needed to clarify this putative role. Obviously 
a more detailed understanding of its pro-atherogenic mechanism is needed to 
assess the role of PLTP in atherosclerotic disease. 
The relationship between PLTP and atherosclerosis appears to be complex 
involving other HDL modulating factors such as CETP. PLTP has also been 
shown to affect lipoprotein metabolism in various ways. As a consequence the 
mechanism of the atherogenic potential of PLTP has not been fully elucidated. 
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This can be accomplished by studying the impact of other factors on PLTP. 
However, it is indisputable that PLTP affects HDL metabolism. Moreover, 
PLTP is expressed in various tissues where it may serve local functions. In 
order to determine the mechanism by which PLTP is atherogenic, it may 
be useful to analyze its local actions. This can be executed by inducing the 
expression, or exclude the expression of PLTP in certain cell types of mice of 
which hepatocytes and macrophages are of most interest. 
If PLTP turns out to be a causal factor for atherosclerosis, pharmacological 
modulators of PLTP or gene therapy targeting PLTP may be useful tools to 
prevent the development of atherosclerosis. 
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Complications of atherosclerosis are the principal cause of mortality in Western 
societies. Epidemiological studies have shown that a high HDL cholesterol 
level in plasma is inversely correlated with the risk for atherosclerosis. The 
exact biological mechanism behind this finding is not known. There are many 
factors that affect HDL metabolism. In vitro and in vivo studies demonstrated 
that plasma phospholipid transfer protein (PLTP) plays a major role in 
phospholipid transfer processes between lipoproteins, and also in modulating 
size and composition of HDL particles. The aim of this thesis was to clarify the 
role of PLTP in HDL metabolism and in the development of atherosclerosis. 
Normal mice lack cholesteryl ester transfer protein (CETP) and have very low 
LDL plasma levels compared with humans. Therefore we used a genetically 
modified mouse model with a humanlike lipoprotein profile. These animals 
are transgenic for CETP and carry one mutated allele of the LDL receptor 
(huCETPtg/LDL-R+I-). 
PLTP could have anti-atherogenic potential due to its ability to generate pre~­
HDL. In vitro studies indicated that both lipid transfer proteins, i.e. CETP and 
PLTP, are implicated in the formation of pre~-HDL. In chapter 2 the relative 
contribution of each of these proteins was investigated in mouse models. We 
compared human CETP transgenic mice (huCETPtg), human PLTP transgenic 
mice (huPLTPtg) and mice expressing both lipid transfer proteins (huCETPtg/ 
huPLTPtg). It was shown by using two different techniques that PLTP was 
much more important than CETP for the formation of pre~-HDL. In both lines 
of PLTP transgenic mice the formation of pre~-HDL was 3-fold higher than in 
huCETPtgmice. Thus, PLTPrather than CETPis responsible for the generation 
of pre~-HDL. 
PLTP may also have pro-atherogenic potential. This was demonstrated in PLTP 
knockout mice, which showed to be less prone to diet-induced atherosclerosis 
compared with control mice which was attributed to a reduction of hepatic 
VLDL secretion. We evaluated the influence of PLTP on VLDL secretion in 
chapter 3 by using our PLTP transgenic model with appreciable CETP activity. 
InhuCETPtg/huPLTPtgmice, the VLDL secretion was 1.5-foldhigher compared 
with huCETPtg mice. The composition of nascent VLDL was similar in both 
strains. Thus, PLTP is involved in VLDL secretion in vivo. 
In chapter 4 we studied the susceptibility to diet-induced atherosclerosis in 
huCETPtg/LDL-R+I- mice with moderately and highly elevated plasma PLTP 
activity. Elevation of PLTP activity gives rise to increased susceptibility to diet-
induced atherosclerosis, which was accompanied by a PLTP dose-dependent 
reduction of HDL as well as by a decrease of apolipoprotein ( apo) B-containing 
lipoproteins. These results indicate that the adverse effect of the reduction in 
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plasma HDL outweighs the beneficial effect of the reduction in apoB-containing 
lipoproteins. In addition, we measured the activity of the two HDL-associated 
anti-atherogenic enzymes, paraoxonase (PON) and platelet-activating factor 
acetyl hydrolase (PAF-AH). It was found that the PLTP-dependent reduction 
of HDL coincides with a decrease of these HDL-associated anti-oxidant 
enzyme activities. Thus, PLTP overexpression is atherogenic. The mechanism 
may comprise various atheroprotective properties of HDL, including the 
association with anti-oxidant enzymes. 
We described two different mechanisms which could explain the atherogenic 
potential of PLTP. First, PLTP stimulates hepatic VLDL secretion. Second, 
PLTP lowers plasma levels of HDL. In chapter 5 we studied which of these 
two pro-atherogenic effects is the most important factor in the development of 
atherosclerosis. To this end, we compared male and female huCETPtg/LDL-
R+I- mice with moderate PLTP overexpression. It is well known that male mice 
are less susceptible to diet-induced atherosclerosis than female mice. This was 
also found in the present study, as atherosclerosis was approximately 7-fold 
higher in female mice than in male mice. The reason for this difference is not 
clear. We used this difference as a starting point to perform a comparative 
study. We found that PLTP activities were similar in both sexes. No differences 
were observed in the rate of hepatic VLDL secretion. However, HDL levels 
were significantly lower in the female mice. From these data we conclude that 
the atherogenic potential of PLTP is caused by a decrease in HDL and not by 
an increase of hepatic VLDL secretion. 
Fenofibrate lowers triglycerides and increases HDL plasma levels in humans. 
In chapter 6 we investigated whether fenofibrate affects PLTP activity levels 
and plasma HDL in mice transgenic for human PLTP. Hepatic human PLTP 
mRNA was unchanged by fenofibrate in transgenic PLTP mice whereas hepatic 
murine PLTP mRNA was increased in both wild-type and PLTP transgenic 
mice. PLTP activity was elevated by fenofibrate in wild-type mice, but not in 
mice transgenic for human PLTP. HDL-cholesterol was substantially increased 
by fenofibrate in PLTP overexpressing mice while it was much less affected in 
wild-type mice. As a result the decline in plasma HDL-cholesterol in PLTP 
transgenic mice is almost completely restored by fenofibrate treatment. The 
data suggest that species differences in PLTP regulation contribute to the 
differences in HDL response upon fenofibrate treatment. 
Finally in chapter 7, the results presented in this thesis were discussed in 
relation to the progress in the field of PLTP-associated atherosclerosis research. 
The results presented in this thesis indicate that PLTP is pro-atherogenic in 
genetically modified mouse models. The pro-atherogenic effect of elevated 
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PLTP activity is attributed to its HDL-lowering capacity. It is not yet known 
whether PLTP is a causal factor for the development of atherosclerosis in 
humans. High plasma PLTP activity is found in disorders with increased 
risk for atherosclerosis and coronary heart disease such as diabetes mellitus, 
obesity and hypertriglyceridemia. In these patients, high PLTP often coincides 
with low HDL, although not in all cases, notably diabetes mellitus type 1. In 
addition, it was found that PLTP is highly expressed by macrophages within 
human atherosclerotic lesions. Although this may indicate that PLTP plays 
a role in the development of atherosclerosis in humans, further research is 
needed to clarify this putative role. 
The findings suggest that PLTP may be a novel risk factor for atherosclerosis. 
A more detailed understanding of its pro-atherogenic mechanism is important 
in order to conclude that PLTP is causal in atherosclerotic disease. If so, 
pharmacological modulators of PLTP or gene therapy targeting PLTP may be 
useful tools to prevent the development of atherosclerosis. 
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Hart- en vaatziekten vormen sinds vele tientallen jaren de belangrijkste 
doodsoorzaak in de Westerse wereld. Er zijn verschillende oorzaken voor 
deze aandoeningen, maar in veel gevallen gaat het om de gevolgen van 
atherosclerose ofwel aderverkalking. Atherosclerose is een langdurig proces 
waarbij vetophopingen in de bloedvatwanden plaatsvinden waardoor de vaten 
op den du-q.r vernauwd kunnen worden. Er zijn verschillende risico factoren 
bekend die een belangrijke rol spelen bij het ontstaan van atherosclerose 
zoals hoge bloeddruk, roken, overgewicht, diabetes mellitus en een verhoogd 
cholesterol gehalte in het bloed. Cholesterol is essentieel voor het functioneren 
van het lichaam. Het komt voor in celmembranen en dient als bouwsteen voor 
o.a. hormonen en componenten van de gal. Cholesterol wordt via het bloed 
door het lichaam vervoerd. Omdat cholesterol een vetachtige niet in water 
oplosbare stof is, kan het niet in vrije vorm in het bloed voorkomen. Om toch 
door het bloed getransporteerd te kunnen worden, wordt cholesterol verpakt 
in zogenaamde lipoprotemen. Deze lipoprotemen bestaan in verschillende 
klassen die naar dichtheid zijn ingedeeld. De belangrijkste lipoprotemen zijn 
de "low density lipoproteins" (LDL) en de "high density lipoproteins" (HDL). 
LDL vervoert cholesterol naar de vaatwand waardoor cholesterolophoping 
kan plaatsvinden. Daarom wordt LDL het slechte cholesterol genoemd. In 
bevolkingsonderzoek wordt dan ook een relatie gevonden tussen een hoog 
LDL gehalte in het bloed en een verhoogde kans op atherosclerose. Voor 
HDL is een omgekeerde relatie gevonden. HDL zorgt er juist voor dat het 
overtollige cholesterol uit de vaatwand kan worden afgevoerd, eerst naar het 
bloed en daarna naar de lever. In de lever wordt het cholesterol deels omgezet 
in galzouten en kan het lichaam verlaten via de ontlasting. 
Toen met het onderzoek beschreven in dit proefschrift werd begonnen, was 
het bekend dat het eiwit "phospholipid transfer protein" (PLTP) een rol speelt 
in de stofwisseling van HDL. Hoe PLTP betrokken is bij de ontwikkeling 
van atherosclerose was echter nog onduidelijk. De studies beschreven in dit 
proefschrift zijn uitgevoerd om meer inzicht te krijgen in de werking van PLTP 
en om de relatie met atherosclerose te onderzoeken. 
Om een goed inzicht te verkrijgen in het ontstaan en de ontwikkeling van 
atherosclerose is het noodzakelijk om gebruik te maken van proefdieren. We 
hebben gebruik gemaakt van muizen, waarin eiwitten selectief kunnen worden 
aangemaakt of uitgeschakeld door middel van genetische modificatie. We 
hebben een muismodel gekozen dat wat betreft de cholesterol stofwisseling 
eigenschappen vertoont zoals die bij mensen worden gevonden. De dieren 
bevatten een extra gen coderend voor het menselijke "cholesteryl ester 
transfer protein" (huCETPtg). Men noemt dit CETP transgene muizen. PLTP 
en CETP zijn beide lipide transfer eiwitten die circuleren in het bloed. Muizen 
hebben van nature geen CETP. CETP heeft echter een belangrijke invloed 
op lipoprotemen en heeft zeer waarschijnlijk een stimulerend effect op de 
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ontwikkeling van atherosclerose. Daarnaast hebben muizen van nature zeer 
lage LDL niveaus in het bloed. Daarom is een extra mutatie ingebracht om 
het LDL te verhogen. Tenslotte is het menselijke gen voor PLTP ingebracht. 
Deze muizen zijn vergeleken met dieren die dit transgen niet bevatten om 
het effect van PLTP op atherosclerose, HDL en lipoprotemen stofwisseling te 
kunnen onderzoeken. Atherosclerose is opgewekt door grate hoeveelheden 
vet en cholesterol aan het muizenvoer toe te voegen. 
PLTP zou anti-atherosclerotisch kunnen zijn omdat het in staat is om een 
specifiek type HDL te genereren nL pref3-HDL, dat zeer efficient is in de 
opname van cholesterol uit de eeL Uit Iiteratuur was al bekend dat CETP ook 
in staat is om dit pref3-HDL te kunnen genereren. Het doel van hoofdstuk 2 
was om een vergelijking te maken tussen deze twee lipide transfer eiwitten 
in dit opzicht. We hebben groepen muizen bestudeerd die transgeen zijn 
voor: 1) CETP 2) PLTP en 3) zowel CETP als PLTP. Door twee verschillende 
technieken te gebruiken hebben we overtuigend kunnen aantonen dat PLTP 
veel belangrijker is voor de vorming van pref3-HDL dan CETP. In de PLTP 
transgene muizen was de vorming van pref3-HDL drie maal hoger dan in de 
CETP transgene muizen. 
Er zijn ook aanwijzingen dat PLTP pro-atherosclerotisch zou kunnen zijn. 
Uit experimenten met gekweekte levercellen is gebleken dat PLTP mogelijk 
betrokken is bij de productie van VLDL deeltjes. Dit zijn grote lipoprotemen 
waaruit LDL ontstaat. In hoofdstuk 3 hebben we onderzocht wat de invloed 
is van PLTP op de afgifte van VLDL uit de lever naar het bloed. We hebben 
aangetoond dat in CETP/PLTP transgene muizen de VLDL afgifte 1,5 maal 
hoger is dan in CETP transgene muizen. PLTP stimuleert dus inderdaad de 
productie van VLDL in een zoogdier. 
Het effect van PLTP op dieet gemduceerde atherosclerose hebben we in 
hoofdstuk 4 getest. Hiervoor hebben we drie muizenlijnen gebruikt die 
verschillen in PLTP activiteit. De mate van atherosclerose in muizen wordt 
bepaald door vetafzettingen te meten die zich het eerst ontwikkelen op 
de aortakleppen. Toenemende PLTP activiteit ging gepaard met meer 
atherosclerose. Dit ging samen met een eveneens PLTP dosis gerelateerde 
afname in HDL en LDL. Daaruit kan worden geconcludeerd dat voor de 
ontwikkeling van atherosclerose vermindering van het goede HDL cholesterol 
zwaarder weegt dan vermindering vanhet slechte LDL cholesteroL Ookhebben 
we de activiteiten van twee enzymen gemeten, die anti-atherosclerotisch 
zijn door anti-oxidatieve werking. Wij hebben gevonden dat deze beide 
enzymactiviteiten afnemen bij een oplopende PLTP activiteit. Deze resultaten 
tonen aan dat PLTP pro-atherosclerotisch is. 
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Er zijn hierboven twee verschillende mechanismen aangetoond die het 
gevonden atherosclerose stimulerende effect van PLTP zouden kunnen 
verklaren. Op de eerste plaats verhoogt PLTP de afgifte van VLDL door de 
lever aan het bloed en op de tweede plaats verlaagt PLTP het HDL niveau in 
het bloed. Het doel van hoofdstuk 5 was vast te stellen welke van de twee 
genoemde werkingen van PLTP de belangrijkste factor is in de ontwikkeling 
van atherosclerose. Daartoe hebben we een vergelijking gemaakt tussen 
mannetjes en vrouwtjes muizen met een matig verhoogde PLTP activiteit. 
Het is een bekend gegeven dat mannetjes muizen veel minder gevoelig zijn 
voor de ontwikkeling van dieet-gei'nduceerde atherosclerose dan vrouwtjes 
muizen. Dat blijkt ook uit onze studie, want de gevonden atherosclerose in 
de vrouwtjes muizen was zeven maal hager dan in de mannetjes muizen. De 
oorzaak hiervan is nog onduidelijk. Wij hebben het geslachtsverschil echter als 
uitgangspunt gebruikt om een vergelijkende studie te kunnen uitvoeren. Het 
bleek dat de PLTP activiteit vergelijkbaar was tussen mannetjes en vrouwtjes 
muizen. Er werden geen verschillen waargenomen in de VLDL afgifte door 
de lever tussen mannetjes en vrouwtjes muizen. De HDL cholesterol waarden 
in de vrouwtjes waren echter duidelijk lager dan die in de mannetjes. Deze 
gegevens tonen aan dat atherosclerose in deze muizen niet veroorzaakt wordt 
door een toegenomen VLDL afgifte maar door een verlaagd HDL niveau. 
Fenofibraat is een geneesmiddel dat bij mensen het vetgehalte (triglyceriden) 
in het bloed verlaagt en het HDL cholesterol niveau verhoogt. Het doel van 
hoofdstuk 6 was om het effect van fenofibraat te onderzoeken op PLTP en 
HDL cholesterol. Hiervoor hebben we controle muizen en PLTP transgene 
muizen behandeld met fenofibraat. Deze behandeling veroorzaakt een sterke 
verhoging van het HDL cholesterol in de PLTP transgene muizen waardoor dit 
gelijk wordt aan de niveaus in de controle muizen. Fenofibraat behandeling 
resulteert dus in een volledige compensatie van het HDL verlagende effect 
van PLTP in PLTP transgene muizen. 
Als laatste worden in hoofdstuk 7 de resultaten uit dit proefschrift 
bediscussieerd. Deze tonen aan dat PLTP pro-atherosclerotisch is in het door 
ons gebruikte muismodel. Dit wordt waarschijnlijk veroorzaakt doordat 
verhoogde PLTP activiteit een verlaging geeft van HDL. Of PLTP ook een 
risicofactor is voor atherosclerose in de mens valt nog niet met zekerheid te 
zeggen. Er zijn echter wel aanwijzingen voor. Een verhoogde PLTP activiteit 
is gevonden in mensen met diabetes mellitus, overgewicht en verhoogde 
triglyceriden in het bloed. In deze groepen is er meestal ook een associatie 
tussen hoog PLTP en laag HDL, hoewel er ook uitzonderingen bestaan (met 
name patienten met diabetes mellitus type 1 ). In sectie materiaal van overleden 
patienten is PLTP aangetoond in de cellen van atherosclerotische bloedvaten. 
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Hoewel de functie hiervan nog niet is opgehelderd, doet deze bevinding wel 
verrnoeden dat PLTP een rol speelt bij atherosclerose bij mensen. 
Om definitieve uitspraken te kunnen doen over de betekenis van PLTP in de 
ontwikkeling van atherosclerose bij de mens is meer onderzoek noodzakelijk. 
Op grand hiervan zal kunnen worden vastgesteld in hoeverre PLTP een 
risicofactor is voor de ontwikke1ing van atherosclerose in mensen. Indien 
PLTP een be1angrijke oorzakelijke factor blijkt te zijn kan gedacht worden aan 
de ontwikkeling van PLTP-verlagende of remmende medicijnen. 
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Dankwoord 
De laatste pagina(s) gebruik ik om een vraag te beantwoorden die na 4 jaar 
onderzoek vaak aan mij werd gesteld: "En wanneer kunnen we je proefschrift 
zien?" Mijn antwoord is nu:"Nou, zoals je ziet is het nu af" .lk wil bij deze echt 
ALLE MENSEN bedanken die op welke manier dan ook hebben bijgedragen 
aan de totstandkoming van dit resultaat, want een promotie bereik je immers 
niet in je eentje. In het bijzonder wil ik een aantal mensen bij naam noemen. 
Allereerst wil ik mijn copromotoren Aad van Tol en Rini de Crom bedanken. 
Beste Aad, jouw vakkennis en ervaring is van grote waarde geweest. Je hebt 
bovendien de kracht mij "op te peppen" door je enthousiasme. Zeker op de 
momenten wanneer ik dacht dat er weinig nieuws uit de brei aan gegevens te 
halen viel, lukte het je om me te motiveren door de positieve resultaten naar 
voren te hal en. ("Alles is mogelijk"). Beste Rini, zonder jouw steun en hulp had 
het ongetwijfeld allemaal veellanger geduurd!! lk waardeer het dat je meer 
dan ruim de tijd nam om mij te begeleiden en dat je altijd interesse toont. Het 
is onmogelijk om in een paar zinnen samen te vatten wat jij voor mij betekent 
hebt. In ieder geval bedankt voor al je chocomelletjes tijdens/na besprekingen 
en/of "computersessies". lk hoop trouwens dat ik het niveau van "Donald 
Duck" of "Libelle" enigszins ben ontstegen. 
Uiteraard wil ik ook Hans Jansen, mijn promotor en de andere leden van de 
promotiecommissie bedanken voor het kritisch beoordelen vanhetmanuscript. 
Ook alle (buitenlandse) coauteurs dank ik voor hun bijdrage aan de artikelen 
die in dit proefschrift staan. 
De afdeling Biochemie. 
De hulp van collega's van Lab3 is de basis van dit proefschrift geweest. Teus 
van Gent, wij spreken dezelfde protocollen taal en denken daarom in dezelfde 
codes. lk kon je te allen tijde raadplegen voor je nauwkeurige vaardigheden. 
Leo Scheek met "geen voorschot op ellende nemen" heb ik nog altijd moeite, 
maar jouw zogenaamde LL-methode heb ik menigmaal succesvol toegepast. 
Inge Lankhuizen, jij zorgde voor de vrouwelijke versterking op Lab3. Ik denk 
dat ik wel mag zeggen dat wij konijntjes lief vinden. Farah Sadeghi-Niaraki, 
inmiddels een goede vriendin, de volgende vrouwelijke versterking van Lab3. 
Farah, je bent altijd in staat geweest om mij "onder controle" te houden als ik 
op het punt stond mij te druk te maken om onnodige dingen. 
Mijn Aio-genootjes Hans Hut en Bas Tomassen alias Bert en Ernie van Labl 
en later Diederik van Deursen alias Dido van Lab2, jullie 3-tjes zorgden naar 
mijn mening voor een "aparte jongensachtige subsfeer", wanneer gaan jullie 
de boel afronden? Gert-Jan Botma en Delfina Vieira van Lab2, voor een tijdje 
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mijn kamergenootjes. Met jullie heb ik vooral de laatste 2 jaren veel mogen 
delen over hoe jullie het Aio zijn hebben ervaren. Bedankt voor de gezeilige 
kletspraatjes en hopelijk blijven we elkaar zien/mailen. 
De afdeling Celbiologie & Genetica. 
Rien van Haperen, de man met twee rechter handen, hartstikke bedankt 
voor het bijbrengen van ailerlei proeven. Je was de eerste persoon bij wie ik 
mocht "prutsen". Ik moest wei even wennen aan je "klutskes" ,"bietjes" en 
jouw "systeem". Jij vormde naast Lab3 de andere steunpilaar voor de basis 
van dit proefschrift. Pim Visser (altijd goed gehumeurd) en Thijs van Aken 
( cafeme en nicotine) bedankt voor o.a. de coupes/kleuringen lessen. Caroline 
Cheng (hyper Aio-genootje, lady in black) ik wens je veel succes met jouw 
proefschrift. 
Enkele personen van het EDC. 
Patrick Molenbeek ( exotische vakanties en kaassou:ffles?) en Danielle 
Zondervan, bedankt voor juilie assistentie en gezellige "muizenisjes" tijdens 
de tapsessies. En John Mahabier als ik weer eens een flesje isofluraan nodig 
had ("Wat schuift het?"). 
En natuurlijk mijn familie. 
Vooral mama, mammie en pappie. Jullie zijn altijd oprecht gemteresseerd 
in wat ik doe en wat mij bezighoudt. Ik kan altijd op jullie rekenen. Mam, 
gelukkig ben jeer nog, dit is dankzij de snelle actie van Han-Sing die ik bij deze 
nogmaals wil bedanken. Richard, mijn broer(tje), je bent niet aileen een kei in 
het ontwerpen van gebouwen en huizen, maar je bent ook nog eens creatie£ 
op li.et gebied van printwerk. Hopelijk is dit proefschrift niet zo erg "su£" als 
aile andere proefschriften. Tenslotte wil ik mijn man Danny bedanken voor 
echt ALLES. Hoewel je een rijbewijs van veel praktischer waarde vindt dan 
promoveren ("laag rendement"), ben je toch wei blij dat ik de eindstreep van 
dit gebeuren heb gehaald. Samen met Kenzi vormen we een prima team dat 
volgend jaar zal worden uitgebreid. Daarna komt het volgen van autorijlessen 
dan toch echt serieus aan bod hoor!!! 
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